



Pfizer Inc.

# CDP Corporate Questionnaire 2026

Word version

**Important: this export excludes unanswered questions**

This document is an export of your organization's CDP questionnaire response. It contains all data points for questions that are answered or in progress. There may be questions or data points that you have been requested to provide, which are missing from this document because they are currently unanswered. Please note that it is your responsibility to verify that your questionnaire response is complete prior to submission. CDP will not be liable for any failure to do so.

[Read full terms of disclosure](#)

# Contents

## C1. Introduction

### (1.1) In which language are you submitting your response?

Select from:

☒ English

### (1.2) Select the currency used for all financial information disclosed throughout your response.

Select from:

☒ USD

### (1.3) Provide an overview and introduction to your organization.

#### (1.3.2) Organization type

Select from:

☒ Publicly traded organization

#### (1.3.3) Description of organization

*Pfizer Inc. is a research-based, global biopharmaceutical company. Our purpose—Breakthroughs that change patients' lives—guides our strategy and how we apply science and our global resources to bring therapies to people that extend and significantly improve their lives through the discovery, development, manufacture, marketing, sale and distribution of biopharmaceutical products worldwide. We work across developed and emerging markets to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. We collaborate with healthcare providers, governments and local communities to support and expand access to reliable, affordable healthcare around the world. The company was incorporated under the laws of the State of Delaware on June 2, 1942. Pfizer's commitment to responsible business practices is rooted in our purpose, as we strive to serve patients and communities with innovation and sustainable approaches to discovering, developing and bringing medicines and vaccines to market. This commitment is overseen by our Board, primarily through the Governance Committee, which is responsible for oversight of our responsible business growth strategy and reporting. Through a comprehensive assessment, we identified 30 key topics, which we organized into six priority areas: product innovation, climate change, equitable access and pricing, product quality and safety, diversity, equity and inclusion, and business ethics. These priority areas are integrated with our purpose and are incorporated into our Enterprise Risk Management process. Pfizer's environmental sustainability program is focused on mitigating climate impact, conserving natural resources, and reducing waste including: •Reducing the greenhouse gas (GHG) emissions associated with our operations. This includes application of engineering and sustainability innovations to how we design and operate our sites (e.g., manufacturing, labs, offices, etc.) and manage our operations (e.g., product transportation, business travel, renewable energy, etc.). •Reducing water*

withdrawal associated with our operations and being effective stewards of the water we use •Decreasing waste generated from our operations through a multifaceted approach including source reduction, waste minimization, recycling, and other opportunities to reuse materials we cannot recycle ourselves •Applying scientific innovation and operational efficiency to reduce the environmental impact of our medicines throughout the product lifecycle •Integrating environmental sustainability criteria into our supplier selection and management processes; and •Engaging with key suppliers of goods and services to drive the adoption of science-based GHG reduction goals. With senior leader support and collaboration at all levels, we aim to improve health outcomes, build trust, create shared value, and make a positive impact on society for years to come. Further information can be found at [www.Pfizer.com](http://www.Pfizer.com) or through Pfizer’s social media including X (formerly known as Twitter) @Pfizer and @Pfizer News, LinkedIn, YouTube and Facebook.com/Pfizer. Disclosure Notice: The information contained in this 2026 CDP submittal is as of September 16, 2026. Pfizer assumes no obligation to update forward-looking statements contained in this response as the result of new information or future events or developments. This response contains forward-looking information about, among other things, potential environmental impacts to Pfizer, including regulatory, physical, and business risks and opportunities, and information related to environmental sustainability strategies and goals, all of which involve substantial risks, uncertainties and assumptions. Such risks, uncertainties and assumptions include, among other things, the uncertainties inherent in determining potential impacts from climate change; changes to existing or implementation of new regulations; projected financial impact and management cost; projected performance on climate change related goals; and the uncertainties inherent in business and financial planning, including, without limitation, risks related to Pfizer’s business and prospects, adverse developments in Pfizer’s markets, or adverse developments in the U.S. or global capital markets, credit markets, regulatory environment or economies generally. Pfizer’s past performance in attaining reductions in GHG emissions is not an indication of future performance. A further description of risks and uncertainties can be found in Pfizer’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, including in the sections thereof captioned “Risk Factors” and “Forward-Looking Information and Factors That May Affect Future Results” and in its subsequent reports on Forms 10-Q and 8-K, all of which are filed with the SEC and are available at [www.sec.gov](http://www.sec.gov) and [www.pfizer.com](http://www.pfizer.com).  
[Fixed row]

**(1.4) State the end date of the year for which you are reporting data. For emissions data, indicate whether you will be providing emissions data for past reporting years.**

|  | End date of reporting year | Alignment of this reporting period with your financial reporting period | Indicate if you are providing emissions data for past reporting years |
|--|----------------------------|-------------------------------------------------------------------------|-----------------------------------------------------------------------|
|  | 12/31/2025                 | Select from:<br><input checked="" type="checkbox"/> Yes                 | Select from:<br><input checked="" type="checkbox"/> No                |

[Fixed row]

**(1.4.1) What is your organization’s annual revenue for the reporting period?**

62579000000

(1.5) Provide details on your reporting boundary.

|  |                                                                                                        |
|--|--------------------------------------------------------------------------------------------------------|
|  | Is your reporting boundary for your CDP disclosure the same as that used in your financial statements? |
|  | Select from:<br><input checked="" type="checkbox"/> Yes                                                |

[Fixed row]

(1.6) Does your organization have an ISIN code or another unique identifier (e.g., Ticker, CUSIP, etc.)?

ISIN code - bond

(1.6.1) Does your organization use this unique identifier?

Select from:

☒ No

ISIN code - equity

(1.6.1) Does your organization use this unique identifier?

Select from:

☒ Yes

(1.6.2) Provide your unique identifier

US7170811035

CUSIP number

### (1.6.1) Does your organization use this unique identifier?

Select from:

☒ Yes

### (1.6.2) Provide your unique identifier

717081103

### Ticker symbol

### (1.6.1) Does your organization use this unique identifier?

Select from:

☒ Yes

### (1.6.2) Provide your unique identifier

PFE

### SEDOL code

### (1.6.1) Does your organization use this unique identifier?

Select from:

☒ No

### LEI number

### (1.6.1) Does your organization use this unique identifier?

Select from:

☒ Yes

### (1.6.2) Provide your unique identifier

## D-U-N-S number

### (1.6.1) Does your organization use this unique identifier?

Select from:

☒ Yes

### (1.6.2) Provide your unique identifier

00-132-6495

## Other unique identifier

### (1.6.1) Does your organization use this unique identifier?

Select from:

☒ No

[Add row]

## (1.7) Select the countries/areas in which you operate.

Select all that apply

☒ Peru

☒ Chile

☒ China

☒ Egypt

☒ India

☒ France

☒ Greece

☒ Israel

☒ Latvia

☒ Italy

☒ Japan

☒ Spain

☒ Brazil

☒ Canada

☒ Norway

☒ Poland

☒ Serbia

☒ Sweden

- ✓ Mexico
- ✓ Austria
- ✓ Belarus
- ✓ Belgium
- ✓ Croatia
- ✓ Czechia
- ✓ Hungary
- ✓ Ireland
- ✓ Morocco
- ✓ Romania
- ✓ Tunisia
- ✓ Pakistan
- ✓ Portugal
- ✓ Slovakia
- ✓ Thailand
- ✓ Argentina
- ✓ Kazakhstan
- ✓ Luxembourg
- ✓ Netherlands
- ✓ New Zealand
- ✓ Philippines
- ✓ Russian Federation
- ✓ Korea (The Republic of)
- ✓ United States of America

- ✓ Algeria
- ✓ Denmark
- ✓ Ecuador
- ✓ Estonia
- ✓ Finland
- ✓ Germany
- ✓ Türkiye
- ✓ Ukraine
- ✓ Uruguay
- ✓ Bulgaria
- ✓ Colombia
- ✓ Australia
- ✓ Indonesia
- ✓ Lithuania
- ✓ Singapore
- ✓ Costa Rica
- ✓ Switzerland
- ✓ Saudi Arabia
- ✓ South Africa
- ✓ Taiwan, China
- ✓ United Kingdom

### **(1.8) Are you able to provide geolocation data for your facilities?**

#### **(1.8.1) Are you able to provide geolocation data for your facilities?**

Select from:  
☒ Yes, for some facilities

**(1.8.2) Comment**

*While we have geolocation data available, due to the large number of facilities included within the scope of this disclosure we are only providing data for the facility relevant to the Supply Chain member requesting our water response.*  
*[Fixed row]*

**(1.8.1) Please provide all available geolocation data for your facilities.**

**Row 1**

**(1.8.1.1) Identifier**

*Newbridge*

**(1.8.1.2) Latitude**

*53.1858*

**(1.8.1.3) Longitude**

*-6.7794*

**(1.8.1.4) Comment**

*Geolocation data provided for the facility relevant to the CDP Supply chain member requesting Water Security information.*

**Row 2**

**(1.8.1.1) Identifier**

*Kalamazoo*

### (1.8.1.2) Latitude

42.2106

### (1.8.1.3) Longitude

-85.5571

### (1.8.1.4) Comment

*Geolocation data provided for the facility relevant to the CDP Supply chain member requesting Water Security information.*  
*[Add row]*

## (1.24) Has your organization mapped its value chain?

### (1.24.1) Value chain mapped

*Select from:*

☒ Yes, we have mapped or are currently in the process of mapping our value chain

### (1.24.2) Value chain stages covered in mapping

*Select all that apply*

☒ Upstream value chain

### (1.24.3) Highest supplier tier mapped

*Select from:*

☒ Tier 1 suppliers

### (1.24.4) Highest supplier tier known but not mapped

*Select from:*

☒ Tier 2 suppliers

## (1.24.7) Description of mapping process and coverage

*Pfizer sets high standards for responsible supply chain management, guided by robust governance processes. This helps ensure the safety and quality of the medicines and vaccines we produce and aligns with our core value of Equity. Compliance with all applicable laws is our baseline expectation, and we also establish other risk-based assessment criteria to help assure our suppliers are responsibly managing environmental, health, and safety (EHS) risks and maintaining a robust supply chain, including establishing a comprehensive supply chain management system. We collect information regarding our suppliers' business entities and business locations. This information is maintained in our enterprise systems.*

*[Fixed row]*

## C2. Identification, assessment, and management of dependencies, impacts, risks, and opportunities

(2.1) How does your organization define short-, medium-, and long-term time horizons in relation to the identification, assessment, and management of your environmental dependencies, impacts, risks, and opportunities?

### Short-term

(2.1.1) From (years)

0

(2.1.3) To (years)

5

(2.1.4) How this time horizon is linked to strategic and/or financial planning

*Pfizer uses a 0-5 year timeframe to assess short-term environmental dependencies, impacts, risks and opportunities. This timeframe is useful to inform business planning and identify capital needs.*

### Medium-term

(2.1.1) From (years)

5

(2.1.3) To (years)

10

(2.1.4) How this time horizon is linked to strategic and/or financial planning

Pfizer uses a 5-10 year timeframe in assessing environmental dependencies, impacts, risks and opportunities. This time horizon aligns with Pfizer's current near-term climate targets and informs strategy and investment needed as we strive to achieve our emission reduction targets.

Long-term

(2.1.1) From (years)

10

(2.1.2) Is your long-term time horizon open ended?

Select from:

☒ No

(2.1.3) To (years)

30

(2.1.4) How this time horizon is linked to strategic and/or financial planning

Pfizer defines long-term as 10-30 years for assessing environmental dependencies, impacts, risks and opportunities. This timeframe aligns with the Corporate Net-Zero Standard as well as decarbonization timelines established by many government healthcare agencies globally.  
[Fixed row]

(2.2) Does your organization have a process for identifying, assessing, and managing environmental dependencies and/or impacts?

|  |                  |                                                       |
|--|------------------|-------------------------------------------------------|
|  | Process in place | Dependencies and/or impacts evaluated in this process |
|  | Select from:     | Select from:                                          |

|  | Process in place                        | Dependencies and/or impacts evaluated in this process             |
|--|-----------------------------------------|-------------------------------------------------------------------|
|  | <input checked="" type="checkbox"/> Yes | <input checked="" type="checkbox"/> Both dependencies and impacts |

[Fixed row]

**(2.2.1) Does your organization have a process for identifying, assessing, and managing environmental risks and/or opportunities?**

|  | Process in place                                        | Risks and/or opportunities evaluated in this process                             | Is this process informed by the dependencies and/or impacts process? |
|--|---------------------------------------------------------|----------------------------------------------------------------------------------|----------------------------------------------------------------------|
|  | Select from:<br><input checked="" type="checkbox"/> Yes | Select from:<br><input checked="" type="checkbox"/> Both risks and opportunities | Select from:<br><input checked="" type="checkbox"/> Yes              |

[Fixed row]

**(2.2.2) Provide details of your organization's process for identifying, assessing, and managing environmental dependencies, impacts, risks, and/or opportunities.**

**Row 1**

**(2.2.2.1) Environmental issue**

Select all that apply

☒ Climate change

#### (2.2.2.2) Indicate which of dependencies, impacts, risks, and opportunities are covered by the process for this environmental issue

*Select all that apply*

- ☒ Dependencies
- ☒ Impacts
- ☒ Risks
- ☒ Opportunities

#### (2.2.2.3) Value chain stages covered

*Select all that apply*

- ☒ Direct operations
- ☒ Upstream value chain
- ☒ Downstream value chain

#### (2.2.2.4) Coverage

*Select from:*

- ☒ Full

#### (2.2.2.5) Supplier tiers covered

*Select all that apply*

- ☒ Tier 1 suppliers

#### (2.2.2.7) Type of assessment

*Select from:*

- ☒ Qualitative and quantitative

#### (2.2.2.8) Frequency of assessment

*Select from:*

- ☒ More than once a year

#### (2.2.2.9) Time horizons covered

*Select all that apply*

- ☒ Short-term
- ☒ Medium-term
- ☒ Long-term

#### (2.2.2.10) Integration of risk management process

*Select from:*

- ☒ Integrated into multi-disciplinary organization-wide risk management process

#### (2.2.2.11) Location-specificity used

*Select all that apply*

- ☒ Site-specific
- ☒ Local
- ☒ National

#### (2.2.2.12) Tools and methods used

Enterprise Risk Management

- ☒ Enterprise Risk Management

International methodologies and standards

- ☒ ISO 14001 Environmental Management Systems
- ☒ Other international methodologies and standards, please specify :The International Best Track Archive for Climate Stewardship (IBTrACS)

Databases

- ☒ Nation-specific databases, tools, or standards, please specify :NASA, European Space Agency
- ☒ Other databases, please specify :World Resources Institute

Other

- ☒ Desk-based research
- ☒ External consultants
- ☒ Internal company methods
- ☒ Scenario analysis
- ☒ Other, please specify :World Climate Research Programme (WCRP), Coupled Model Intercomparison Project (CMIP6)

### (2.2.2.15) Risk types and criteria considered

Acute physical

- ☒ Drought
- ☒ Avalanche
- ☒ Heat wave
- ☒ Landslide
- ☒ Wildfires
- ☒ Flood (coastal, fluvial, pluvial, ground water)
- ☒ Storm (including blizzards, dust, and sandstorms)
- ☒ Subsidence
- ☒ Cold wave/frost
- ☒ Glacial lake outburst
- ☒ Cyclone, hurricane, typhoon
- ☒ Heavy precipitation (rain, hail, snow/ice)

Chronic physical

- ☒ Heat stress
- ☒ Soil erosion
- ☒ Solifluction
- ☒ Water stress
- ☒ Sea level rise
- ☒ Temperature variability
- ☒ Water quality at a basin/catchment level
- ☒ Precipitation or hydrological variability
- ☒ Increased severity of extreme weather events
- ☒ Water availability at a basin/catchment level
- ☒ Coastal erosion
- ☒ Soil degradation
- ☒ Permafrost thawing
- ☒ Ocean acidification
- ☒ Changing wind patterns
- ☒ Changing temperature (air, freshwater, marine water)
- ☒ Changing precipitation patterns and types (rain, hail, snow/ice)

#### Policy

- ☒ Carbon pricing mechanisms
- ☒ Changes to international law and bilateral agreements
- ☒ Changes to national legislation

#### Market

- ☒ Changing customer behavior
- ☒ Lack of availability and/or increased cost of raw materials

#### Reputation

- ☒ Impact on human health
- ☒ Increased concern and/or negative feedback from partners and stakeholders

#### Technology

- ☒ Transition to lower emissions technology and products

#### Liability

- ☒ Exposure to sanctions and litigation

### (2.2.2.16) Partners and stakeholders considered

*Select all that apply*

- |                                               |                                                       |
|-----------------------------------------------|-------------------------------------------------------|
| <input checked="" type="checkbox"/> NGOs      | <input checked="" type="checkbox"/> Regulators        |
| <input checked="" type="checkbox"/> Customers | <input checked="" type="checkbox"/> Local communities |
| <input checked="" type="checkbox"/> Employees |                                                       |
| <input checked="" type="checkbox"/> Investors |                                                       |
| <input checked="" type="checkbox"/> Suppliers |                                                       |

### (2.2.2.17) Has this process changed since the previous reporting year?

*Select from:*

- ☒ No

### (2.2.2.18) Further details of process

*Pfizer assesses climate change risk as part of our enterprise-level EHS and business continuity risk management processes. We conduct structured evaluations of risks with the potential to have a substantive impact on Pfizer and the effectiveness of controls through our Operational Risk Review (ORR) process. Under our ORR process, cross-functional program leaders and subject matter experts assess potential climate-related risks to Pfizer's direct operations and full value chain across four risk areas (external and reputational, physical, regulatory and legal, and market and technology). Acute and chronic physical risks related to climate change are managed through Pfizer's Loss Prevention and Business Resilience teams at the enterprise and local levels. Pfizer uses natural hazard analysis and mapping tools to monitor short-, medium- and long-term physical threats to internal operations and for more than 5,000 contract manufacturers and material suppliers. To gain insight into Pfizer's current and projected resilience to acute and chronic physical risks and opportunities, we conducted a TCFD-aligned risk assessment using a panel of criteria and hazards developed in partnership with a global sustainability consultancy. The qualitative scenario analyses for physical risk were guided using IPCC-aligned predictive modeling and usage of a blend of national and global datasets, setting a foundation for further engagement with internal stakeholders spanning across Pfizer's operational geographical footprint. After a validation process with internal stakeholders, we assigned impact ratings using Pfizer methodology applied in our Enterprise Risk Management (ERM) framework. Twenty risks and opportunities with the highest potential for impact were prioritized for further comprehensive assessment. Risks identified through these assessments are prioritized based on potential severity and the effectiveness of existing controls and, if necessary, risk mitigation actions are identified. This information is reviewed as part of the ORR, and mitigation of risk is monitored through Pfizer's Loss Prevention and Business Resilience programs and escalated to company leadership as needed to inform business strategy. Key risks identified through these processes are escalated to the Pfizer Global Supply (PGS) Quality & Risk Committee (PGS QRC). PGS QRC reports key risks to the Executive Compliance Committee, chaired by the CEO, and to the Regulatory and Compliance Committee (RCC) of the Board of Directors. The PGS QRC risk management process also informs Pfizer's ERM program, overseen by the Audit Committee of the Board of Directors. Pfizer's ERM program provides a framework for the identification and management of significant risks. Pfizer also monitors progress on climate commitments throughout the year. Issues or events that may impact our ability to achieve established commitments are identified and escalated.*

### Row 2

#### (2.2.2.1) Environmental issue

Select all that apply

☒ Water

#### (2.2.2.2) Indicate which of dependencies, impacts, risks, and opportunities are covered by the process for this environmental issue

Select all that apply

☒ Dependencies

☒ Impacts

☒ Risks

- ☒ Opportunities

### (2.2.2.3) Value chain stages covered

*Select all that apply*

- ☒ Direct operations
- ☒ Upstream value chain

### (2.2.2.4) Coverage

*Select from:*

- ☒ Full

### (2.2.2.5) Supplier tiers covered

*Select all that apply*

- ☒ Tier 1 suppliers

### (2.2.2.7) Type of assessment

*Select from:*

- ☒ Qualitative and quantitative

### (2.2.2.8) Frequency of assessment

*Select from:*

- ☒ More than once a year

### (2.2.2.9) Time horizons covered

*Select all that apply*

- ☒ Short-term
- ☒ Medium-term
- ☒ Long-term

### (2.2.2.10) Integration of risk management process

Select from:

- ☒ Integrated into multi-disciplinary organization-wide risk management process

### (2.2.2.11) Location-specificity used

Select all that apply

- ☒ Site-specific
- ☒ Local

### (2.2.2.12) Tools and methods used

Commercially/publicly available tools

- ☒ WRI Aqueduct
- ☒ Other commercially/publicly available tools, please specify :WBCSD Global Water Tool

Enterprise Risk Management

- ☒ Enterprise Risk Management

International methodologies and standards

- ☒ IPCC Climate Change Projections

Other

- ☒ External consultants
- ☒ Internal company methods
- ☒ Scenario analysis
- ☒ Other, please specify :Swiss RE CatNet; FEMA Flood Zone Maps

### (2.2.2.15) Risk types and criteria considered

Acute physical

- ☒ Cyclone, hurricane, typhoon

- ☒ Drought
- ☒ Flood (coastal, fluvial, pluvial, ground water)
- ☒ Storm (including blizzards, dust, and sandstorms)

#### Chronic physical

- ☒ Water stress
- ☒ Sea level rise
- ☒ Groundwater depletion
- ☒ Declining water quality
- ☒ Water quality at a basin/catchment level
- ☒ Increased severity of extreme weather events
- ☒ Water availability at a basin/catchment level
- ☒ Changing precipitation patterns and types (rain, hail, snow/ice)
- ☒ Increased levels of environmental pollutants in freshwater or marine bodies

#### Policy

- ☒ Changes to national legislation
- ☒ Poor enforcement of environmental regulation
- ☒ Regulation of discharge quality/volumes
- ☒ Statutory water withdrawal limits/changes to water allocation

#### Market

- ☒ Changing customer behavior
- ☒ Inadequate access to water, sanitation, and hygiene services (WASH)

#### Reputation

- ☒ Impact on human health
- ☒ Stakeholder conflicts concerning water resources at a basin/catchment level

### (2.2.2.16) Partners and stakeholders considered

*Select all that apply*

- ☒ NGOs
- ☒ Customers
- ☒ Employees
- ☒ Investors
- ☒ Regulators
- ☒ Local communities
- ☒ Water utilities at a local level
- ☒ Other water users at the basin/catchment level

☒ Suppliers

### (2.2.2.17) Has this process changed since the previous reporting year?

Select from:

☒ No

### (2.2.2.18) Further details of process

*Pfizer uses multiple tools to assess water-related risks. We use the World Resources Institute (WRI) Aqueduct, World Business Council for Sustainable Development (WBCSD), and Intergovernmental Panel on Climate Change (IPCC) Global Water tools to identify water-related risks with the potential to have substantive financial or strategic impact to the business. For WRI Aqueduct, we consider all the tool indicators in our assessment, including those related to water scarcity, water quality, environmental flows, and the accessibility of water. We perform a site-level assessment of water-related system operations and program management using an assessment methodology and risk weighting factors specific to the pharma industry developed with input from WRI, WSP and Antea (among others). Our process assesses short-, medium- and long-term acute and chronic water risks. As part of the site level assessment, Pfizer's Business Continuity Program undertakes a multi-step review of water supply for both production and fire protection for all Pfizer operations. Sites are also mapped against published flood maps and recommendations are made regarding flood prevention. Business continuity methodology is used to identify critical processes and products and then complete a dependency analysis/risk assessment. After applying this process, sites found to be vulnerable to water stress are required to develop water stewardship and business continuity plans. These assessments are conducted annually, or more frequently if there are significant changes to a facility. Subject matter experts conduct focused reviews for sites determined to be at higher risk. To gain insight into Pfizer's current and projected resilience to acute and chronic water-related risks and opportunities, we conducted a TCFD-aligned risk assessment using a panel of criteria and hazards developed in partnership with a multi-national sustainability advisory firm. We further refined our assessment process in 2023, expanding the scope of hazards considered and improving data quality by evaluating impacts at the asset level. The qualitative scenario analyses for physical risk were guided using IPCC-aligned predictive modeling and usage of a blend of national and global datasets, setting a foundation for further engagement with internal stakeholders spanning across Pfizer's operational geographical footprint. After a validation process with internal stakeholders, we assigned impact ratings using Pfizer methodology applied in our Enterprise Risk Management (ERM) framework. The conclusions of these risk assessment activities are used to inform an annual review of water-related risk through our Operational Risk Review process (ORR). Key risks are escalated to the Pfizer Global Supply (PGS) Quality & Risk Committee (PGS QRC). PGS QRC reports key risks to the Executive Compliance Committee, chaired by the CEO, and to the Regulatory and Compliance Committee (RCC) of the Board of Directors. The PGS QRC risk management process also informs Pfizer's ERM program, overseen by the Audit Committee of the Board of Directors. Pfizer's ERM program provides a framework for the identification and management of significant risks. Pfizer's Water Stewardship Position Statement, published in 2022, states our commitment to assessing water stress of our internal sites and key suppliers. Our position statement can be found on our website at: [Pfizer\\_Water\\_Stewardship\\_Public\\_Position\\_Statement\\_2022.pdf](#).*

[Add row]

### (2.2.7) Are the interconnections between environmental dependencies, impacts, risks and/or opportunities assessed?

#### (2.2.7.1) Interconnections between environmental dependencies, impacts, risks and/or opportunities assessed

Select from:

☒ Yes

### (2.2.7.2) Description of how interconnections are assessed

*The assessment of potential interconnections between environmental dependencies, impacts, risks and opportunities is integrated into our enterprise-level EHS and business continuity risk management processes. For example, a reliable supply of high quality water is critical to Pfizer's manufacturing operations, so water quality and availability in the short-, medium- and long-term timeframes are taken into consideration when assigning a weighting to water-related risk for these sites. Business continuity methodology is used to identify critical processes and products and then complete a dependency analysis/risk assessment. After applying this process, sites found to be vulnerable to water stress are required to develop water stewardship and business continuity plans.*

[Fixed row]

## (2.3) Have you identified priority locations across your value chain?

### (2.3.1) Identification of priority locations

Select from:

☒ Yes, we have identified priority locations

### (2.3.2) Value chain stages where priority locations have been identified

Select all that apply

☒ Direct operations

### (2.3.3) Types of priority locations identified

Locations with substantive dependencies, impacts, risks, and/or opportunities

☒ Locations with substantive dependencies, impacts, risks, and/or opportunities relating to water

### (2.3.4) Description of process to identify priority locations

*Pfizer uses multiple tools to assess climate- and water-related risks. We use the WRI Aqueduct, WBCSD, and IPCC Global Water tools to identify water-related risks with the potential to have substantive financial or strategic impact to the business. For WRI Aqueduct, we consider all the tool indicators in our assessment, including those related to water scarcity, water quality, environmental flows, and the accessibility of water. We perform a site-level assessment of water-related system*

operations and program management using an assessment methodology and risk weighting factors specific to the pharma industry developed with input from WRI, WSP and Antea (among others). Our process assesses short-, medium- and long-term acute and chronic water risks. As part of the site level assessment, Pfizer's Business Continuity Program undertakes a multi-step review of water supply for both production and fire protection for all Pfizer operations. Sites are also mapped against published flood maps and recommendations are made regarding flood prevention. Business continuity methodology is used to identify critical processes and products and then complete a dependency analysis/risk assessment. After applying this process, sites found to be vulnerable to water stress are required to develop water stewardship and business continuity plans. These assessments are conducted annually, or more frequently if there are significant changes to a facility. Subject matter experts conduct focused reviews for sites determined to be at higher risk. To improve our understanding of Pfizer's resilience to the impacts of climate change, we conducted an in-depth assessment of our potential exposure to physical risks and opportunities that could have a potential impact on our business using scenario analysis informed by data modeling insights from a global sustainability consultancy. Through this process we assessed risks, opportunities and impacts, with consideration of key sensitivities, site aspects, exposures, drivers and uncertainties.

### (2.3.5) Will you be disclosing a list/spatial map of priority locations?

Select from:

☒ Yes, we will be disclosing the list/geospatial map of priority locations

### (2.3.6) Provide a list and/or spatial map of priority locations

Q2.3\_Priority locations across value chain.pdf  
[Fixed row]

## (2.4) How does your organization define substantive effects on your organization?

### Risks

#### (2.4.1) Type of definition

Select all that apply

☒ Qualitative

☒ Quantitative

#### (2.4.2) Indicator used to define substantive effect

Select from:

☒ Other, please specify :Any costs (operating and/or capital)

### (2.4.3) Change to indicator

Select from:

☒ Absolute increase

### (2.4.5) Absolute increase/ decrease figure

100000000

### (2.4.6) Metrics considered in definition

Select all that apply

☒ Frequency of effect occurring

☒ Time horizon over which the effect occurs

☒ Likelihood of effect occurring

### (2.4.7) Application of definition

*For the purposes of this response, Pfizer defines “substantive” environmental risk as any climate-related or water security-related impact that could adversely impact the company’s business or financial condition or disrupt, delay or inhibit the supply of products designated as financially critical, medically necessary, and/or medically significant. For environmental risks that can be evaluated financially, Pfizer generally applies a threshold of \$100M for considering a risk substantive in this context. We also consider certain market, reputational, regulatory and technology risks to Pfizer as part of the assessment. Pfizer applies these criteria when assessing both direct and indirect environmental risks and opportunities. For the avoidance of doubt, CDP’s phrasing of “substantive” and our response to questions presenting “substantive” climate- or water-related risks should not be considered to relate to matters or facts that could be deemed “material” to a reasonable investor as referred to under US securities laws, similar requirements of other jurisdictions, or other voluntary frameworks. Investors should refer to disclosures in our Annual Report on Form 10-K (10-K) and in our other filings with the US SEC, including our quarterly reports on Form 10-Q and our current reports on Form 8-K, for a discussion of “material” matters.*

## Opportunities

### (2.4.1) Type of definition

Select all that apply

☒ Qualitative

☒ Quantitative

## (2.4.2) Indicator used to define substantive effect

Select from:

☒ Revenue

## (2.4.3) Change to indicator

Select from:

☒ Absolute increase

## (2.4.5) Absolute increase/ decrease figure

100000000

## (2.4.6) Metrics considered in definition

Select all that apply

☒ Frequency of effect occurring

☒ Time horizon over which the effect occurs

☒ Likelihood of effect occurring

## (2.4.7) Application of definition

*For the purposes of this response, Pfizer defines a “substantive” environmental opportunity as one that could potentially result in a reduction in operating expenses or an increase in revenue. Pfizer generally applies a threshold of \$100M for considering an opportunity substantive in this context. We also consider certain market, reputational, product, operational efficiency, and business resilience opportunities in our assessment. Pfizer applies these criteria when assessing both direct and indirect environmental opportunities. For the avoidance of doubt, CDP's phrasing of "substantive" and our response to questions presenting "substantive" climate- or water-related risks and opportunities should not be considered to relate to matters or facts that could be deemed “material” to a reasonable investor as referred to under US securities laws, similar requirements of other jurisdictions, or other voluntary frameworks. Investors should refer to disclosures in our Annual Report on Form 10-K (10-K) and in our other filings with the US SEC, including our quarterly reports on Form 10-Q and our current reports on Form 8-K, for a discussion of "material" matters.*

[Add row]

## **(2.5) Does your organization identify and classify potential water pollutants associated with its activities that could have a detrimental impact on water ecosystems or human health?**

### **(2.5.1) Identification and classification of potential water pollutants**

Select from:

☒ Yes, we identify and classify our potential water pollutants

### **(2.5.2) Details of policies and processes in place to identify and classify potential water pollutants**

*Pfizer identifies and classifies potential water pollutants through site-level environmental management processes designed to protect human health and the environment. We work to meet applicable local water quality requirements and use Pfizer corporate environmental standards to help ensure consistent environmental protection across sites globally. Indicators used include wastewater discharges, compliance with local water quality requirements, and wastewater Predicted No Effect Concentrations (PNECs) for active pharmaceutical ingredients. Pfizer also uses risk-based assessments for manufacturing discharges and follows the AMR Industry Alliance Antibiotic Manufacturing Standard and related framework for antibiotic wastewater management. Methodologies are based on applicable local requirements, Pfizer corporate standards, recognized international frameworks, and industry-published PNECs where relevant. Potential impacts are monitored and tracked through regular site assessments, water stewardship plans with actions, timelines and metrics, project risk assessments for new capital projects, and management of change reviews for major manufacturing process changes.*

*[Fixed row]*

## **(2.5.1) Describe how your organization minimizes the adverse impacts of potential water pollutants on water ecosystems or human health associated with your activities.**

Row 1

### **(2.5.1.1) Water pollutant category**

Select from:

☒ Other synthetic organic compounds

### **(2.5.1.2) Description of water pollutant and potential impacts**

*Pfizer is committed to limiting discharges to wastewater from our manufacturing processes, including organic compounds and active pharmaceutical ingredients, using environmental risk assessment methodologies, wastewater discharge control practices and technologies, and responsible waste management.*

### **(2.5.1.3) Value chain stage**

*Select all that apply*

- ☒ Direct operations
- ☒ Upstream value chain
- ☒ Downstream value chain
- ☒ Other, please specify :Product use phase

### **(2.5.1.4) Actions and procedures to minimize adverse impacts**

*Select all that apply*

- ☒ Upgrading of process equipment/methods
- ☒ Reduction or phase out of hazardous substances
- ☒ Provision of best practice instructions on product use
- ☒ Implementation of integrated solid waste management systems
- ☒ Requirement for suppliers to comply with regulatory requirements
- ☒ Industrial and chemical accidents prevention, preparedness, and response
- ☒ Assessment of critical infrastructure and storage condition (leakages, spillages, pipe erosion etc.) and their resilience
- ☒ Other, please specify :Requirement for suppliers to comply with standards beyond regulatory requirements; discharge treatment using sector-specific processes to ensure compliance with regulatory requirements.

### **(2.5.1.5) Indicators for measuring and evaluating the success of the procedure**

*Select all that apply*

- ☒ Compliance with discharge permits / regulatory limits
- ☒ Reduction in pollutant concentration or load against a baseline
- ☒ Third-party audits and/or certification

### **(2.5.1.6) Please explain**

*Pfizer is committed to minimizing our impact on water resources and ensuring our operations protect human health and the environment. We are committed to compliance with all applicable laws, including managing wastewater in line with permit requirements. Our global Water Stewardship Standard requires sites to assess and control risks to water from hazardous substances. We are committed to managing wastewater responsibly at our sites and collaborating with suppliers to do the same. We remain dedicated to limiting discharge of active pharmaceutical ingredients (API) to wastewater from our manufacturing processes following the responsible manufacturing practices set out in the AMR Industry Alliance (AMRIA) Antibiotic Manufacturing Standard (AMR Standard). Pfizer maintains a leadership role within AMRIA, where we currently chair the manufacturing working group's science team. In 2025, Pfizer substantially advanced our pharmaceuticals in the environment program, building on certifications achieved in prior years and demonstrating continued progress against the AMR Standard across our dynamic global supply chain. Since its launch in 2023, three Pfizer sites and four of our suppliers have achieved the independent third-party British Standards Institution Kitemark for Minimized Risk of Antimicrobial Resistance certification for certain antibiotic APIs and drug products (DPs). In 2025, we received certification for one of our DPs manufactured at our Melbourne, Australia site.*

*[Add row]*

## C3. Disclosure of risks and opportunities

**(3.1) Have you identified any environmental risks which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?**

### Climate change

#### (3.1.1) Environmental risks identified

Select from:

☒ Yes, both in direct operations and upstream/downstream value chain

### Water

#### (3.1.1) Environmental risks identified

Select from:

☒ No

#### (3.1.2) Primary reason why your organization does not consider itself to have environmental risks in your direct operations and/or upstream/downstream value chain

Select from:

☒ Environmental risks exist, but none with the potential to have a substantive effect on our organization

#### (3.1.3) Please explain

*Pfizer uses a comprehensive risk assessment methodology to identify and evaluate water-related risks with the potential to have substantive financial or strategic impact to the business. These assessments are refreshed annually, or more frequently if there are significant changes to a facility. We have also completed detailed asset-level scenario analyses to assess potential medium- and long-term water-related risks. Based on the findings of these assessments, we consider our current business model and strategy to be resilient and have not identified any water-related risks that pose a substantive risk to our overall operations.*

*[Fixed row]*

**(3.1.1) Provide details of the environmental risks identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future.**

## **Climate change**

### **(3.1.1.1) Risk identifier**

*Select from:*

☒ Risk1

### **(3.1.1.3) Risk types and primary environmental risk driver**

Market

☒ Changing customer behavior

### **(3.1.1.4) Value chain stage where the risk occurs**

*Select from:*

☒ Downstream value chain

### **(3.1.1.6) Country/area where the risk occurs**

*Select all that apply*

☒ Canada

☒ France

☒ Norway

☒ Sweden

☒ Austria

☒ Luxembourg

☒ Netherlands

☒ Switzerland

☒ United Kingdom

☒ Belgium

☒ Denmark

☒ Iceland

☒ Ireland

☒ Kazakhstan

### (3.1.1.9) Organization-specific description of risk

*Pfizer has identified transition risks associated with evolving healthcare system policies and procurement practices as countries and national healthcare systems advance toward Net-Zero and other ambitious greenhouse gas reduction objectives. Pfizer has received sustainability-related information requests from healthcare systems and procurement authorities in 14 countries where it sells medicines, many of which have established Net-Zero targets in law or policy. Meeting these expectations requires coordinated decarbonization across Pfizer's value chain. If product-level and upstream decarbonization efforts do not keep pace with changing tender requirements, Pfizer may face reduced competitiveness, resulting in revenue being at risk, including potential loss of tender opportunities or reduced market share.*

### (3.1.1.11) Primary financial effect of the risk

Select from:

- ☒ Decreased revenues due to reduced demand for products and services

### (3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

- ☒ Medium-term

### (3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

- ☒ Likely

### (3.1.1.14) Magnitude

Select from:

- ☒ Medium

### (3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

*The primary financial effect of this risk is revenue at risk due to potential exclusion from, or reduced competitiveness within, healthcare procurement and tender processes where sustainability criteria are applied. As environmental requirements become more embedded in tender evaluations, there is an increased risk that Pfizer products may be less competitive if they do not meet evolving criteria, which may result in reduced tender success rates or lower awarded volumes.*

### (3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☒ Yes

### (3.1.1.21) Anticipated financial effect figure in the medium-term – minimum (currency)

0

### (3.1.1.22) Anticipated financial effect figure in the medium-term – maximum (currency)

100000000

### (3.1.1.25) Explanation of financial effect figure

*The disclosed range reflects an internal assessment of potential revenue at risk from increasing sustainability requirements in healthcare procurement, evaluated across four scenario combinations (business-as-usual vs. Net-Zero) that compare Pfizer's internal decarbonization pathway with external healthcare system scenarios based on stated policies and Net-Zero-aligned pathways. For the medium-term (2035), the lower bound is \$0, reflecting scenarios where either (i) sustainability requirements remain at an early or pre-enforcement stage or (ii) Pfizer's performance remains aligned with applicable criteria, resulting in no revenue exposure. The upper bound of approximately \$100M reflects a scenario in which external requirements become more stringent while Pfizer follows a slower decarbonization pathway, leading to potential misalignment with tender criteria. The estimate is based on comparing product- and country-level environmental performance (e.g., emissions, packaging, and related metrics) against anticipated procurement criteria across key markets. Where misalignment is identified and requirements are enforced, a portion of product revenue is considered at risk, reflecting potential impacts such as reduced tender success rates, lower awarded volumes, or increased pricing pressure, rather than automatic market exclusion. Key assumptions include holding product revenues constant over time, applying a maximum exposure ceiling of 100% at the product level, and treating early-stage requirements as forward-looking signals rather than immediate financial impacts. The potential financial impact should not be interpreted as a precise prediction of future financial performance. Rather, it is a scenario-based estimate intended to illustrate the possible magnitude of exposure and represents Pfizer's acknowledgement that, under certain scenarios and assumptions, this risk could become financially substantive. This analysis is not a financial forecast, but an exploratory assessment designed to inform strategic planning and risk management.*

### (3.1.1.26) Primary response to risk

Compliance, monitoring and targets

☒ Establish organization-wide targets

### (3.1.1.27) Cost of response to risk

### (3.1.1.28) Explanation of cost calculation

*The annual cost of response provided (\$106M) includes an estimated \$10M in staffing and consulting costs and approximately \$96M in incremental OPEX and CAPEX investment to identify, evaluate and advance energy efficiency and decarbonization projects completed in 2025. The estimated OPEX and CAPEX spend is derived from project data entered by sites in Pfizer's enterprise environmental reporting system. The portion of that spend associated with emissions reduction was estimated based on project type, and the resulting values were aggregated to provide total projected incremental OPEX and CAPEX spend. The estimated \$10M in staffing and consulting costs were added to the \$96M project spend to arrive at the \$106M estimate. Our annual energy efficiency and decarbonization investment, which is integrated within our annual operating planning cycle, may change in the future subject to market and technological developments as we seek opportunities to decarbonize our company operations.*

### (3.1.1.29) Description of response

*Pfizer evaluates climate change risk as part of its Operating Risk Review process. We monitor regulatory risks arising from current and/or expected local, state, regional, national, or international regulations or legislation related to climate change and evaluate the impact on an ongoing basis. Pfizer manages risk associated with emerging regulations and/or carbon pricing initiatives through effective GHG emission reduction goals and internal energy efficiency targets to reduce potential costs associated with the purchase or generation of energy. In 2025 we invested \$96M, not including staffing costs for internal energy conservation program management, to implement around 300 projects across the company that are expected to result in an annual GHG emissions reduction of over 35,800 mt CO<sub>2</sub>e and an estimated annual savings of around \$11.7M.*

## Climate change

### (3.1.1.1) Risk identifier

Select from:

☒ Risk2

### (3.1.1.3) Risk types and primary environmental risk driver

Acute physical

☒ Tornado

### (3.1.1.4) Value chain stage where the risk occurs

Select from:

- ☒ Direct operations

#### (3.1.1.6) Country/area where the risk occurs

Select all that apply

- ☒ United States of America

#### (3.1.1.9) Organization-specific description of risk

*Climate change presents risks to our operations, including more frequent and severe weather events that could impact our facilities and those of our suppliers. Pfizer conducts comprehensive risk assessments to evaluate acute and chronic physical climate risks across our sites and key supplier locations. We use advanced modeling tools like NathanRE and ERM's Climate Impact Platform to assess short-, medium-, and long-term risks from major climate hazards. Many Pfizer sites in the U.S. are in regions prone to severe storms, including tornadoes. NathanRE modeling, confirmed by site-specific risk assessments, indicates high tornado risk for several Midwest facilities: four manufacturing sites (two in Michigan, one in Wisconsin, one in Kansas), one R&D site in Missouri, and two logistics centers (Wisconsin and Tennessee). We also identified five manufacturing sites, four R&D locations, one office, and three storage facilities across North America with medium tornado risk, including sites in Massachusetts (2), North Carolina (5), Ohio (1), Connecticut (2), New Jersey (1), and New York (2). In July 2023, our Rocky Mount, NC manufacturing site—located in a medium-risk region—was damaged by a tornado but returned to full operation by mid-2024. While future climate-related risks may affect operations or supply chains, we've implemented mitigation measures including business continuity plans, structural resilience actions, and active weather monitoring and crisis response protocols.*

#### (3.1.1.11) Primary financial effect of the risk

Select from:

- ☒ Other, please specify :Inventory losses, disruption in production capacity, and increased indirect costs

#### (3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

- ☒ Short-term

#### (3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

- ☒ About as likely as not

#### (3.1.1.14) Magnitude

Select from:

☒ Medium-low

#### (3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

*While it is unlikely that a severe weather event would result in the complete loss of a Pfizer facility, a tornado strike at one of our sites in the U.S. could result in significant operational disruptions, including physical damage to buildings, equipment, and infrastructure. This may lead to temporary or prolonged shutdowns, delays in production or research activities, and interruptions in the distribution of critical medicines. Damage to utilities and transportation networks could further hinder recovery efforts. Additionally, such an event could impact employee safety, increase costs related to repairs and business continuity, and strain supply chain resilience—especially if the affected site plays a key role in manufacturing or logistics.*

#### (3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☒ Yes

#### (3.1.1.19) Anticipated financial effect figure in the short-term – minimum (currency)

50000000

#### (3.1.1.20) Anticipated financial effect figure in the short-term – maximum (currency)

500000000

#### (3.1.1.25) Explanation of financial effect figure

*Given that it is unlikely that a severe weather event, such as a tornado, would result in the complete loss of a Pfizer facility, the potential financial impact estimate is based on a percentage of the total insurable value of facilities identified as being at risk. This approach reflects our actual experience, which shows that such events typically cause partial damage rather than total loss. As a result, while the estimate provides a conservative view of potential exposure, the actual financial impact is expected to be significantly lower.*

#### (3.1.1.26) Primary response to risk

Policies and plans

☒ Other policies or plans, please specify :Maintain business resilience and loss prevention plans

### (3.1.1.27) Cost of response to risk

8000000

### (3.1.1.28) Explanation of cost calculation

*The estimated cost of response includes approximately \$2.3M in staffing costs to manage business continuity programs at the site and corporate level and approximately \$5.7M for subscriptions and services to perform loss prevention assessments at sites and maintain access to predictive tools to facilitate risk assessment.*

### (3.1.1.29) Description of response

*Pfizer's primary controls for the management of acute and chronic physical risks are our infrastructure, systems, and resilience programs. Given our global footprint, certain facilities are exposed to physical risks, including severe weather events in some regions. Through site-specific risk assessments, enterprise risk management processes, and Loss Prevention and Business Resilience programs, Pfizer identifies and mitigates potential vulnerabilities, implements resilience measures, and maintains business continuity plans that include alternative sourcing options and buffer inventory, as appropriate. Pfizer maintains resources for assessing and establishing business continuity arrangements. Business continuity professionals are retained as staff and consultants to help ensure these plans are updated and exercised at least annually, and key colleagues on site are trained on the plans' content and implementation.*

[Add row]

## (3.1.2) Provide the amount and proportion of your financial metrics from the reporting year that are vulnerable to the substantive effects of environmental risks.

### Climate change

#### (3.1.2.1) Financial metric

Select from:

☒ Other, please specify :Cost of sales, partially offset by insurance recoveries.

#### (3.1.2.2) Amount of financial metric vulnerable to transition risks for this environmental issue (unit currency as selected in 1.2)

**(3.1.2.3) % of total financial metric vulnerable to transition risks for this environmental issue**

Select from:

☒ Less than 1%**(3.1.2.4) Amount of financial metric vulnerable to physical risks for this environmental issue (unit currency as selected in 1.2)**

500000000

**(3.1.2.5) % of total financial metric vulnerable to physical risks for this environmental issue**

Select from:

☒ 1-10%**(3.1.2.7) Explanation of financial figures**

*The financial exposure to physical risk was estimated based on a percentage of the total insurable value of at-risk facilities, reflecting the likelihood of partial damage rather than total loss from severe weather events.*

**Climate change****(3.1.2.1) Financial metric**

Select from:

☒ Revenue**(3.1.2.2) Amount of financial metric vulnerable to transition risks for this environmental issue (unit currency as selected in 1.2)**

100000000

**(3.1.2.3) % of total financial metric vulnerable to transition risks for this environmental issue**

Select from:  
☒ Less than 1%

(3.1.2.4) Amount of financial metric vulnerable to physical risks for this environmental issue (unit currency as selected in 1.2)

0

(3.1.2.5) % of total financial metric vulnerable to physical risks for this environmental issue

Select from:  
☒ Less than 1%

(3.1.2.7) Explanation of financial figures

The financial exposure to transition risk (changing customer behavior) reflects an internal assessment of potential revenue at risk from increasing sustainability requirements in healthcare procurement. The estimated value of approximately \$100M (less than 1% of total revenue) represents scenarios where external requirements become more stringent and may be enforced, leading to potential misalignment with product environmental performance and resulting in impacts such as reduced tender success.  
[Add row]

(3.3) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations?

|  | Water-related regulatory violations                    | Comment                                          |
|--|--------------------------------------------------------|--------------------------------------------------|
|  | Select from:<br><input checked="" type="checkbox"/> No | There were no water-related violations for 2025. |

[Fixed row]

### **(3.5) Are any of your operations or activities regulated by a carbon pricing system (i.e. ETS, Cap & Trade or Carbon Tax)?**

Select from:

☒ Yes

#### **(3.5.1) Select the carbon pricing regulation(s) which impact your operations.**

Select all that apply

☒ EU ETS

☒ Ireland carbon tax

☒ Spain carbon tax

☒ Other carbon tax, please specify :Canada Carbon Tax, Croatia Carbon Tax, German Fuel Emissions Trading Act, UK Climate Change Levy

#### **(3.5.2) Provide details of each Emissions Trading Scheme (ETS) your organization is regulated by.**

##### **EU ETS**

##### **(3.5.2.1) % of Scope 1 emissions covered by the ETS**

11.87

##### **(3.5.2.2) Scope 2 emissions approach**

Select from:

☒ Market-based

##### **(3.5.2.3) % of Scope 2 emissions covered by the ETS**

0

##### **(3.5.2.4) Period start date**

01/01/2025

#### (3.5.2.5) Period end date

12/31/2025

#### (3.5.2.6) Allowances allocated

15724

#### (3.5.2.7) Allowances purchased

52778

#### (3.5.2.8) Verified Scope 1 emissions in metric tons CO2e

72891

#### (3.5.2.9) Verified Scope 2 emissions in metric tons CO2e

0

#### (3.5.2.10) Details of ownership

Select from:

☒ Facilities we own and operate

#### (3.5.2.11) Comment

N/A

[Fixed row]

**(3.5.3) Complete the following table for each of the tax systems you are regulated by.**

**Ireland carbon tax**

#### (3.5.3.1) Period start date

01/01/2025

**(3.5.3.2) Period end date**

12/31/2025

**(3.5.3.3) % of total Scope 1 emissions covered by tax**

10.8

**(3.5.3.4) Total cost of tax paid**

1043278

**Spain carbon tax**

**(3.5.3.1) Period start date**

01/01/2025

**(3.5.3.2) Period end date**

12/31/2025

**(3.5.3.3) % of total Scope 1 emissions covered by tax**

0.4

**(3.5.3.4) Total cost of tax paid**

7732

**Other carbon tax, please specify**

**(3.5.3.1) Period start date**

**(3.5.3.2) Period end date**

12/31/2025

**(3.5.3.3) % of total Scope 1 emissions covered by tax**

2.8

**(3.5.3.4) Total cost of tax paid**

591131

**(3.5.3.5) Comment**

*Includes UK Climate Change Levy, German Fuel Emissions Trading Act, and Croatia Carbon Tax  
[Fixed row]*

**(3.5.4) What is your strategy for complying with the systems you are regulated by or anticipate being regulated by?**

*Pfizer's strategy is to set corporate GHG reduction goals aligned with IPCC recommendations which in turn drive the sites to implement energy reduction projects and equipment upgrades to reduce their carbon footprint. Through three successive emissions reduction goals, Pfizer reduced GHG emissions by more than 60% from 2000 through 2020. We have established a near-term goal to further reduce GHG emissions by 46% by 2030 from a 2019 baseline and aim to achieve the voluntary Net-Zero Standard by 2040. Pfizer's Scope 1 and 2 GHG emissions in 2025 were approximately 34% lower than 2024 and 41% lower than the 2019 baseline. By reducing our carbon footprint, we help minimize the impact of the carbon pricing requirements that apply to our operations. In 2025, Pfizer continued to advance efforts to reduce GHG emissions from our facilities by focusing on energy efficiency, procuring low-carbon and renewable energy, and operational optimization across our global portfolio. Among our actions, we implemented energy efficiency projects at manufacturing and research and development (R&D) sites, increased the use of renewable electricity where it makes good business sense, and advanced electrification and process improvements to reduce on-site reliance on fossil fuels. These efforts were supported by capital investments, engineering and design practices, and site-level performance management to identify and address emissions hotspots. For example, Pfizer's Kalamazoo Modular Aseptic Processing project achieved LEED Gold certification, reflecting the integration of green building principles into facility design and construction. Facility-level actions are complemented by Pfizer's investments in no- and low-carbon technologies at our sites and through virtual power purchase agreements (VPPAs) that enable sourcing of renewable energy. VPPAs supporting solar projects in Spain and the United States that became operational in 2025 generate Renewable Energy Certificates (RECs) that cover 100% of Pfizer's purchased electricity in North America and the European Union, representing approximately 59% of our global electricity consumption. Pfizer continues to explore and advance country- and market-specific solutions to source renewable electricity across the remainder of our global operations, taking into account local market structures, availability, and regulatory requirements. Certain refrigerants (particularly fluorinated ("F") gases), while essential for the safe and reliable manufacture of medicines and vaccines, can contribute to global warming.*

That is why we set expectations for our sites to manage the refrigerants we use in air conditioning, refrigeration, and cooling systems responsibly and lawfully. This includes minimizing releases, eliminating use of certain ozone-depleting compounds and high global warming potential materials, advancing leak detection and repair practices, and requiring a review process for new refrigerants to ensure they align with our environmental and operational expectations. Refrigerant emissions currently account for approximately 6% of Pfizer’s Scope 1 GHG emissions. Pfizer’s fleet of vehicles, the majority of which are used by our commercial teams to reach healthcare providers to facilitate education and engagement, accounted for approximately 11% percent of our total Scope 1 GHG emissions in 2025. Pfizer’s multifaceted strategy to reduce GHG emissions from our fleet includes increasing the use of hybrid and other low-emissions vehicles, and transitioning to battery electric vehicles (BEVs) where feasible. Pfizer continued to advance our transition to BEVs in 2025, expanding deployment to three additional markets for a total of 13 markets globally. BEVs currently represent approximately 6% of Pfizer’s global fleet, totaling about 900 vehicles. In the United Kingdom, 91% of Pfizer’s fleet is now BEVs, reflecting continued progress along Pfizer’s roadmap toward 2040. For internal combustion vehicles that remain in service, we continue to advance responsible driving practices including effective route planning to ensure fuel efficiency until those vehicles can be retired.

**(3.6) Have you identified any environmental opportunities which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?**

|                |                                                                                                                            |
|----------------|----------------------------------------------------------------------------------------------------------------------------|
|                | Environmental opportunities identified                                                                                     |
| Climate change | Select from:<br><input checked="" type="checkbox"/> Yes, we have identified opportunities, and some/all are being realized |
| Water          | Select from:<br><input checked="" type="checkbox"/> Yes, we have identified opportunities, and some/all are being realized |

[Fixed row]

**(3.6.1) Provide details of the environmental opportunities identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future.**

**Climate change**

**(3.6.1.1) Opportunity identifier**

Select from:

☒ Opp1

### (3.6.1.3) Opportunity type and primary environmental opportunity driver

Resource efficiency

☒ Increased efficiency of production and/or distribution processes

### (3.6.1.4) Value chain stage where the opportunity occurs

Select from:

☒ Direct operations

### (3.6.1.5) Country/area where the opportunity occurs

Select all that apply

☒ China

☒ India

☒ Italy

☒ Japan

☒ Spain

☒ Croatia

☒ Germany

☒ Ireland

☒ Morocco

☒ Argentina

☒ Brazil

☒ Mexico

☒ Sweden

☒ Austria

☒ Belgium

☒ Australia

☒ Indonesia

☒ Singapore

☒ United States of America

### (3.6.1.8) Organization specific description

*Pfizer continually seeks to drive efficiency improvements within our operations. By replacing and/or optimizing efficiency of existing production, HVAC, and utility equipment such as boilers, we strive to reduce energy consumption and GHG emissions and lower our operating costs. Pfizer aims to achieve the voluntary Net-Zero Standard by 2040 and has near-term commitments to reduce Scope 1 and 2 emissions by 46% by 2030 from a 2019 baseline. We expect to achieve these targets in part by investing in equipment optimization and replacement at our sites. We have established internal targets to drive project implementation at our manufacturing facilities, and manufacturing leadership monitors progress toward these targets. We completed around 300 emission reduction projects at 35 sites around the world in*

2025, investing approximately \$96M in both incremental OPEX and CAPEX expenditures to reduce emissions by nearly 35,8000 mt CO2e annually. These projects are projected to reduce operating costs by approximately \$11.7M annually, with approximately 33% of savings resulting from the replacement and optimization of HVAC systems, and the rest from a combination of chiller, boiler, compressed air, steam, lighting, and other improvement projects.

### (3.6.1.9) Primary financial effect of the opportunity

Select from:

☒ Reduced indirect (operating) costs

### (3.6.1.10) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization

Select all that apply

☒ Short-term

### (3.6.1.11) Likelihood of the opportunity having an effect within the anticipated time horizon

Select from:

☒ Virtually certain (99–100%)

### (3.6.1.12) Magnitude

Select from:

☒ Medium-low

### (3.6.1.14) Anticipated effect of the opportunity on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Savings from the implementation of emissions reduction projects are projected to have low impact on Pfizer's financial position, financial performance, and cash flows.

### (3.6.1.15) Are you able to quantify the financial effects of the opportunity?

Select from:

☒ Yes

#### **(3.6.1.17) Anticipated financial effect figure in the short-term - minimum (currency)**

0

#### **(3.6.1.18) Anticipated financial effect figure in the short-term – maximum (currency)**

58000000

#### **(3.6.1.23) Explanation of financial effect figures**

*The estimated financial impact of approximately \$58M reflects the total projected savings from all energy-related projects completed in 2025. Estimated annual savings for each project are used to calculate total savings, beginning 2026 and continuing through the end of 2030.*

#### **(3.6.1.24) Cost to realize opportunity**

96000000

#### **(3.6.1.25) Explanation of cost calculation**

*The cost to realize the opportunity outlined above includes approximately \$96M in incremental OPEX and CAPEX investments to identify, evaluate, and implement energy efficiency and decarbonization projects completed in 2025. These projects typically have a payback period of 4-10 years or less and have a lifetime greater than 6 years.*

#### **(3.6.1.26) Strategy to realize opportunity**

*Pfizer's Environmental Impact Reduction Standard requires all sites to develop a systematic approach to conserve energy and improve efficiency. Sites identified as medium and large energy users are required to establish environmental sustainability teams and to develop and maintain sustainability master plans that include prioritized emission reduction opportunities. Project implementation is monitored at the corporate level with performance reports provided to company leadership quarterly. Pfizer has historically invested each year to reduce energy demand through end-of-life asset replacement, efficiency improvements, and installation of renewable technologies. In 2025, we invested approximately \$96M in both OPEX and CAPEX expenditures (incremental) in energy efficiency projects. These projects are projected to reduce operating costs by approximately \$11.7M annually. Projects with the most significant annual savings include HVAC-related improvements at our site in Catania, Italy and Grange Castle, Ireland; energy efficiency projects in Kalamazoo, Michigan and Rocky Mount, North Carolina; green design initiatives in Freiburg, Germany; and steam distribution upgrades in Groton, Connecticut. Projects completed in 2025 are expected to reduce Pfizer's Scope 1 and 2 emissions by nearly 35,800 mt CO<sub>2</sub>e annually.*

## **Water**

### (3.6.1.1) Opportunity identifier

Select from:

☒ Opp2

### (3.6.1.3) Opportunity type and primary environmental opportunity driver

Resource efficiency

☒ Reduced water usage and consumption

### (3.6.1.4) Value chain stage where the opportunity occurs

Select from:

☒ Direct operations

### (3.6.1.5) Country/area where the opportunity occurs

Select all that apply

☒ India

☒ Spain

☒ Brazil

☒ Ireland

☒ Argentina

☒ Australia

☒ United States of America

### (3.6.1.6) River basin where the opportunity occurs

Select all that apply

☒ Other, please specify :Multiple river basins

### (3.6.1.8) Organization specific description

*Pfizer requires our manufacturing and research and development sites to maintain site master plans that identify opportunities to reduce their environmental footprint. Sites are expected to set annual performance targets and to identify, prioritize, and implement water conservation projects to offset increases due to increased*

production. Project information is entered into a global database where it is monitored by sustainability champions at the site, business, and corporate levels. Progress is reported to business leadership quarterly.

#### **(3.6.1.9) Primary financial effect of the opportunity**

Select from:

☒ Reduced indirect (operating) costs

#### **(3.6.1.10) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization**

Select all that apply

☒ Short-term

#### **(3.6.1.11) Likelihood of the opportunity having an effect within the anticipated time horizon**

Select from:

☒ Virtually certain (99–100%)

#### **(3.6.1.12) Magnitude**

Select from:

☒ Low

#### **(3.6.1.14) Anticipated effect of the opportunity on the financial position, financial performance and cash flows of the organization in the selected future time horizons**

*While not considered substantive as defined for the purposes of this submittal, we have included this opportunity as it may be of interest to our stakeholders. Savings from the implementation of water conservation projects are projected to have minimal impact on Pfizer's financial position, financial performance and cash flows.*

#### **(3.6.1.15) Are you able to quantify the financial effects of the opportunity?**

Select from:

☒ Yes

#### **(3.6.1.17) Anticipated financial effect figure in the short-term - minimum (currency)**

### (3.6.1.18) Anticipated financial effect figure in the short-term – maximum (currency)

586000

### (3.6.1.23) Explanation of financial effect figures

*The estimated financial impact of approximately \$586,000 reflects the total projected savings from all water-related projects completed in 2025. Estimated annual savings for each project are used to calculate total savings, beginning in 2026 and continuing through the end of 2030.*

### (3.6.1.24) Cost to realize opportunity

179000

### (3.6.1.25) Explanation of cost calculation

*The cost to realize the opportunity outlined above includes approximately \$179,000 in incremental OPEX and CAPEX investments to identify, evaluate, and implement water conservation projects completed in 2025.*

### (3.6.1.26) Strategy to realize opportunity

*The availability of and access to clean water is a basic human need globally that must be addressed locally. Pfizer's Water Stewardship position statement describes our commitment to being good stewards of the water we use to make medicines and vaccines, particularly in water-stressed areas. To this end, we completed water stress assessments at all Pfizer sites to identify water quality, scarcity, and availability risks across our network and are developing action plans for sites with elevated risk scores. These plans include elements such as quantifying water use, implementing mitigation plans and establishing water conservation targets, protecting water quality, improving wastewater treatment where necessary, evaluating recycling practices, and engaging with surrounding communities. We will measure progress at our internal sites while engaging with our key suppliers in water stressed areas to encourage them to develop and implement similar action plans.*

## Climate change

### (3.6.1.1) Opportunity identifier

Select from:

☒ Opp3

### (3.6.1.3) Opportunity type and primary environmental opportunity driver

Markets

- ☒ Use of public sector incentives

### (3.6.1.4) Value chain stage where the opportunity occurs

Select from:

- ☒ Downstream value chain

### (3.6.1.5) Country/area where the opportunity occurs

Select all that apply

- |                                                    |                                                |
|----------------------------------------------------|------------------------------------------------|
| <input checked="" type="checkbox"/> Canada         | <input checked="" type="checkbox"/> Belgium    |
| <input checked="" type="checkbox"/> France         | <input checked="" type="checkbox"/> Denmark    |
| <input checked="" type="checkbox"/> Norway         | <input checked="" type="checkbox"/> Iceland    |
| <input checked="" type="checkbox"/> Sweden         | <input checked="" type="checkbox"/> Ireland    |
| <input checked="" type="checkbox"/> Austria        | <input checked="" type="checkbox"/> Kazakhstan |
| <input checked="" type="checkbox"/> Luxembourg     |                                                |
| <input checked="" type="checkbox"/> Netherlands    |                                                |
| <input checked="" type="checkbox"/> Switzerland    |                                                |
| <input checked="" type="checkbox"/> United Kingdom |                                                |

### (3.6.1.8) Organization specific description

*Across key healthcare markets, national healthcare systems are advancing toward Net-Zero objectives and increasingly integrating sustainability criteria into procurement and tender processes. These developments include requirements related to supplier Net-Zero commitments, product lifecycle emissions, environmental management systems, and sustainable packaging. As a result, healthcare providers are increasingly requesting environmental data and sustainability information from pharmaceutical suppliers to support procurement decisions. Pfizer is actively responding to these requests and aligning its operations and value chain with evolving expectations. This trend presents an opportunity for Pfizer to strengthen its competitive positioning in tender processes by demonstrating progress against its climate commitments. By continuing to advance its decarbonization strategy and providing transparent environmental data, Pfizer may increase its attractiveness as a supplier and support continued or enhanced participation in key markets where sustainability-linked procurement is expanding.*

### (3.6.1.9) Primary financial effect of the opportunity

Select from:

- ☒ Increased revenues resulting from increased demand for products and services

### (3.6.1.10) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization

Select all that apply

- ☒ Medium-term

### (3.6.1.11) Likelihood of the opportunity having an effect within the anticipated time horizon

Select from:

- ☒ Likely (66–100%)

### (3.6.1.12) Magnitude

Select from:

- ☒ Medium

### (3.6.1.14) Anticipated effect of the opportunity on the financial position, financial performance and cash flows of the organization in the selected future time horizons

*This opportunity has the potential to result in increased revenues through improved competitiveness in healthcare procurement and tender processes. As sustainability criteria become more embedded in purchasing decisions, alignment with these expectations may support Pfizer in maintaining or increasing market share and securing additional tender opportunities.*

### (3.6.1.15) Are you able to quantify the financial effects of the opportunity?

Select from:

- ☒ Yes

### (3.6.1.19) Anticipated financial effect figure in the medium-term - minimum (currency)

0

### (3.6.1.20) Anticipated financial effect figure in the medium-term - maximum (currency)

100000000

### (3.6.1.23) Explanation of financial effect figures

*The disclosed range reflects an internal scenario-based assessment of the potential revenue upside associated with increasing sustainability requirements in healthcare procurement, evaluated across four scenario combinations (business-as-usual vs. Net-Zero) that compare Pfizer's internal decarbonization pathway with external healthcare system scenarios based on stated policies and Net-Zero-aligned pathways. For the medium-term (2035), the lower bound of \$0 reflects scenarios where sustainability criteria remain at an early stage or where Pfizer's existing performance already meets expectations, resulting in no incremental financial benefit. The upper bound of approximately \$100M reflects a scenario in which sustainability criteria become more stringent and broadly enforced, and Pfizer's alignment with these criteria enhances its competitiveness in tender processes. Under this scenario, improved positioning may result in higher tender success rates, increased awarded volumes, or favorable pricing dynamics. This estimate is based on evaluating product- and country-level environmental performance against anticipated procurement criteria across key markets. It assumes constant product revenues over time and reflects a potential upside case rather than a financial forecast. The potential financial benefit should not be interpreted as a precise prediction of future financial performance. Rather, it is a scenario-based estimate intended to illustrate the possible magnitude of the opportunity and represents Pfizer's acknowledgement that, under certain scenarios and assumptions, this opportunity could become financially substantive. The analysis is intended to inform strategic planning and decision-making related to product sustainability and competitiveness in evolving healthcare procurement markets.*

### (3.6.1.24) Cost to realize opportunity

106000000

### (3.6.1.25) Explanation of cost calculation

*The annual cost to realize the opportunity provided (\$106M) includes an estimated \$10M in staffing and consulting costs and approximately \$96M incremental OPEX and CAPEX investment to identify, evaluate and advance energy efficiency and decarbonization projects completed in 2025. The estimated OPEX and CAPEX spend is derived from project data entered by sites in Pfizer's enterprise environmental reporting system. The portion of that spend associated with emissions reduction was estimated based on project type, and the resulting values were aggregated to provide total projected incremental OPEX and CAPEX spend. The estimated \$10M in staffing and consulting costs was added to the \$96M project spend to arrive at the \$106M estimate. Our annual energy efficiency and decarbonization investment, which is integrated within our annual operating planning cycle, may change in the future subject to market and technological developments as we seek opportunities to decarbonize our company operations.*

### (3.6.1.26) Strategy to realize opportunity

*Pfizer is advancing its strategy to address climate change through enterprise-wide emissions reduction targets, operational improvements, and value chain engagement. The company has established near-term greenhouse gas reduction targets aligned with a 1.5°C pathway and is progressing toward its long-term ambition to achieve Net-Zero emissions across operations and value chain activities. To support this strategy, Pfizer continues to implement energy efficiency*

projects, transition to renewable electricity, and engage suppliers to set science-based targets. These actions are complemented by enhanced data collection, governance, and reporting processes to meet increasing customer demand for environmental disclosures. By aligning its decarbonization efforts with evolving healthcare system expectations, Pfizer aims to strengthen its position in sustainability-linked procurement processes and capture the associated market opportunity.  
[Add row]

### **(3.6.2) Provide the amount and proportion of your financial metrics in the reporting year that are aligned with the substantive effects of environmental opportunities.**

#### **Climate change**

##### **(3.6.2.1) Financial metric**

Select from:

☒ OPEX

##### **(3.6.2.2) Amount of financial metric aligned with opportunities for this environmental issue (unit currency as selected in 1.2)**

11700000

##### **(3.6.2.3) % of total financial metric aligned with opportunities for this environmental issue**

Select from:

☒ Less than 1%

##### **(3.6.2.4) Explanation of financial figures**

*The OPEX annual savings associated with the implementation of energy conservation projects in 2025 was well below 1% of total OPEX spend.*

#### **Water**

##### **(3.6.2.1) Financial metric**

Select from:

☒ OPEX

### (3.6.2.2) Amount of financial metric aligned with opportunities for this environmental issue (unit currency as selected in 1.2)

117000

### (3.6.2.3) % of total financial metric aligned with opportunities for this environmental issue

Select from:

☒ Less than 1%

### (3.6.2.4) Explanation of financial figures

*The OPEX annual savings associated with the implementation of water conservation projects in 2025 was well below 1% of total OPEX spend.*  
[Add row]

## C4. Governance

### (4.1) Does your organization have a board of directors or an equivalent governing body?

#### (4.1.1) Board of directors or equivalent governing body

Select from:

☒ Yes

#### (4.1.2) Frequency with which the board or equivalent meets

Select from:

☒ More frequently than quarterly

#### (4.1.3) Types of directors your board or equivalent is comprised of

Select all that apply

☒ Executive directors or equivalent

☒ Independent non-executive directors or equivalent

#### (4.1.4) Board diversity and inclusion policy

Select from:

☒ Yes, and it is publicly available

#### (4.1.5) Briefly describe what the policy covers

*For the purposes of this response, we are defining policy broadly to include Pfizer Inc. Corporate Governance Principles. Pfizer's Corporate Governance Principles address Board composition by providing that directors should be selected to ensure the Board reflects a broad range of backgrounds and perspectives, as well as the knowledge and skills needed to effectively oversee the Company's business and long-term strategy.*

*[Fixed row]*

#### (4.1.1) Is there board-level oversight of environmental issues within your organization?

|                | Board-level oversight of this environmental issue       |
|----------------|---------------------------------------------------------|
| Climate change | Select from:<br><input checked="" type="checkbox"/> Yes |
| Water          | Select from:<br><input checked="" type="checkbox"/> Yes |

[Fixed row]

#### (4.1.2) Identify the positions (do not include any names) of the individuals or committees on the board with accountability for environmental issues and provide details of the board's oversight of environmental issues.

##### Climate change

##### (4.1.2.1) Positions of individuals or committees with accountability for this environmental issue

Select all that apply

- ☒ Board chair
- ☒ Chief Executive Officer (CEO)
- ☒ Board-level committee

##### (4.1.2.2) Positions' accountability for this environmental issue is outlined in policies applicable to the board

Select from:

- ☒ Yes

##### (4.1.2.3) Policies which outline the positions' accountability for this environmental issue

Select all that apply

☒ Other policy applicable to the board, please specify :Committee charters, available at <https://investors.pfizer.com/Investors/Corporate-Governance/Board-Committees--Charters/>

#### (4.1.2.4) Frequency with which this environmental issue is a scheduled agenda item

Select from:

☒ Scheduled agenda item in some board meetings – at least annually

#### (4.1.2.5) Governance mechanisms into which this environmental issue is integrated

Select all that apply

- ☒ Overseeing the setting of corporate targets
- ☒ Monitoring progress towards corporate targets
- ☒ Approving corporate policies and/or commitments
- ☒ Approving and/or overseeing employee incentives
- ☒ Overseeing reporting, audit, and verification processes
- ☒ Monitoring the implementation of a climate transition plan
- ☒ Overseeing and guiding the development of a business strategy
- ☒ Monitoring compliance with corporate policies and/or commitments
- ☒ Reviewing and guiding the assessment process for dependencies, impacts, risks, and opportunities

#### (4.1.2.7) Please explain

*Pfizer's CEO and Chairman of the Board is responsible, in his capacity as CEO and member of the Executive Leadership Team, for guiding Pfizer's climate strategy and approving environmental sustainability-related public goals. In June 2022 he committed Pfizer to accelerating the decarbonization of our value chain, aiming to achieve the voluntary Net-Zero standard by 2040. Pfizer's management reports progress on our sustainability goals, including Net-Zero as needed, twice per year to the CEO and Chairman of the Board, and the Board of Directors. The Board of Directors is fully engaged and supportive of Pfizer's sustainability program. The Governance Committee of the Board (GC) is primarily responsible for oversight of the company's responsible business growth strategy and reporting, of which sustainability and climate-related matters are key components. The GC receives updates from company leaders regarding our sustainability priorities and progress, and changes in the sustainability external environment.*

## Water

#### (4.1.2.1) Positions of individuals or committees with accountability for this environmental issue

*Select all that apply*

- ☒ Board chair
- ☒ Chief Executive Officer (CEO)
- ☒ Board-level committee

#### (4.1.2.2) Positions' accountability for this environmental issue is outlined in policies applicable to the board

*Select from:*

- ☒ Yes

#### (4.1.2.3) Policies which outline the positions' accountability for this environmental issue

*Select all that apply*

- ☒ Other policy applicable to the board, please specify :Committee charters, available at <https://investors.pfizer.com/Investors/Corporate-Governance/Board-Committees--Charters/>

#### (4.1.2.4) Frequency with which this environmental issue is a scheduled agenda item

*Select from:*

- ☒ Scheduled agenda item in some board meetings – at least annually

#### (4.1.2.5) Governance mechanisms into which this environmental issue is integrated

*Select all that apply*

- ☒ Overseeing and guiding the development of a business strategy
- ☒ Monitoring the implementation of the business strategy

#### (4.1.2.7) Please explain

*Pfizer's enterprise EHS risk program is managed by the Safety and Environmental Operations team in partnership with Legal and with active engagement from a cross-disciplinary team of leaders representing Engineering, Facilities, Procurement, and scientific and manufacturing lines. Through our Operational Risk Review process, key risks are escalated to the Pfizer Global Supply (PGS) Quality & Risk Committee (PGS QRC). PGS QRC reports on priority risks and mitigation, including those related to environmental issues, to the Executive Compliance Committee (ECC), chaired by the CEO, and to the Regulatory and Compliance Committee (RCC)*

of the Board of Directors. The PGS QRC risk management process also informs Pfizer's Enterprise Risk Management (ERM) program, overseen by the Audit Committee of the Board of Directors. Pfizer's ERM process assesses on an annual basis our operations and risk management priorities, including risks related to environmental issues and the long-term sustainability of the business. Each risk is prioritized and assigned to a member or members, as appropriate, of Pfizer's Executive Leadership Team. The Audit Committee of the Board of Directors has primary responsibility for overseeing Pfizer's ERM program. Periodically, the RCC and the Audit Committee hold joint sessions to discuss risks relevant to both Committees' areas of risk oversight, including an annual discussion of the ERM program. Throughout 2025, the Board was kept informed of its committees' risk oversight and other activities through reports by the committee chairs to the full Board. Our cross-functional management Sustainability Steering Committee, chaired by our Responsible Business Governance Lead, advised on key issues and guided the integration and implementation of Pfizer's non-financial reporting related to sustainability. This Committee is overseen by a dedicated Executive Sustainability Committee, chaired by the Senior Vice President and Chief Risk Officer, who has reporting relationships to the Chief Legal Officer and the Board of Directors. Our sustainability governance has as its foundation oversight by the Board of Directors, commitment and accountability by leadership, and engagement by colleagues across the company. Diverse perspectives from internal and external stakeholders inform our sustainability strategy and priorities. The Board of Directors is fully engaged and supportive of Pfizer's sustainability program. The Governance Committee of the Board (GC) is primarily responsible for oversight of the company's responsible business growth strategy and reporting, of which sustainability and climate-related matters are key components. Throughout the year, the GC receives updates from company leaders regarding our sustainability priorities and progress and changes in the sustainability external environment.

[Fixed row]

## **(4.2) Does your organization's board have competency on environmental issues?**

### **Climate change**

#### **(4.2.1) Board-level competency on this environmental issue**

Select from:

☒ Yes

#### **(4.2.2) Mechanisms to maintain an environmentally competent board**

Select all that apply

☒ Having at least one board member with expertise on this environmental issue

#### **(4.2.3) Environmental expertise of the board member**

Experience

☒ Executive-level experience in a role focused on environmental issues

☒ Experience in an organization that is exposed to environmental-scrutiny and is going through a sustainability transition

Water

(4.2.1) Board-level competency on this environmental issue

Select from:

☒ Yes

(4.2.2) Mechanisms to maintain an environmentally competent board

Select all that apply

☒ Other, please specify :Pfizer's BoD is composed of a diverse group of esteemed medical professionals, scientists, academics, and business leaders with skills, experience and academic training that provides them with competence to oversee environmental matters.

[Fixed row]

(4.3) Is there management-level responsibility for environmental issues within your organization?

|                | Management-level responsibility for this environmental issue |
|----------------|--------------------------------------------------------------|
| Climate change | Select from:<br><input checked="" type="checkbox"/> Yes      |
| Water          | Select from:<br><input checked="" type="checkbox"/> Yes      |

[Fixed row]

(4.3.1) Provide the highest senior management-level positions or committees with responsibility for environmental issues (do not include the names of individuals).

## Climate change

### (4.3.1.1) Position of individual or committee with responsibility

Executive level

- ☒ Chief Executive Officer (CEO)

### (4.3.1.2) Environmental responsibilities of this position

Dependencies, impacts, risks and opportunities

- ☒ Managing environmental dependencies, impacts, risks, and opportunities

Policies, commitments, and targets

- ☒ Monitoring compliance with corporate environmental policies and/or commitments
- ☒ Setting corporate environmental policies and/or commitments
- ☒ Setting corporate environmental targets

Strategy and financial planning

- ☒ Developing a business strategy which considers environmental issues

### (4.3.1.4) Reporting line

*Select from:*

- ☒ Reports to the board directly

### (4.3.1.5) Frequency of reporting to the board on environmental issues

*Select from:*

- ☒ Half-yearly

### (4.3.1.6) Please explain

*The CEO and Chairman of the Board is responsible, in his capacity as CEO and member of the Executive Leadership Team (ELT), for guiding Pfizer's climate strategy and approving environmental sustainability-related public goals. In June 2022 he committed Pfizer to accelerating the decarbonization of our value chain, aiming to achieve the voluntary Net-Zero standard by 2040. The CEO is informed of climate-related dependencies, impacts, risks, opportunities, and performance through Pfizer's established environmental risk management, sustainability governance, and Enterprise Risk Management (ERM) processes. Environmental and climate-related risks are identified and managed through Pfizer's enterprise EHS risk program, led by the Safety and Environmental Operations team in partnership with Legal and cross-functional leaders from Engineering, Facilities, Procurement, and scientific and manufacturing operations. Significant risks and mitigation plans are reviewed through the Operational Risk Review process and escalated to the Pfizer Global Supply Quality & Risk Committee, which reports priority risks, including climate- and environment-related matters, to the Executive Compliance Committee, chaired by the CEO. In addition, climate-related risks and opportunities are assessed annually through Pfizer's ERM program, which evaluates a broad range of enterprise risks and assigns accountability to ELT members. The CEO also receives updates through Pfizer's sustainability governance structure, including the Executive Sustainability Committee and Sustainability Steering Committee, which guide sustainability strategy, target implementation, and reporting. Through these governance forums, risk reviews, and the annual ERM assessment, the CEO receives information on climate-related issues at least annually and as appropriate, when significant risks, opportunities, performance updates, or strategic decisions are escalated, enabling oversight of climate strategy and business planning.*

## Water

### (4.3.1.1) Position of individual or committee with responsibility

Executive level

☒ Chief Executive Officer (CEO)

### (4.3.1.2) Environmental responsibilities of this position

Dependencies, impacts, risks and opportunities

☒ Managing environmental dependencies, impacts, risks, and opportunities

Strategy and financial planning

☒ Developing a business strategy which considers environmental issues

### (4.3.1.4) Reporting line

Select from:

☒ Reports to the board directly

#### (4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

☒ Half-yearly

#### (4.3.1.6) Please explain

*The Pfizer Global Supply (PGS) Quality & Risk Committee (PGS QRC) provides updates on priority risks and mitigation, including those related to climate change and pharmaceuticals in the environment, to the Executive Compliance Committee (ECC), chaired by the CEO, and to the Regulatory and Compliance Committee (RCC) of the Board of Directors twice each year. The PGS QRC risk management process also informs Pfizer's Enterprise Risk Management (ERM) program, overseen by the Audit Committee of the Board of Directors.*

### Climate change

#### (4.3.1.1) Position of individual or committee with responsibility

Executive level

☒ President

#### (4.3.1.2) Environmental responsibilities of this position

Policies, commitments, and targets

☒ Monitoring compliance with corporate environmental policies and/or commitments

Strategy and financial planning

☒ Implementing a climate transition plan

☒ Implementing the business strategy related to environmental issues

☒ Managing annual budgets related to environmental issues

☒ Managing major capital and/or operational expenditures relating to environmental issues

#### (4.3.1.4) Reporting line

Select from:

- ☒ Reports to the Chief Executive Officer (CEO)

#### (4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

- ☒ Not reported to the board

#### (4.3.1.6) Please explain

*Pfizer's Executive Vice President, Chief Global Supply and Quality Officer, leads Pfizer's Global Supply division (PGS), and is responsible for implementation of Pfizer's Net-Zero strategy. He also sponsors Pfizer's Net-Zero Core Team, which provides cross-functional oversight for the development and execution of strategies and programs aligned with Pfizer's Net-Zero goals. Product manufacturing at our internal network of sites, managed by PGS, accounts for approximately 68% of the company's energy consumption and Scope 1 & 2 GHG emissions. The EVP, Chief Global Supply and Quality Officer, has operational control over PGS operations and strategy, including OPEX/CAPEX investment in emission reduction projects and oversight of Pfizer's manufacturing supply chain which accounts for the majority of our Scope 3 emissions. Environmental sustainability has been integrated into the overarching PGS strategy and GHG emissions reduction is monitored as a key performance indicator (KPI).*

### Climate change

#### (4.3.1.1) Position of individual or committee with responsibility

Committee

- ☒ Sustainability committee

#### (4.3.1.2) Environmental responsibilities of this position

Policies, commitments, and targets

- ☒ Monitoring compliance with corporate environmental policies and/or commitments

Strategy and financial planning

- ☒ Developing a business strategy which considers environmental issues

#### (4.3.1.4) Reporting line

Select from:

☒ Other, please specify :Reports to the Executive Sustainability Committee which is composed of Executive Leadership Team members

#### (4.3.1.5) Frequency of reporting to the board on environmental issues

Select from:

☒ Half-yearly

#### (4.3.1.6) Please explain

*Our cross-functional Sustainability Steering Committee advises on key issues and guides the integration and implementation of Pfizer's non-financial reporting related to sustainability. Our sustainability governance has as its foundation oversight by the Board of Directors, commitment and accountability by leadership, and engagement by colleagues across the company. Diverse perspectives from internal and external stakeholders inform our sustainability strategy and priorities. The Board of Directors is engaged and supportive of Pfizer's sustainability program. The Governance Committee (GC) of the Board is primarily responsible for oversight of the company's responsible business growth strategy and reporting, of which sustainability and climate-related matters are key components. Throughout the year, the GC receives updates from company leaders regarding our sustainability priorities and progress and changes in the external sustainability environment.*

[Add row]

### (4.5) Do you provide monetary incentives for the management of environmental issues, including the attainment of targets?

#### Climate change

#### (4.5.1) Provision of monetary incentives related to this environmental issue

Select from:

☒ Yes

#### (4.5.2) % of total C-suite and board-level monetary incentives linked to the management of this environmental issue

0

#### (4.5.3) Please explain

*Pfizer Global Supply (PGS) operations, including our manufacturing network, account for approximately 68% of Pfizer's greenhouse gas emissions and more than 95% of the company's water consumption. Climate- and water-related targets are incorporated into the PGS performance management framework and are regularly tracked and reviewed alongside other operational objectives. Performance against these targets contributes to recognition programs, including awards with monetary value. We embed environmental performance and sustainability principles into our core operations. Because environmental performance is an expected component of the operational responsibilities and overall performance assessment of certain leaders responsible for implementing Pfizer's climate strategy, it is a component of PGS leadership's compensation and not associated with a distinct compensation metric or weighting for C-suite or Board members. As a result, Pfizer cannot quantify a specific percentage and reports 0%*

## Water

### (4.5.1) Provision of monetary incentives related to this environmental issue

Select from:

☒ Yes

### (4.5.2) % of total C-suite and board-level monetary incentives linked to the management of this environmental issue

0

### (4.5.3) Please explain

*Pfizer Global Supply (PGS) operations, including our manufacturing network, account for approximately 68% of Pfizer's greenhouse gas emissions and more than 95% of the company's water consumption. Climate- and water-related targets are incorporated into the PGS performance management framework and are regularly tracked and reviewed alongside other operational objectives. Performance against these targets contributes to site- and organization-level recognition programs, which include awards and other forms of recognition, including awards with monetary value. While these programs apply broadly across PGS organizations and sites, they do not include members of the C-suite or Board of Directors.*

*[Fixed row]*

**(4.5.1) Provide further details on the monetary incentives provided for the management of environmental issues (do not include the names of individuals).**

## Climate change

### (4.5.1.1) Position entitled to monetary incentive

Board or executive level

☒ President

#### (4.5.1.2) Incentives

*Select all that apply*

☒ Bonus - % of salary

#### (4.5.1.3) Performance metrics

Targets

☒ Progress towards environmental targets

☒ Achievement of environmental targets

☒ Reduction in absolute emissions in line with net-zero target

Strategy and financial planning

☒ Achievement of climate transition plan

Emission reduction

☒ Increased share of renewable energy in total energy consumption

☒ Reduction in absolute emissions

#### (4.5.1.4) Incentive plan the incentives are linked to

*Select from:*

☒ Short-Term Incentive Plan, or equivalent, only (e.g. contractual annual bonus)

#### (4.5.1.5) Further details of incentives

*Pfizer's Executive Vice President (EVP), Chief Global Supply and Quality Officer, leads Pfizer's Global Supply division (PGS), and is responsible for implementation of Pfizer's Net-Zero strategy and environmental targets. Climate and environmental performance is an important component of the EVP's organizational responsibilities. The EVP's annual bonus is determined based on overall performance, which includes progress made toward Pfizer's climate and environmental objectives.*

#### (4.5.1.6) How the position's incentives contribute to the achievement of your environmental commitments and/or climate transition plan

*The EVP, Chief Global Supply and Quality Officer is accountable for Pfizer's environmental commitments and climate transition plan which are considered in the evaluation of overall business performance used to inform incentive decisions, helping drive execution of these objectives.*

### Water

#### (4.5.1.1) Position entitled to monetary incentive

Facility/Unit/Site management

☒ Site manager

#### (4.5.1.2) Incentives

*Select all that apply*

☒ Other, please specify :Site performance awards

#### (4.5.1.3) Performance metrics

Targets

☒ Progress towards environmental targets

☒ Achievement of environmental targets

Resource use and efficiency

☒ Reduction of water withdrawals – direct operations

#### (4.5.1.4) Incentive plan the incentives are linked to

*Select from:*

☒ The incentives are not linked to an incentive plan, or equivalent (e.g. discretionary bonus in the reporting year)

(4.5.1.5) Further details of incentives

Site-specific water withdrawal targets are monitored through established performance management processes and are linked to recognition programs that may include monetary awards.

(4.5.1.6) How the position’s incentives contribute to the achievement of your environmental commitments and/or climate transition plan

Pfizer's manufacturing sites account for approximately 96% of the company's water withdrawals. As a result, water stewardship efforts are focused primarily within our manufacturing network, where sites establish withdrawal reduction targets that drive conservation activities and water efficiency projects. Key actions include process optimization, equipment upgrades, leak detection and repair, and water reuse initiatives, as appropriate. Progress toward site-level targets is monitored regularly, and performance against these targets is factored into annual performance assessments, helping to drive accountability and implementation across our manufacturing network.

[Add row]

(4.6) Does your organization have an environmental policy that addresses environmental issues?

|  |                                                         |
|--|---------------------------------------------------------|
|  | Does your organization have any environmental policies? |
|  | Select from:<br><input checked="" type="checkbox"/> Yes |

[Fixed row]

(4.6.1) Provide details of your environmental policies.

Row 1

(4.6.1.1) Environmental issues covered

Select all that apply

- ☒ Climate change

#### (4.6.1.2) Level of coverage

Select from:

- ☒ Organization-wide

#### (4.6.1.3) Value chain stages covered

Select all that apply

- ☒ Direct operations
- ☒ Upstream value chain

#### (4.6.1.4) Explain the coverage

*At Pfizer, we recognize global climate change as one of the defining issues of our time requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. In our publicly available Climate Change Position Statement, we affirm our commitment to collaborating to reduce GHG emissions across our value chain, including our near-term goal to reduce company GHG emissions by 46% compared with a 2019 baseline, aligned with a 1.5°C trajectory, and to drive action by encouraging suppliers to also set science-based GHG emissions reduction goals. Pfizer's internal corporate environmental, health and safety (EHS) policy and corporate EHS standards further reinforce this commitment by establishing a global framework for risk mitigation, regulatory compliance, and sustainability integration across operations. In addition, Pfizer's Blue Book—our publicly available Code of Conduct—outlines our commitment to promoting gender equality and respecting other internationally recognized human rights. It also provides detailed mechanisms for raising concerns, including a publicly available grievance and whistleblower system to report issues including potential non-compliance with our environmental policy. The Blue Book is accessible on our website.*

#### (4.6.1.5) Environmental policy content

Environmental commitments

- ☒ Commitment to comply with regulations and mandatory standards
- ☒ Commitment to take environmental action beyond regulatory compliance
- ☒ Commitment to stakeholder engagement and capacity building on environmental issues

Climate-specific commitments

- ☒ Commitment to 100% renewable energy

☒ Commitment to net-zero emissions

#### Social commitments

☒ Commitment to promote gender equality and women's empowerment

☒ Commitment to respect internationally recognized human rights

#### Additional references/Descriptions

☒ Description of environmental requirements for procurement

☒ Description of grievance/whistleblower mechanism to monitor non-compliance with the environmental policy and raise/address/escalate any other greenwashing concerns

☒ Description of membership and financial support provided to organizations that seek to influence public policy

☒ Recognition of environmental linkages and trade-offs

☒ Reference to timebound environmental milestones and targets

### (4.6.1.6) Indicate whether your environmental policy is in line with global environmental treaties or policy goals

*Select all that apply*

☒ Yes, in line with the Paris Agreement

### (4.6.1.7) Public availability

*Select from:*

☒ Publicly available

### (4.6.1.8) Attach the policy

*Climate\_Change\_Position\_Statement\_December\_2024.pdf*

## Row 2

### (4.6.1.1) Environmental issues covered

*Select all that apply*

- ☒ Water

#### (4.6.1.2) Level of coverage

Select from:

- ☒ Organization-wide

#### (4.6.1.3) Value chain stages covered

Select all that apply

- ☒ Direct operations
- ☒ Upstream value chain

#### (4.6.1.4) Explain the coverage

*Our publicly available Water Stewardship Position Statement acknowledges the global significance of access to clean water and reiterates Pfizer's commitment to conserving water. Specifically, in water-stressed areas, conservation includes minimizing water withdrawal, mitigating potential impact on water quality from our own operations and those of our supply chain, and responsibly managing discharges to water. Pfizer's corporate environmental, health and safety (EHS) policy and corporate EHS standards further reinforce this commitment by establishing a global framework for risk mitigation, regulatory compliance, and sustainability integration across operations. In addition, Pfizer's Blue Book—our publicly available Code of Conduct—outlines our commitment to promoting gender equality and respecting other internationally recognized human rights. It also provides detailed mechanisms for raising concerns, including a publicly available grievance and whistleblower system to report issues including potential non-compliance with our environmental policy. The Blue Book is accessible on our website.*

#### (4.6.1.5) Environmental policy content

Environmental commitments

- ☒ Commitment to comply with regulations and mandatory standards
- ☒ Commitment to take environmental action beyond regulatory compliance

Water-specific commitments

- ☒ Commitment to reduce water consumption volumes
- ☒ Commitment to reduce water withdrawal volumes
- ☒ Commitment to reduce or phase out hazardous substances
- ☒ Commitment to control/reduce/eliminate water pollution
- ☒ Commitment to water stewardship and/or collective action

☒ Commitment to the conservation of freshwater ecosystems

#### Social commitments

☒ Commitment to promote gender equality and women's empowerment

☒ Commitment to respect internationally recognized human rights

#### Additional references/Descriptions

☒ Acknowledgement of the human right to water and sanitation

☒ Description of grievance/whistleblower mechanism to monitor non-compliance with the environmental policy and raise/address/escalate any other greenwashing concerns

☒ Description of membership and financial support provided to organizations that seek to influence public policy

☒ Recognition of environmental linkages and trade-offs

☒ Reference to timebound environmental milestones and targets

### **(4.6.1.6) Indicate whether your environmental policy is in line with global environmental treaties or policy goals**

*Select all that apply*

☒ Yes, in line with Sustainable Development Goal 6 on Clean Water and Sanitation

### **(4.6.1.7) Public availability**

*Select from:*

☒ Publicly available

### **(4.6.1.8) Attach the policy**

*Pfizer\_Water\_Stewardship\_Public\_Position\_Statement\_2022.pdf*

*[Add row]*

## **(4.10) Are you a signatory or member of any environmental collaborative frameworks or initiatives?**

### **(4.10.1) Are you a signatory or member of any environmental collaborative frameworks or initiatives?**

Select from:

☒ Yes

#### (4.10.2) Collaborative framework or initiative

Select all that apply

- ☒ RE100
- ☒ Science-Based Targets Initiative (SBTi)
- ☒ Task Force on Climate-related Financial Disclosures (TCFD)
- ☒ UN Global Compact
- ☒ Other, please specify :AMR Industry Alliance (AMRIA)

#### (4.10.3) Describe your organization's role within each framework or initiative

*RE100: Pfizer is a member of Renewable Energy 100 (RE100) and has a goal to achieve 100% renewable electricity by 2030. SBTi: In 2015, we were one of the first companies to have our then GHG emissions reduction goal validated by the Science Based Targets Initiative (SBTi), and we remain committed to developing and implementing a science-based climate action strategy. Our current near-term climate targets have been validated by the SBTi. TCFD: As described in our Climate Change Position Statement, we conduct robust risk assessments to safeguard resiliency of our research, manufacturing, and commercial activities and to transparently report on our progress, risks, and opportunities aligned with Task Force on Climate-related Financial Disclosure (TCFD) recommendations. UN Global Compact: Pfizer is proud to have been one of the early signatories to the United Nations (UN) Global Compact, an initiative that calls on companies to align strategies and operations with universal principles on human rights, labor, environment, and anti-corruption, and to take actions that advance societal goals. AMR Industry Alliance (AMRIA): Pharmaceuticals in the environment and antimicrobial resistance (AMR) continue to be important environmental issues for our industry. Pfizer is an active member of the AMRIA pharmaceutical sector coalition established to provide sustainable solutions to curb antimicrobial resistance.*

[Fixed row]

**(4.11) In the reporting year, did your organization engage in activities that could directly or indirectly influence policy, law, or regulation that may (positively or negatively) impact the environment?**

#### (4.11.1) External engagement activities that could directly or indirectly influence policy, law, or regulation that may impact the environment

Yes

- ☒ Yes, we engaged indirectly through, and/or provided financial or in-kind support to a trade association or other intermediary organization or individual whose activities could influence policy, law, or regulation

#### **(4.11.2) Indicate whether your organization has a public commitment or position statement to conduct your engagement activities in line with global environmental treaties or policy goals**

*Select from:*

- ☒ Yes, we have a public commitment or position statement in line with global environmental treaties or policy goals

#### **(4.11.3) Global environmental treaties or policy goals in line with public commitment or position statement**

*Select all that apply*

- ☒ Paris Agreement
- ☒ Sustainable Development Goal 6 on Clean Water and Sanitation

#### **(4.11.4) Attach commitment or position statement**

*Pfizer - Climate & Water Position Statements.pdf*

#### **(4.11.5) Indicate whether your organization is registered on a transparency register**

*Select from:*

- ☒ Yes, my organization is registered

#### **(4.11.6) Types of transparency register your organization is registered on**

*Select all that apply*

- ☒ Mandatory government register

#### **(4.11.7) Disclose the transparency registers on which your organization is registered & the relevant ID numbers for your organization**

*For the US, Pfizer's Federal Lobbying ID numbers are: House: 313540000; Senate: 31326-12. For the EU Transparency Register, Pfizer's ID is: 4263301811-33*

#### **(4.11.8) Describe the process your organization has in place to ensure that your external engagement activities are consistent with your environmental commitments and/or transition plan**

*Our climate and water-related engagement activities with policy makers, trade associations, and other organizations are guided by our Climate Change Position Statement and our Water Stewardship Position Statement, which outline Pfizer's approach to these environmental issues and the policies that will help support Pfizer's climate change and water stewardship strategy. Pfizer maintains robust governance and oversight processes to help ensure that its external engagement activities, including lobbying, political contributions, and participation in trade associations, are aligned with the company's policies, priorities, and commitments. Political contributions and lobbying activities are subject to internal procedures, compliance requirements, training, and reporting processes designed to ensure compliance with applicable laws and alignment with Pfizer's vision and values for healthcare. The Governance Committee of Pfizer's Board of Directors receives periodic updates on issues related to public policy, including political spending policies and practices, and lobbying priorities and activities, providing oversight of external engagement activities. Pfizer also conducts annual reviews of its memberships in trade associations and other organizations through its U.S. Government Relations function. Memberships are evaluated based on the organizations' expertise, advocacy activities, and support for issues important to Pfizer. Where differences arise on specific policy issues, Pfizer engages directly through its representatives serving on boards and committees to communicate the company's positions and concerns. In addition, Pfizer publishes information regarding political contributions, lobbying activities, certain trade association memberships, and maintains an Industry Associations Congruency Report, which supports transparency and accountability for alignment between external engagement activities and corporate commitments. Through these governance, review, oversight, and transparency mechanisms, Pfizer seeks to ensure that its external engagement activities support the company's long-term business strategy, sustainability priorities, and environmental commitments, including the objectives outlined in its climate transition plan.*

[Fixed row]

#### **(4.11.2) Provide details of your indirect engagement on policy, law, or regulation that may (positively or negatively) impact the environment through trade associations or other intermediary organizations or individuals in the reporting year.**

##### **Row 1**

##### **(4.11.2.1) Type of indirect engagement**

Select from:

☒ Indirect engagement via a trade association

##### **(4.11.2.4) Trade association**

North America

☒ US Chamber of Commerce

#### (4.11.2.5) Environmental issues relevant to the policies, laws, or regulations on which the organization or individual has taken a position

Select all that apply

☒ Climate change

#### (4.11.2.6) Indicate whether your organization's position is consistent with the organization or individual you engage with

Select from:

☒ Mixed

#### (4.11.2.7) Indicate whether your organization attempted to influence the organization or individual's position in the reporting year

Select from:

☒ Yes, we attempted to influence them but they did not change their position

#### (4.11.2.8) Describe how your organization's position is consistent with or differs from the organization or individual's position, and any actions taken to influence their position

*Pfizer recognizes climate change as one of the defining issues of our time requiring collective action to mitigate the potential risks it poses. As such, Pfizer committed to further reducing GHG emissions aligned with science by aiming to achieve the voluntary Net-Zero Standard by 2040, ten years earlier than the timeline described in the standard and reporting transparently on our progress. Pfizer appreciates that voluntary measures often offer the greatest opportunity for companies to design innovative solutions that work best for their situation, product range, and investment timelines. Tackling climate change, however, will require action from all parties across all sectors, and Pfizer supports policy efforts that are science- and market-based to encourage and advance such action. The company also seeks to engage its value chain partners to support them in achieving science aligned reductions in GHG emissions. The Chamber acknowledges the severity of the climate threat and that steps need to be taken to address the crisis. The organization recognizes the role that business and market-driven solutions can play in slowing the effects of climate change. In addition, the Chamber has noted that governments and technological solutions should be leveraged but solutions must be realistic, durable, and reinforce U.S. economic competitiveness. On climate change, both Pfizer and the Chamber favor market-based and technology-based solutions. Pfizer is committed to taking responsible climate action and reducing environmental impact; the Chamber also advocates for corporations to take such actions. Pfizer continues to actively engage with the Chamber on relevant policy issues, seeking opportunities to identify common ground where our positions are aligned and to constructively communicate our perspective when differences arise. Pfizer participates in the Energy, Environment, Climate & Sustainability Committee and the ESG Working Group, through which we provide comments on relevant topics consistent with our Climate Change Position Statement and commitment to transparency.*

#### (4.11.2.9) Funding figure your organization provided to this organization or individual in the reporting year (currency)

#### (4.11.2.10) Describe the aim of this funding and how it could influence policy, law or regulation that may impact the environment

*Pfizer is a member of several industry and trade groups that represent both the pharmaceutical industry and the business community at large to bring about consensus on broad policy issues that can impact Pfizer's business objectives and ability to serve patients. The funding figure reported represents the portion of Pfizer's dues used for US federal lobbying activity in 2025 as reported by the trade association.*

#### (4.11.2.11) Indicate if you have evaluated whether your organization's engagement is aligned with global environmental treaties or policy goals

Select from:

☒ Yes, we have evaluated, and it is aligned

#### (4.11.2.12) Global environmental treaties or policy goals aligned with your organization's engagement on policy, law or regulation

Select all that apply

☒ Paris Agreement

### Row 2

#### (4.11.2.1) Type of indirect engagement

Select from:

☒ Indirect engagement via a trade association

#### (4.11.2.4) Trade association

Europe

☒ Other trade association in Europe, please specify :European Federation of Pharmaceutical Industries and Associations (EFPIA)

#### (4.11.2.5) Environmental issues relevant to the policies, laws, or regulations on which the organization or individual has taken a position

Select all that apply

☒ Water

#### (4.11.2.6) Indicate whether your organization's position is consistent with the organization or individual you engage with

Select from:

☒ Consistent

#### (4.11.2.7) Indicate whether your organization attempted to influence the organization or individual's position in the reporting year

Select from:

☒ Yes, and they have changed their position

#### (4.11.2.8) Describe how your organization's position is consistent with or differs from the organization or individual's position, and any actions taken to influence their position

*The joint AESGP – EFPIA – EGA Position Paper on Pharmaceuticals in the Environment (PiE) (<https://www.efpia.eu/media/25274/eps-position-paper-october-2015.pdf>) states: "The European pharmaceutical industry, represented by the Association of the European Self-Medication Industry (AESGP), the European Federation of Pharmaceutical Industries (EFPIA), and the European Generic and Biosimilar Medicines Association (EGA), recognizes and understands the concerns raised by stakeholders as regards the presence of pharmaceuticals in the environment (PiE). For this reason, we have come together to develop the Eco-Pharmaco-Stewardship (EPS) concept, a proposal that strives to protect patients' access to medicines while appropriately considering environmental aspects." On PiE, both Pfizer and EFPIA propose actions in three areas: 1. Encouraging further research to assess the impact of PiE; 2. Manage pharmaceutical sites' effluents effectively; 3. Monitor environmental impact through extended Environmental Risk Assessment (eERA). Pfizer has collaborated with EFPIA in shaping their position on water issues by providing multidisciplinary input including technical, legal, and government affairs expertise.*

#### (4.11.2.9) Funding figure your organization provided to this organization or individual in the reporting year (currency)

1221200

#### (4.11.2.10) Describe the aim of this funding and how it could influence policy, law or regulation that may impact the environment

*The fees disclosed represent Pfizer's total 2025 core membership contributions to EFPIA. This funding supports EFPIA's role as a trade association representing the pharmaceutical industry in Europe, enabling coordinated engagement with EU institutions on science-based, innovation-friendly policy frameworks. Through EFPIA, Pfizer contributes to shaping environmental policy discussions on topics such as climate change, pharmaceuticals in the environment (PiE), water stewardship, and chemical legislation. This funding enables EFPIA to advocate for balanced, evidence-based regulation that protects public health and the environment while supporting continued access to medicines and innovation.*

#### **(4.11.2.11) Indicate if you have evaluated whether your organization's engagement is aligned with global environmental treaties or policy goals**

Select from:

☒ Yes, we have evaluated, and it is aligned

#### **(4.11.2.12) Global environmental treaties or policy goals aligned with your organization's engagement on policy, law or regulation**

Select all that apply

☒ Sustainable Development Goal 6 on Clean Water and Sanitation

[\[Add row\]](#)

#### **(4.12) Have you published information about your organization's response to environmental issues for this reporting year in places other than your CDP response?**

Select from:

☒ Yes

**(4.12.1) Provide details on the information published about your organization's response to environmental issues for this reporting year in places other than your CDP response. Please attach the publication.**

**Row 1**

##### **(4.12.1.1) Publication**

Select from:

- ☒ In voluntary sustainability reports

#### (4.12.1.2) Is your publication in line with a standard or framework?

Select from:

- ☒ Yes

#### (4.12.1.3) Standard or framework the publication is in line with

Select all that apply

- ☒ GRI  
☒ TCFD

#### (4.12.1.4) Environmental issues covered in publication

Select all that apply

- ☒ Climate change  
☒ Water  
☒ Biodiversity

#### (4.12.1.5) Status of the publication

Select from:

- ☒ Complete

#### (4.12.1.6) Content elements

Select all that apply

- |                                                            |                                                                                             |
|------------------------------------------------------------|---------------------------------------------------------------------------------------------|
| <input checked="" type="checkbox"/> Strategy               | <input checked="" type="checkbox"/> Climate-related targets                                 |
| <input checked="" type="checkbox"/> Governance             | <input checked="" type="checkbox"/> Water accounting figures                                |
| <input checked="" type="checkbox"/> Risks & Opportunities  | <input checked="" type="checkbox"/> Greenhouse gas emissions figures                        |
| <input checked="" type="checkbox"/> Value chain engagement | <input checked="" type="checkbox"/> Other, please specify : <b>Waste accounting figures</b> |
| <input checked="" type="checkbox"/> Dependencies & Impacts |                                                                                             |

#### (4.12.1.7) Page/section reference

*Planet section, pp 30-40; Environmental performance, pp. 65-68*

#### (4.12.1.8) Attach the relevant publication

*Pfizer\_2025\_Impact\_Report\_02JUN2026 (1).pdf*

#### (4.12.1.9) Comment

*Pfizer's 2025 Impact Report is available online at: [https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)*

### Row 2

#### (4.12.1.1) Publication

*Select from:*

☒ In mainstream reports

#### (4.12.1.2) Is your publication in line with a standard or framework?

*Select from:*

☒ Yes

#### (4.12.1.3) Standard or framework the publication is in line with

*Select all that apply*

☒ TCFD

#### (4.12.1.4) Environmental issues covered in publication

*Select all that apply*

☒ Climate change

#### (4.12.1.5) Status of the publication

Select from:

☒ Complete

#### (4.12.1.6) Content elements

Select all that apply

☒ Risks & Opportunities

☒ Strategy

☒ Climate-related targets

#### (4.12.1.7) Page/section reference

*Responsible Business Practices, p. 25.*

#### (4.12.1.8) Attach the relevant publication

*10-K-without-Exhibits.pdf*

#### (4.12.1.9) Comment

*Pfizer's 2025 10-K Report is available online at: [https://s206.q4cdn.com/795948973/files/doc\\_financials/2025/ar/10-K-without-Exhibits.pdf](https://s206.q4cdn.com/795948973/files/doc_financials/2025/ar/10-K-without-Exhibits.pdf)*

### Row 3

#### (4.12.1.1) Publication

Select from:

☒ In voluntary communications

#### (4.12.1.2) Is your publication in line with a standard or framework?

Select from:

☒ No

#### (4.12.1.4) Environmental issues covered in publication

Select all that apply

☒ Climate change

#### (4.12.1.5) Status of the publication

Select from:

☒ Complete

#### (4.12.1.6) Content elements

Select all that apply

☒ Public policy engagement

☒ Strategy

#### (4.12.1.7) Page/section reference

Full document

#### (4.12.1.8) Attach the relevant publication

Climate\_Change\_Position\_Statement\_December\_2024.pdf

#### (4.12.1.9) Comment

Pfizer's Climate Change Position Statement is available online at: [https://cdn.pfizer.com/pfizercom/about/Climate\\_Change\\_Position\\_Statement\\_December\\_2024.pdf](https://cdn.pfizer.com/pfizercom/about/Climate_Change_Position_Statement_December_2024.pdf)

### Row 4

#### (4.12.1.1) Publication

Select from:

☒ In voluntary communications

#### (4.12.1.2) Is your publication in line with a standard or framework?

Select from:

☒ No

#### (4.12.1.4) Environmental issues covered in publication

Select all that apply

☒ Water

#### (4.12.1.5) Status of the publication

Select from:

☒ Complete

#### (4.12.1.6) Content elements

Select all that apply

☒ Strategy

☒ Value chain engagement

#### (4.12.1.7) Page/section reference

Full document

#### (4.12.1.8) Attach the relevant publication

*Pfizer\_Water\_Stewardship\_Public\_Position\_Statement\_2022.pdf*

#### (4.12.1.9) Comment

*Pfizer's Water Stewardship Position Statement is available online at:*

*[https://cdn.pfizer.com/pfizercom/Pfizer\\_Water\\_Stewardship\\_Public\\_Position\\_Statement\\_2022.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_Water_Stewardship_Public_Position_Statement_2022.pdf)*

*[Add row]*

## C5. Business strategy

(5.1) Does your organization use scenario analysis to identify environmental outcomes?

### Climate change

#### (5.1.1) Use of scenario analysis

Select from:

☒ Yes

#### (5.1.2) Frequency of analysis

Select from:

☒ More than once a year

### Water

#### (5.1.1) Use of scenario analysis

Select from:

☒ Yes

#### (5.1.2) Frequency of analysis

Select from:

☒ More than once a year

[Fixed row]

(5.1.1) Provide details of the scenarios used in your organization's scenario analysis.

### Climate change

#### (5.1.1.1) Scenario used

Physical climate scenarios

☒ RCP 2.6

#### (5.1.1.2) SSPs used in conjunction with scenario

*Select from:*

☒ SSP1

#### (5.1.1.3) Approach to scenario

*Select from:*

☒ Qualitative and quantitative

#### (5.1.1.4) Scenario coverage

*Select from:*

☒ Organization-wide

#### (5.1.1.5) Risk types considered in scenario

*Select all that apply*

☒ Acute physical

☒ Chronic physical

#### (5.1.1.6) Temperature alignment of scenario

*Select from:*

☒ 1.6°C - 1.9°C

#### (5.1.1.7) Reference year

2020

### (5.1.1.8) Timeframes covered

Select all that apply

☒ 2030

☒ 2050

### (5.1.1.9) Driving forces in scenario

Direct interaction with climate

☒ On asset values, on the corporate

### (5.1.1.10) Assumptions, uncertainties and constraints in scenario

*This physical risk scenario is aligned to the current commitments under the Paris Agreement. The world shifts towards a more sustainable path, emphasizing more inclusive development, driven by an increasing commitment to achieving development goals. Key parameters and assumptions: global Net-Zero is reached in 2050; renewables account for more than half of the energy supply by 2050; and there are few challenges to climate mitigation and adaptation.*

### (5.1.1.11) Rationale for choice of scenario

*Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100+ Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net-Zero target, international and national climate policy milestones, and the expected lifetime of our assets.*

## Water

### (5.1.1.1) Scenario used

Water scenarios

☒ WRI Aqueduct

### (5.1.1.3) Approach to scenario

Select from:

- ☒ Qualitative and quantitative

#### (5.1.1.4) Scenario coverage

Select from:

- ☒ Organization-wide

#### (5.1.1.5) Risk types considered in scenario

Select all that apply

- ☒ Acute physical
- ☒ Chronic physical
- ☒ Policy
- ☒ Reputation
- ☒ Liability

#### (5.1.1.7) Reference year

2023

#### (5.1.1.8) Timeframes covered

Select all that apply

- ☒ 2025

#### (5.1.1.9) Driving forces in scenario

Local ecosystem asset interactions, dependencies and impacts

- ☒ Climate change (one of five drivers of nature change)

Stakeholder and customer demands

- ☒ Impact of nature footprint on reputation
- ☒ Impact of nature service delivery on consumer
- ☒ Sensitivity to inequity of nature impacts

Direct interaction with climate

☒ On asset values, on the corporate

#### (5.1.1.10) Assumptions, uncertainties and constraints in scenario

*No additional assumptions, uncertainties or constraints beyond those inherent in WRI's Aqueduct Tool (version 4.0).*

#### (5.1.1.11) Rationale for choice of scenario

*WRI's Aqueduct Tool is used to identify potential baseline/short-term risks and assess the adequacy of site Water Stewardship plans. Medium- and long-term water-related risks are assessed as part of the climate change physical risk analysis using the RCP 2.6 and RCP 8.5 scenarios.*

### Climate change

#### (5.1.1.1) Scenario used

Physical climate scenarios

☒ RCP 8.5

#### (5.1.1.2) SSPs used in conjunction with scenario

Select from:

☒ SSP5

#### (5.1.1.3) Approach to scenario

Select from:

☒ Qualitative and quantitative

#### (5.1.1.4) Scenario coverage

Select from:

- ☒ Organization-wide

#### (5.1.1.5) Risk types considered in scenario

Select all that apply

- ☒ Acute physical
- ☒ Chronic physical

#### (5.1.1.6) Temperature alignment of scenario

Select from:

- ☒ 4.0°C and above

#### (5.1.1.7) Reference year

2020

#### (5.1.1.8) Timeframes covered

Select all that apply

- ☒ 2030
- ☒ 2050

#### (5.1.1.9) Driving forces in scenario

Direct interaction with climate

- ☒ On asset values, on the corporate

#### (5.1.1.10) Assumptions, uncertainties and constraints in scenario

*This is a physical risk high emissions scenario with no additional climate policy (business-as-usual). The push for economic and social development is coupled with the exploitation of abundant fossil fuel resources and the adoption of resource and energy intensive lifestyles around the world. Key parameters and assumptions: energy demand triples by 2100, dominated by fossil fuels; current atmospheric CO2 levels double by 2050; there are many challenges to climate mitigation, with few challenges to adaptation.*

#### (5.1.1.11) Rationale for choice of scenario

*Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100+ Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net-Zero target, international and national climate policy milestones, and the expected lifetime of our assets.*

### Climate change

#### (5.1.1.1) Scenario used

Climate transition scenarios

☒ NGFS scenarios framework, please specify :Net-Zero 2050

#### (5.1.1.3) Approach to scenario

*Select from:*

☒ Qualitative and quantitative

#### (5.1.1.4) Scenario coverage

*Select from:*

☒ Organization-wide

#### (5.1.1.5) Risk types considered in scenario

*Select all that apply*

☒ Policy

☒ Market

☒ Reputation

☒ Technology

☒ Liability

#### (5.1.1.6) Temperature alignment of scenario

Select from:

☒ 1.5°C or lower

#### (5.1.1.7) Reference year

2020

#### (5.1.1.8) Timeframes covered

Select all that apply

☒ 2030

☒ 2040

☒ 2050

#### (5.1.1.9) Driving forces in scenario

Stakeholder and customer demands

☒ Consumer sentiment

Regulators, legal and policy regimes

☒ Global regulation

☒ Global targets

☒ Other regulators, legal and policy regimes driving forces, please specify :Carbon pricing and geography-specific climate regulations.

Relevant technology and science

☒ Other relevant technology and science driving forces, please specify :New technologies to enable decarbonization

#### (5.1.1.10) Assumptions, uncertainties and constraints in scenario

*This is an ambitious transition scenario that limits global warming to 1.5 °C in 2100 through stringent climate policies and innovation. Key parameters and assumptions include the immediate introduction of ambitious climate policy and that global Net-Zero is reached in 2050.*

#### (5.1.1.11) Rationale for choice of scenario

Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100+ Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net-Zero target, international and national climate policy milestones, and the expected lifetime of our assets.

## Climate change

### (5.1.1.1) Scenario used

Climate transition scenarios

☒ NGFS scenarios framework, please specify :Current Policies

### (5.1.1.3) Approach to scenario

Select from:

☒ Qualitative and quantitative

### (5.1.1.4) Scenario coverage

Select from:

☒ Organization-wide

### (5.1.1.5) Risk types considered in scenario

Select all that apply

☒ Policy

☒ Market

☒ Reputation

☒ Technology

☒ Liability

### (5.1.1.6) Temperature alignment of scenario

Select from:

☒ 3.0°C - 3.4°C

#### (5.1.1.7) Reference year

2020

#### (5.1.1.8) Timeframes covered

*Select all that apply*

☒ 2030

☒ 2040

☒ 2050

#### (5.1.1.9) Driving forces in scenario

Regulators, legal and policy regimes

☒ Global regulation

☒ Global targets

Direct interaction with climate

☒ Other direct interaction with climate driving forces, please specify :Energy Security

Macro and microeconomy

☒ Domestic growth

☒ Globalizing markets

#### (5.1.1.10) Assumptions, uncertainties and constraints in scenario

*This transition risk scenario assumes that only currently implemented policies are preserved, with an expected temperature outcome of ~3°C in 2100. This scenario assumes that emissions peak in 2080.*

#### (5.1.1.11) Rationale for choice of scenario

Scenario selection was based upon a review of guidance from TCFD, CDP, Climate Action 100+ Benchmark, and IIGCC and considered temperature outcomes, sectoral and geographical coverage, data availability, time horizons, and market recognition. Timeframes selected align with Pfizer's strategic planning, including our 2040 Net-Zero target, international and national climate policy milestones, and the expected lifetime of our assets.

[Add row]

## **(5.1.2) Provide details of the outcomes of your organization's scenario analysis.**

### **Climate change**

#### **(5.1.2.1) Business processes influenced by your analysis of the reported scenarios**

Select all that apply

- ☒ Risk and opportunities identification, assessment and management
- ☒ Strategy and financial planning
- ☒ Resilience of business model and strategy
- ☒ Capacity building
- ☒ Target setting and transition planning

#### **(5.1.2.2) Coverage of analysis**

Select from:

- ☒ Organization-wide

#### **(5.1.2.3) Summarize the influence of the scenario analysis on the selected business processes**

*Physical Risk: Scenario analysis indicated that by 2030, under a high emissions scenario, almost half of Pfizer's manufacturing and R&D sites assessed are at a high risk of water scarcity and drought, and several of our manufacturing sites are at high risk of flooding. Risk remains high through 2050. Potential financial impacts include increased capital expenditures, increased direct (operating) costs, decreased asset value or asset useful life leading to write-offs, and decreased revenues due to reduced production capacity. Also, while scenario analysis does not show extreme heat as presenting a high risk to Pfizer in the near term, by 2050, under a high emissions scenario, approximately 14% of the manufacturing and R&D sites assessed were at a high risk of extreme heat. Extreme heat may increase potential financial risk for Pfizer by increasing operating costs associated with running air conditioning and backup generators, and/or reducing revenue due to production shutdowns. In 2025, we continued to use the output of this analysis to drive the development and implementation of site-specific mitigation plans to address identified climate risks. Transition (Market): National healthcare systems in certain countries are increasingly committing to Net-Zero goals and strengthening supplier sustainability requirements, increasing pressure for pharmaceutical companies to reduce emissions across the full product life cycle, from R&D through manufacturing, supply chain, and distribution. Competitors offering lower life-cycle emissions or stronger product-level sustainability credentials may gain a*

competitive advantage. If product-level and upstream decarbonization efforts do not keep pace with changing tender requirements, Pfizer may face reduced competitiveness, resulting in revenue at risk, including potential loss of tender opportunities or reduced market share. Given that approximately 80% of Pfizer's emissions are Scope 3, supplier decarbonization and product-level emissions transparency will be increasingly important to maintaining competitiveness and meeting customer procurement requirements. This risk was rated moderate today and is projected to increase significantly over time, reaching critical levels under lower-carbon scenarios. Transition (Technology): Achieving Pfizer's Net-Zero ambition will require sustained investment in manufacturing assets, including energy efficiency improvements, electrification, equipment replacement, and refrigerant transition activities. Technology risk was rated low in the baseline assessment, increasing to moderate under higher-carbon scenarios and high under lower-carbon scenarios by 2040 and beyond. Potential financial impacts include increased capital and operating expenditures, misallocation of capital, and slower progress toward decarbonization goals, which could affect competitiveness and long-term value creation. The analysis also highlighted the importance of effective governance, capital allocation, and prioritization of resources to support timely implementation of Net-Zero solutions across the portfolio. Transition (Supply Chain): As a significant share of Pfizer's emissions originates in the supply chain, progress toward Net-Zero goals depends on supplier decarbonization and timely emissions transparency. Variability in supplier readiness, evolving reporting requirements, and increasing expectations for Scope 3 emissions management may create operational, compliance, and reputational risks. This risk was rated moderate in the near term and high under lower-carbon scenarios by 2040 and beyond. Potential financial impacts include increased indirect operating costs associated with supplier data, assurance, logistics, and compliance activities. Pfizer manages these transition risks through implementation of its Net-Zero strategy, including greenhouse gas reduction goals, energy efficiency initiatives, renewable energy procurement, supplier engagement programs, and efforts to increase emissions transparency across the value chain. In 2025 we invested \$96M in incremental CAPEX and OPEX spend, not including staffing costs for internal energy conservation program management, to implement projects to reduce GHG emissions across the company. While a number of risks and opportunities with the potential to impact financial performance and position were identified through our analysis, we concluded that Pfizer's current business model and strategy is resilient under the assessed scenarios.

## Water

### (5.1.2.1) Business processes influenced by your analysis of the reported scenarios

Select all that apply

- ☒ Risk and opportunities identification, assessment and management
- ☒ Resilience of business model and strategy

### (5.1.2.2) Coverage of analysis

Select from:

- ☒ Organization-wide

### (5.1.2.3) Summarize the influence of the scenario analysis on the selected business processes

Through scenario analysis we have currently identified six manufacturing and two R&D facilities that are currently exposed to water stress risks, and one additional manufacturing facility that is projected to be exposed to water stress risk in the 2030 and 2050 time horizons. These risks were determined not to be substantive and will continue to be monitored and managed through our Water Stewardship and Business Resilience programs.

[Fixed row]

## **(5.2) Does your organization's strategy include a climate transition plan?**

### **(5.2.1) Transition plan**

Select from:

☒ Yes, we have a climate transition plan which aligns with a 1.5°C world

### **(5.2.3) Publicly available climate transition plan**

Select from:

☒ Yes

### **(5.2.4) Plan explicitly commits to cease all spending on, and revenue generation from, activities that contribute to fossil fuel expansion**

Select from:

☒ No, and we do not plan to add an explicit commitment within the next two years

### **(5.2.6) Explain why your organization does not explicitly commit to cease all spending on and revenue generation from activities that contribute to fossil fuel expansion**

*Pfizer uses fossil fuels and fossil fuel-based materials in our operations to manufacture pharmaceuticals. Through our Net-Zero goal we anticipate our demand for these materials will decrease over time. Therefore, we do not anticipate that our use will contribute to fossil fuel expansion. Pfizer is a member of RE100 and has committed to achieve 100% renewable electricity by 2030. Transitioning away from fossil fuels is part of our strategy to achieve the Net-Zero standard.*

### **(5.2.10) Mechanism by which feedback is collected from shareholders on your climate transition plan**

Select from:

☒ We have a different feedback mechanism in place

### (5.2.11) Description of feedback mechanism

*Pfizer has established a strategic plan to advance our Net-Zero goal and therefore our responses in this questionnaire align to CDP's expectations of a transition plan per CDP guidance. Our annual Impact Report provides stakeholders with prior-year GHG emissions data and updates on our progress toward achieving Net-Zero. Each year, Pfizer aims to engage with investors who, in the aggregate, hold approximately 50% of our outstanding stock. We share our Impact Report with these investors and invite them to meet with representatives of Pfizer's Corporate Governance, Sustainability, and Investor Relations teams. These meetings offer an opportunity to gather feedback and address specific questions related to our responsible business strategy and performance. In addition to these semi-annual engagements, we maintain ongoing dialogue with investors on sustainability issues through one-on-one conversations, written correspondence, surveys, questionnaires, and targeted communications—for example, via our Responsible Business webpages on Pfizer.com.*

### (5.2.12) Frequency of feedback collection

Select from:

☒ More frequently than annually

### (5.2.13) Description of key assumptions and dependencies on which the transition plan relies

*Pfizer's Net-Zero transition plan is grounded in the assumption that emerging technologies—particularly those enabling low/no-carbon heat and steam generation—will become available and scalable within the required timeframe. Our strategy depends on the evolution of regulatory frameworks that support decarbonization and incentivize innovation. We assume continued progress across sectors in electrification infrastructure, renewable energy markets, and the development of alternative fuels. Our internal decarbonization efforts rely on the successful implementation of Net-Zero design guidelines and master plans across our global network, as well as employee engagement and behavioral change. A key dependency is the active participation of our value chain. Approximately 80% of our emissions are Scope 3, and we rely on suppliers to adopt science-aligned targets and implement emissions-reduction strategies. As of the end of 2025, 72% of our suppliers (by spend) had adopted or committed to science-based targets, exceeding our 2025 goal of 64%. We also depend on reliable logistics systems and the availability of low-emission fuels and electric vehicles to reduce transportation-related emissions. Our plan assumes that voluntary corporate action will remain a key driver of climate progress, however, stabilizing global temperature rise at 1.5°C will require action from all sectors supported by robust governmental climate policies.*

### (5.2.14) Description of progress against transition plan disclosed in current or previous reporting period

*Pfizer has made measurable progress across key elements of our Net-Zero transition plan. Internal Operations (Scope 1 & 2): In 2025, Pfizer continued to advance efforts to reduce GHG emissions from our facilities by focusing on energy efficiency, procuring low-carbon and renewable energy, and operational optimization across our global portfolio. We implemented energy efficiency projects at manufacturing and research and development (R&D) sites, increased the use of renewable electricity where it makes good business sense, and advanced electrification and process improvements to reduce on-site reliance on fossil fuels. Pfizer also continued to advance its transition to battery electric vehicles (BEVs), expanding deployment to 13 markets globally. These efforts, combined with renewable electricity procurement, support our goal to reduce Scope 1 and 2 emissions by 46% by 2030 (vs. 2019). As of the end of 2025, our combined Scope 1 and 2 emissions were 40.9% below our 2019 baseline. Supplier Engagement (Scope 3): By the end of 2025, 72% of our suppliers by spend had set or committed to develop science-based GHG emissions reduction targets—well above our 64% target—reflecting continued progress in engaging and influencing our value chain on climate action. Transportation & Logistics (Scope 3): Pfizer achieved its 2025 target for reducing GHG emissions from upstream transportation and distribution,*

delivering a 45% reduction from the 2019 baseline when including low-emission fuel vehicle certificates, or a 15% reduction excluding certificates. This progress reflects continued efforts to optimize transportation modes and work with logistics partners to adopt lower-emission fuels and vehicles. Business Travel (Scope 3): Pfizer also reached its 2025 target for reducing travel-related GHG emissions, with emissions remaining 58% below the 2019 baseline—well beyond the 25% reduction goal. This achievement reflects continued use of digital tools to reduce travel and a focus on preferred carriers advancing their own emissions-reduction efforts. Product Life Cycle Innovation (Scope 1, 2 & 3): Sustainable product design and lifecycle management are important enablers of Pfizer's long-term Net-Zero strategy. In 2025, Pfizer developed the Net-Zero by Design Sustainability Playbook, a framework to embed sustainability across product development and commercialization. The playbook is informed by insights from more than 20 Life Cycle Assessments and supports identification of carbon hotspots, prioritization of lower-emission design choices, and evaluation of tradeoffs across the product lifecycle. As the playbook is rolled out in 2026, Pfizer is educating colleagues through targeted communications and engagement to support consistent application across the organization. While challenges remain, our achievements to date demonstrate continued progress toward our Net-Zero ambition while maintaining our focus on delivering breakthroughs that change patients' lives.

#### (5.2.16) Other environmental issues that your climate transition plan considers

Select all that apply

☒ No other environmental issue considered

#### (5.2.18) Adaptation-specific objectives included within your climate transition plan

Select from:

☒ Yes

#### (5.2.19) Describe the adaptation objectives included in your climate transition plan or standalone adaptation plan

Pfizer's adaptation objectives are focused on strengthening the resilience of our operations and supply chain to acute and chronic climate-related physical risks. Our objectives include assessing climate-related vulnerabilities across our facilities and value chain, maintaining resilient infrastructure and systems, and implementing measures to reduce the potential impacts of climate-related disruptions. Through our Loss Prevention and Business Continuity programs, we seek to enhance preparedness for climate-related events by maintaining business continuity plans, establishing alternative sourcing and supply chain arrangements where appropriate, and maintaining contingency measures such as buffer inventory based on product needs. To support organizational resilience, these plans are reviewed and exercised at least annually, and key colleagues are trained on their implementation. Together, these adaptation objectives help support business continuity, supply chain resilience, and the reliable delivery of medicines to patients in a changing climate.

[Fixed row]

### (5.3) Have environmental risks and opportunities affected your strategy and/or financial planning?

#### (5.3.1) Environmental risks and/or opportunities have affected your strategy and/or financial planning

Select from:

- ☒ Yes, both strategy and financial planning

### (5.3.2) Business areas where environmental risks and/or opportunities have affected your strategy

Select all that apply

- ☒ Products and services  
☒ Upstream/downstream value chain  
☒ Investment in R&D  
☒ Operations

[Fixed row]

### (5.3.1) Describe where and how environmental risks and opportunities have affected your strategy.

#### Products and services

#### (5.3.1.1) Effect type

Select all that apply

- ☒ Opportunities

#### (5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

Select all that apply

- ☒ Climate change  
☒ Water

#### (5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

*Pfizer has leveraged our achievements in green chemistry, success with our public GHG emission reduction goals and water stewardship program, and commitment to science-based targets to develop substantiated environmental information which has been shared with potential customers/retailers and in governmental tenders in response to their requests for such information. We anticipate that our goal to achieve Net-Zero GHG emissions, as well as our ability to provide environmental footprint details for our products, will become increasingly important to our customers in the next 3-5 years.*

## Upstream/downstream value chain

### (5.3.1.1) Effect type

Select all that apply

☒ Transition risks

### (5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

Select all that apply

☒ Climate change

### (5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

*As one of the first companies to receive validation of our then current GHG emission reduction goal by the Science Based Target Initiative (SBTi) in 2015, Pfizer remains committed to ambitious long-term actions aligned with science. As part of our near-term targets, approved by SBTi, we aim to use our influence to catalyze similar reductions across our value chain. Procurement of goods and services, which is essential to producing medicines and vaccines, is the most significant contributor to our Scope 3 emissions. We are therefore urging all our suppliers to commit to ambitious, science-based GHG reduction targets and have integrated environmental sustainability criteria in our supplier sourcing, contracting, and performance management processes. As a result of our engagement efforts, by the end of 2025, 72% of our suppliers by spend had set or committed to develop science-based GHG emissions reduction targets. By 2040 Pfizer aims to decrease its company GHG emissions by 95% and its value chain emissions by 90% from 2019 levels by reducing the energy demand of our operations, transitioning away from fossil fuels, sourcing renewable electricity, and engaging suppliers to catalyze equivalent action.*

## Investment in R&D

### (5.3.1.1) Effect type

Select all that apply

☒ Opportunities

### (5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

Select all that apply

☒ Climate change

☒ Water

### (5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

*Pfizer is committed to developing medicines that not only improve patient health but also have a reduced environmental impact throughout the product lifecycle when compared to traditional research, development, manufacturing, and supply methods. Building on our long history of applying green chemistry principles and promoting them across the industry, we continue to innovate in sustainable science. Our approach aims to encompass the entire product lifecycle, from early-stage research through manufacturing and end-of-life management. We are integrating sustainable product design principles within our R&D processes, aiming to systematically conserve energy, reduce water and raw material usage, minimize waste, and embrace circular solutions where possible. We continue to educate our colleagues, define key metrics and performance targets, and encourage innovation through collaboration and partnerships. In 2025, Pfizer developed the Net-Zero by Design Sustainability Playbook, a framework to embed sustainability across product development and commercialization. The playbook is informed by insights from more than 20 Life Cycle Assessments (LCAs) across a wide range of product modalities, including small molecules, large molecules, vaccines, and medical devices. These insights enable a better understanding of emissions across the product lifecycle and support identification and management of carbon hotspots, prioritization of lower-emission design choices, and evaluation of tradeoffs across materials, manufacturing, logistics, packaging, and end-of-life considerations. As the playbook is rolled out in 2026, Pfizer is also educating colleagues through targeted communications and engagement to build awareness, capability, and consistent application. By translating Net-Zero ambitions into actionable, fit-for-purpose guidance by modality, the playbook supports informed decision-making early in development and positions sustainability as a source of both environmental and commercial value.*

## Operations

### (5.3.1.1) Effect type

*Select all that apply*

☒ Opportunities

### (5.3.1.2) Environmental issues relevant to the risks and/or opportunities that have affected your strategy in this area

*Select all that apply*

☒ Climate change

☒ Water

### (5.3.1.3) Describe how environmental risks and/or opportunities have affected your strategy in this area

*We are reducing our environmental footprint by expanding the availability of renewable energy through Virtual Power Purchase Agreements (VPPAs), enhancing energy efficiency at our manufacturing and R&D facilities, and increasing our fleet of electric vehicles, among other measures. We continue to collaborate with our partners to drive adoption of science-based GHG reduction targets across our value chain. Reducing GHG emissions from our manufacturing and R&D facilities is a key element of our efforts to reach Net-Zero emissions by 2040. In 2025, Pfizer continued to advance efforts to reduce GHG emissions from our facilities by focusing on energy efficiency, procuring low-carbon and renewable energy, and operational optimization across our global portfolio. We implemented energy efficiency projects at manufacturing and R&D sites, increased the use of renewable electricity where it makes good business sense, and advanced electrification and process*

improvements to reduce on-site reliance on fossil fuels. Facility-level actions are complemented by investments in no- and low-carbon technologies and VPPAs that support renewable energy sourcing. VPPAs supporting solar projects in Spain and the United States that became operational in 2025 generate RECs covering 100% of Pfizer's purchased electricity in North America and the European Union, representing approximately 59% of global electricity consumption. In 2025, Pfizer continued to advance its water stewardship efforts through implementation of its comprehensive water management strategy, including quantifying water use, implementing mitigation plans, establishing water conservation targets, protecting water quality, improving wastewater treatment where necessary, evaluating recycling practices, and engaging with surrounding communities. Pfizer remains committed to conserving water resources, particularly in water-stressed areas, by minimizing water withdrawal, mitigating potential impacts on water quality, and managing discharges into water bodies in a responsible manner. Pfizer's Groton, Connecticut and Sanford, North Carolina sites also advanced more efficient water management through adoption of a plant-based water treatment technology for cooling towers, enabling water to be reused longer within cooling systems and supporting water savings.

[Add row]

## **(5.3.2) Describe where and how environmental risks and opportunities have affected your financial planning.**

### **Row 1**

#### **(5.3.2.1) Financial planning elements that have been affected**

Select all that apply

- ☒ Revenues
- ☒ Indirect costs
- ☒ Capital expenditures
- ☒ Assets

#### **(5.3.2.2) Effect type**

Select all that apply

- ☒ Physical risks
- ☒ Transition risks
- ☒ Opportunities

#### **(5.3.2.3) Environmental issues relevant to the risks and/or opportunities that have affected these financial planning elements**

Select all that apply

- ☒ Climate change
- ☒ Water

**(5.3.2.4) Describe how environmental risks and/or opportunities have affected these financial planning elements**

Climate-related risks and opportunities have influenced Pfizer’s business strategy and are incorporated into financial planning. Assets: Physical climate risks such as water scarcity, flooding, and extreme heat—identified through scenario analysis—have influenced asset management decisions. For example, our physical climate risk analysis concluded that by 2030, under a high emissions scenario, nearly half of Pfizer’s manufacturing and R&D sites are at high risk of water scarcity and drought, with several manufacturing sites also at risk of flooding; these risks remain high through 2050. These risks have prompted asset-level assessments and the development of mitigation plans, including infrastructure upgrades and resilience investments, to protect asset value and extend useful life. Revenues: Environmental performance is increasingly a factor in customer engagement and procurement decisions. Pfizer continues to receive requests for environmental data from customers with associated revenues exceeding \$100M. While the precise influence on purchasing decisions is difficult to quantify, this trend is considered in revenue forecasts and customer relationship strategies. Indirect Costs and Capital Expenditures: Operational costs are affected by both physical and transition risks. For example, extreme heat may increase energy consumption for cooling and backup systems, while regulatory and stakeholder expectations drive ongoing investments in sustainability reporting, risk engineering, and supply chain resilience. These costs are recurring and incorporated into annual budgets. Pfizer invests in no- and low-carbon technologies at our sites and through VPPAs that enable sourcing of renewable energy. VPPAs supporting solar projects in Spain and the United States that became operational in 2025 generate RECs that cover 100% of Pfizer’s purchased electricity in North America and the European Union, representing approximately 59% of our global electricity consumption. Pfizer continues to explore and advance country- and market-specific solutions to source renewable electricity across the remainder of our global operations, taking into account local market structures, availability, and regulatory requirements.

[Add row]

**(5.4) In your organization’s financial accounting, do you identify spending/revenue that is aligned with your organization’s climate transition?**

|  | Identification of spending/revenue that is aligned with your organization’s climate transition | Methodology or framework used to assess alignment with your organization’s climate transition |
|--|------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------|
|  | Select from:<br><input checked="" type="checkbox"/> Yes                                        | Select all that apply<br><input checked="" type="checkbox"/> Other methodology or framework   |

[Fixed row]

**(5.4.1) Quantify the amount and percentage share of your spending/revenue that is aligned with your organization's climate transition.**

**Row 1**

**(5.4.1.1) Methodology or framework used to assess alignment**

Select from:

☒ Other, please specify :Internal tracking of emission reduction plan-related OPEX and CAPEX spend

**(5.4.1.5) Financial metric**

Select from:

☒ CAPEX

**(5.4.1.6) Amount of selected financial metric that is aligned in the reporting year (currency)**

96000000

**(5.4.1.7) Percentage share of selected financial metric aligned in the reporting year (%)**

3.7

**(5.4.1.8) Percentage share of selected financial metric planned to align in 2030 (%)**

0

**(5.4.1.9) Percentage share of selected financial metric planned to align in 2035 (%)**

0

**(5.4.1.12) Details of the methodology or framework used to assess alignment with your organization's climate transition**

*Pfizer integrates climate transition considerations directly into our capital allocation and operational planning processes. We track spending on Net-Zero initiatives by embedding them into our financial and strategic decision-making frameworks. This includes: - Net-Zero master plans that prioritize emission reduction opportunities. -*

*Design standards applied to capital project concepts to ensure alignment with Net-Zero goals. - Lifecycle cost analysis to evaluate long-term sustainability and financial impact. - Net-Zero tracking tags within our capital management systems to monitor investments. - Inclusion of physical and financial climate risk considerations in capital allocation and financing decisions. These tools help ensure that Net-Zero projects are not only considered but actively prioritized in both operational and capital planning cycles, enabling transparent tracking of climate-related spending. Expenses and capital spending related to our emissions reduction plan in 2025 were not material to our consolidated financial statements. While we anticipate incurring additional capital and operational expenditures to achieve our climate goals, we do not currently expect these costs to have a material impact on our financial position in the near term (i.e., through 2025 or 2030). As such, the percentage share of revenue for these periods has been reported as zero.*

*[Add row]*

## **(5.9) What is the trend in your organization's water-related capital expenditure (CAPEX) and operating expenditure (OPEX) for the reporting year, and the anticipated trend for the next reporting year?**

### **(5.9.1) Water-related CAPEX (+/- % change)**

100

### **(5.9.2) Anticipated forward trend for CAPEX (+/- % change)**

-95

### **(5.9.3) Water-related OPEX (+/- % change)**

0

### **(5.9.4) Anticipated forward trend for OPEX (+/- % change)**

0

### **(5.9.5) Please explain**

*Water-related CAPEX increased in the reporting year due to investments in wastewater treatment projects supporting Pfizer's goal of achieving published Predicted No Effect Concentrations (PNECs) for antibiotics across internal manufacturing sites by the end of 2025. These investments supported strengthened environmental risk assessment, controls, and governance across our manufacturing network. CAPEX is expected to decline significantly in the next reporting year as major wastewater treatment projects are completed. Water-related costs continue to represent less than 1% of Pfizer's total OPEX spend.*

[Fixed row]

## (5.10) Does your organization use an internal price on environmental externalities?

### Carbon

#### (5.10.1) Use of internal pricing for this environmental externality

Select from:

☒ Yes

### Water

#### (5.10.1) Use of internal pricing for this environmental externality

Select from:

☒ No, and we do not plan to in the next two years

#### (5.10.2) Primary reason for not pricing this environmental externality

Select from:

☒ Not an immediate strategic priority

#### (5.10.3) Explain why your organization does not price this environmental externality

*Pfizer does not currently apply an internal water price; water-related risks and opportunities are managed through water stewardship programs, risk assessments, and operational targets.*

### Other

#### (5.10.1) Use of internal pricing for this environmental externality

Select from:

☒ No, and we do not plan to in the next two years

[Fixed row]

## **(5.10.1) Provide details of your organization's internal price on carbon.**

### **Row 1**

#### **(5.10.1.1) Type of pricing scheme**

Select from:

- ☒ Shadow price

#### **(5.10.1.2) Objectives for implementing internal price**

Select all that apply

- ☒ Incentivize consideration of climate-related issues in decision making
- ☒ Incentivize consideration of climate-related issues in risk assessment
- ☒ Influence strategy and/or financial planning
- ☒ Setting and/or achieving of climate-related policies and targets

#### **(5.10.1.3) Factors considered when determining the price**

Select all that apply

- ☒ Alignment to scientific guidance
- ☒ Alignment with the price of a carbon tax
- ☒ Scenario analysis

#### **(5.10.1.4) Calculation methodology and assumptions made in determining the price**

*Pfizer uses a \$50-\$200/mtCO<sub>2</sub>e internal carbon price to assess certain portfolios of capital projects and opportunities. This price aligns with current and projected international tax schemes that may apply to Pfizer based on its operational locations.*

#### **(5.10.1.5) Scopes covered**

Select all that apply

- ☒ Scope 1
- ☒ Scope 2

#### (5.10.1.6) Pricing approach used – spatial variance

Select from:

- ☒ Differentiated

#### (5.10.1.7) Indicate how and why the price is differentiated

*Variable globally and between markets.*

#### (5.10.1.8) Pricing approach used – temporal variance

Select from:

- ☒ Evolutionary

#### (5.10.1.9) Indicate how you expect the price to change over time

*Our strategic modeling assumes a gradual increase in carbon price from 2020 through 2029, reflecting anticipated regulatory and market developments. From 2030 onwards, the model holds the carbon price constant.*

#### (5.10.1.10) Minimum actual price used (currency per metric ton CO2e)

50

#### (5.10.1.11) Maximum actual price used (currency per metric ton CO2e)

200

#### (5.10.1.12) Business decision-making processes the internal price is applied to

Select all that apply

- ☒ Capital expenditure

- ☒ Risk management
- ☒ Opportunity management

**(5.10.1.13) Internal price is mandatory within business decision-making processes**

Select from:

☒ No

**(5.10.1.14) % total emissions in the reporting year in selected scopes this internal price covers**

18

**(5.10.1.15) Pricing approach is monitored and evaluated to achieve objectives**

Select from:

☒ Yes

**(5.10.1.16) Details of how the pricing approach is monitored and evaluated to achieve your objectives**

*Pfizer applies a shadow carbon price to help assess the financial implications of decarbonization strategies as part of the overall governance of its climate goals. This pricing mechanism has been, and will continue to be, used where appropriate to inform the identification, evaluation, and prioritization of initiatives supporting the company's Net-Zero transition. By considering multiple carbon price scenarios, Pfizer can better understand the potential impacts of evolving regulatory, market, and stakeholder expectations on the capital and operational investments required to achieve its climate objectives.*

[Add row]

**(5.11) Do you engage with your value chain on environmental issues?**

|           | Engaging with this stakeholder on environmental issues | Environmental issues covered |
|-----------|--------------------------------------------------------|------------------------------|
| Suppliers | Select from:                                           | Select all that apply        |

|                                | Engaging with this stakeholder on environmental issues  | Environmental issues covered                                                                                             |
|--------------------------------|---------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------|
|                                | <input checked="" type="checkbox"/> Yes                 | <input checked="" type="checkbox"/> Climate change<br><input checked="" type="checkbox"/> Water                          |
| Customers                      | Select from:<br><input checked="" type="checkbox"/> Yes | Select all that apply<br><input checked="" type="checkbox"/> Climate change<br><input checked="" type="checkbox"/> Water |
| Investors and shareholders     | Select from:<br><input checked="" type="checkbox"/> Yes | Select all that apply<br><input checked="" type="checkbox"/> Climate change                                              |
| Other value chain stakeholders | Select from:<br><input checked="" type="checkbox"/> Yes | Select all that apply<br><input checked="" type="checkbox"/> Climate change<br><input checked="" type="checkbox"/> Water |

[Fixed row]

### (5.11.1) Does your organization assess and classify suppliers according to their dependencies and/or impacts on the environment?

#### Climate change

##### (5.11.1.1) Assessment of supplier dependencies and/or impacts on the environment

Select from:

☒ Yes, we assess the dependencies and/or impacts of our suppliers

##### (5.11.1.2) Criteria for assessing supplier dependencies and/or impacts on the environment

Select all that apply

- ☒ Contribution to supplier-related Scope 3 emissions

#### **(5.11.1.3) % Tier 1 suppliers assessed**

Select from:

- ☒ 100%

#### **(5.11.1.4) Define a threshold for classifying suppliers as having substantive dependencies and/or impacts on the environment**

*Pfizer uses risk assessment and spend-based GHG emissions estimates to identify suppliers with substantive dependencies or potential impacts on the environment. For climate change, this includes roughly 500 parent suppliers that represent approximately 78% of our scope 3 emissions of purchased goods and services and capital goods.*

#### **(5.11.1.5) % Tier 1 suppliers meeting the threshold for substantive dependencies and/or impacts on the environment**

Select from:

- ☒ 1-25%

#### **(5.11.1.6) Number of Tier 1 suppliers meeting the thresholds for substantive dependencies and/or impacts on the environment**

500

### **Water**

#### **(5.11.1.1) Assessment of supplier dependencies and/or impacts on the environment**

Select from:

- ☒ Yes, we assess the dependencies and/or impacts of our suppliers

#### **(5.11.1.2) Criteria for assessing supplier dependencies and/or impacts on the environment**

Select all that apply

- ☒ Impact on pollution levels

### (5.11.1.3) % Tier 1 suppliers assessed

Select from:

☒ 100%

### (5.11.1.4) Define a threshold for classifying suppliers as having substantive dependencies and/or impacts on the environment

*We classify suppliers as having potential substantive environmental dependencies and/or impacts based on their role in our antibiotic supply chain. Specifically, we have evaluated 100% of our antibiotic supply chain against the AMR Industry Alliance (AMRIA) Antibiotic Manufacturing Standard, which includes science-based discharge targets. We actively engage these suppliers to uphold responsible water stewardship, including driving adherence to the AMRIA standard expectations.*

### (5.11.1.5) % Tier 1 suppliers meeting the threshold for substantive dependencies and/or impacts on the environment

Select from:

☒ Less than 1%

### (5.11.1.6) Number of Tier 1 suppliers meeting the thresholds for substantive dependencies and/or impacts on the environment

95

[Fixed row]

## (5.11.2) Does your organization prioritize which suppliers to engage with on environmental issues?

### Climate change

#### (5.11.2.1) Supplier engagement prioritization on this environmental issue

Select from:

☒ Yes, we prioritize which suppliers to engage with on this environmental issue

#### (5.11.2.2) Criteria informing which suppliers are prioritized for engagement on this environmental issue

Select all that apply

- ☒ In line with the criteria used to classify suppliers as having substantive dependencies and/or impacts relating to climate change
- ☒ Business risk mitigation
- ☒ Procurement spend
- ☒ Regulatory compliance
- ☒ Supplier performance improvement

#### (5.11.2.4) Please explain

*Our Scope 3 (value chain) GHG emissions are nearly four times our Scope 1 and 2 GHG emissions. Procurement of goods and services, which is essential to producing medicines and vaccines, is the most significant contributor to our Scope 3 emissions. We therefore expect all our suppliers to commit to ambitious, science-based GHG reduction targets and have embedded environmental sustainability criteria in our supplier sourcing, contracting, and performance management processes. In 2025, Pfizer surpassed its short-term, SBTi-validated supplier engagement target, with 72% of our suppliers establishing science-aligned emissions reductions targets—exceeding our 64% target. This achievement reflects the effectiveness of our long-term, collaborative approach to supplier engagement and underscores the importance of action across the value chain in reducing impacts of climate change on global health. Pfizer supports suppliers at varying levels of sustainability maturity. We train colleagues to implement our “supplier engagement playbook,” with a focus on emissions reduction and data verification. We also conducted focused outreach to about 50 priority suppliers, encouraging participation in programs such as SBTi and Energize. In addition, as co-chair of the Sustainable Procurement Pledge, Pfizer co-hosted capacity building sessions for procurement professionals on key external sustainability programs.*

## Water

#### (5.11.2.1) Supplier engagement prioritization on this environmental issue

Select from:

- ☒ Yes, we prioritize which suppliers to engage with on this environmental issue

#### (5.11.2.2) Criteria informing which suppliers are prioritized for engagement on this environmental issue

Select all that apply

- ☒ In line with the criteria used to classify suppliers as having substantive dependencies and/or impacts relating to water
- ☒ Business risk mitigation
- ☒ Regulatory compliance
- ☒ Supplier performance improvement

#### (5.11.2.4) Please explain

Pharmaceuticals in the environment (PiE) and antimicrobial resistance (AMR) continue to be important environmental issues for our industry. Proactively managing PiE and AMR helps protect the environment, safeguard patient trust, and improve the sustainability of our medicines and vaccines. We remain dedicated to limiting discharge of active pharmaceutical ingredients (API) to wastewater from our manufacturing processes following the responsible manufacturing practices set out in the AMR Industry Alliance (AMRIA) Antibiotic Manufacturing Standard (AMR Standard). Pfizer maintains a leadership role within AMRIA, where we currently chair the manufacturing working group's science team. In 2025, Pfizer substantially advanced our PiE program, building on certifications achieved in prior years and demonstrating continued progress against the AMR Standard across our dynamic global supply chain. Since its launch in 2023, three Pfizer sites and four of our suppliers have achieved the independent third-party British Standards Institution Kitemark for Minimized Risk of Antimicrobial Resistance certification for certain antibiotic APIs and drug products (DPs). In 2025, we received certification for one of our DPs manufactured at our Melbourne, Australia site. Pfizer continues to pursue opportunities with our internal API and DP network and external suppliers to implement certification of our antibiotic products, underscoring our long-term commitment to responsible antibiotic manufacturing.

[Fixed row]

## **(5.11.5) Do your suppliers have to meet environmental requirements as part of your organization's purchasing process?**

### **Climate change**

#### **(5.11.5.1) Suppliers have to meet specific environmental requirements related to this environmental issue as part of the purchasing process**

Select from:

☒ Yes, environmental requirements related to this environmental issue are included in our supplier contracts

#### **(5.11.5.2) Policy in place for addressing supplier non-compliance**

Select from:

☒ Yes, we have a policy in place for addressing non-compliance

#### **(5.11.5.3) Comment**

Through our contracts, we require our suppliers to establish a science-based GHG emissions reduction target for their operations (i.e., covering Scope 1 and 2) or provide evidence of a comparable alternative in effect and, during the duration of the agreement, demonstrate progress in achieving the target.

### **Water**

### **(5.11.5.1) Suppliers have to meet specific environmental requirements related to this environmental issue as part of the purchasing process**

Select from:

☒ Yes, environmental requirements related to this environmental issue are included in our supplier contracts

### **(5.11.5.2) Policy in place for addressing supplier non-compliance**

Select from:

☒ Yes, we have a policy in place for addressing non-compliance

### **(5.11.5.3) Comment**

*Pfizer is a founding member of the Pharmaceutical Supply Chain Initiative (PSCI), a collaboration of pharma companies with a purpose to define, implement and champion responsible supply chain practices. The PSCI Principles for Responsible Supply Chain Management articulate the members' expectations for suppliers to operate in a manner that minimizes adverse impacts on the environment, including ensuring the safe handling of wastewater discharge and preventing and mitigating releases to the environment. Pfizer has incorporated the PSCI Principles into our supply agreement templates and our Supplier Conduct Principles. Additionally, Pfizer is committed to limiting discharge of active pharmaceutical ingredients (API) to wastewater from our manufacturing processes. Pfizer has incorporated into our supply agreement templates requirements for suppliers to assess and mitigate, if needed, discharges of API.*

[Fixed row]

## **(5.11.6) Provide details of the environmental requirements that suppliers have to meet as part of your organization's purchasing process, and the compliance measures in place.**

### **Climate change**

#### **(5.11.6.1) Environmental requirement**

Select from:

☒ Setting a science-based emissions reduction target

#### **(5.11.6.2) Mechanisms for monitoring compliance with this environmental requirement**

Select all that apply

- ☒ Certification
- ☒ First-party verification

#### **(5.11.6.3) % tier 1 suppliers by procurement spend required to comply with this environmental requirement**

Select from:

- ☒ 51-75%

#### **(5.11.6.4) % tier 1 suppliers by procurement spend in compliance with this environmental requirement**

Select from:

- ☒ 51-75%

#### **(5.11.6.7) % tier 1 supplier-related scope 3 emissions attributable to the suppliers required to comply with this environmental requirement**

Select from:

- ☒ 51-75%

#### **(5.11.6.8) % tier 1 supplier-related scope 3 emissions attributable to the suppliers in compliance with this environmental requirement**

Select from:

- ☒ 51-75%

#### **(5.11.6.9) Response to supplier non-compliance with this environmental requirement**

Select from:

- ☒ Retain and engage

#### **(5.11.6.10) % of non-compliant suppliers engaged**

Select from:

- ☒ 76-99%

#### **(5.11.6.11) Procedures to engage non-compliant suppliers**

*Select all that apply*

- ☒ Providing information on appropriate actions that can be taken to address non-compliance

#### **(5.11.6.12) Comment**

*Responses to this question are based on suppliers of purchased goods and services (Scope 3 Category 1) only and based on spend. Our Scope 3 (value chain) GHG emissions are nearly four times our Scope 1 and 2 GHG emissions. Procurement of goods and services, which is essential to producing medicines and vaccines, is the most significant contributor to our Scope 3 emissions. We therefore expect all our suppliers to commit to ambitious, science-based GHG reduction targets and have embedded environmental sustainability criteria in our supplier sourcing, contracting, and performance management processes. In 2025, Pfizer surpassed its short-term, SBTi-validated supplier engagement target, with 72% of our suppliers by spend establishing science-aligned emissions reductions targets—exceeding our 64% target. This achievement reflects the effectiveness of our long-term, collaborative approach to supplier engagement and underscores the importance of action across the value chain in reducing impacts of climate change on global health.*

### **Water**

#### **(5.11.6.1) Environmental requirement**

*Select from:*

- ☒ Setting and monitoring water pollution-related targets

#### **(5.11.6.2) Mechanisms for monitoring compliance with this environmental requirement**

*Select all that apply*

- ☒ First-party verification  
☒ Supplier self-assessment

#### **(5.11.6.3) % tier 1 suppliers by procurement spend required to comply with this environmental requirement**

*Select from:*

- ☒ 1-25%

#### **(5.11.6.4) % tier 1 suppliers by procurement spend in compliance with this environmental requirement**

Select from:

☒ 1-25%

**(5.11.6.5) % tier 1 suppliers with substantive environmental dependencies and/or impacts related to this environmental issue required to comply with this environmental requirement**

Select from:

☒ 100%

**(5.11.6.6) % tier 1 suppliers with substantive environmental dependencies and/or impacts related to this environmental issue that are in compliance with this environmental requirement**

Select from:

☒ 100%

**(5.11.6.9) Response to supplier non-compliance with this environmental requirement**

Select from:

☒ Retain and engage

**(5.11.6.10) % of non-compliant suppliers engaged**

Select from:

☒ 100%

**(5.11.6.11) Procedures to engage non-compliant suppliers**

Select all that apply

☒ Developing quantifiable, time-bound targets and milestones to bring suppliers back into compliance

**(5.11.6.12) Comment**

*Pfizer has made significant progress toward our goal of achieving industry-published Predicted No Effect Concentrations (PNECs) for antibiotics by 2025 through sustained investment in environmental risk assessment, controls, and governance across our manufacturing network. As of 2025, Pfizer's supplier governance*

framework and assessment processes confirmed that PNECs were met across all antibiotics produced by our current supplier network, reinforcing our commitment to responsible sourcing.  
[Add row]

## **(5.11.7) Provide further details of your organization's supplier engagement on environmental issues.**

### **Climate change**

#### **(5.11.7.2) Action driven by supplier engagement**

Select from:

☒ Emissions reduction

#### **(5.11.7.3) Type and details of engagement**

Capacity building

☒ Provide training, support and best practices on how to mitigate environmental impact

☒ Support suppliers to set their own environmental commitments across their operations

Innovation and collaboration

☒ Collaborate with suppliers on innovative business models and corporate renewable energy sourcing mechanisms

#### **(5.11.7.4) Upstream value chain coverage**

Select all that apply

☒ Tier 1 suppliers

#### **(5.11.7.5) % of tier 1 suppliers by procurement spend covered by engagement**

Select from:

☒ 76-99%

#### **(5.11.7.6) % of tier 1 supplier-related scope 3 emissions covered by engagement**

Select from:

☒ 76-99%

#### (5.11.7.9) Describe the engagement and explain the effect of your engagement on the selected environmental action

*Our Scope 3 (value chain) GHG emissions are nearly four times our Scope 1 and 2 GHG emissions. Procurement of goods and services, which is essential to producing medicines and vaccines, is the most significant contributor to our Scope 3 emissions. We therefore expect all our suppliers to commit to ambitious, science-based GHG reduction targets and have embedded environmental sustainability criteria in our supplier sourcing, contracting, and performance management processes. In 2025, Pfizer surpassed its short-term, SBTi-validated supplier engagement target, with 72% of our suppliers, by spend establishing science-aligned emissions reductions targets—exceeding our 64% target. This achievement reflects the effectiveness of our long-term, collaborative approach to supplier engagement and underscores the importance of action across the value chain in reducing impacts of climate change on global health. Pfizer supports suppliers at varying levels of sustainability maturity. We train colleagues to implement our “supplier engagement playbook,” with a focus on emissions reduction and data verification. We also conducted focused outreach to about 50 priority suppliers, encouraging participation in programs such as SBTi and Energize. In addition, as co-chair of the Sustainable Procurement Pledge, Pfizer co-hosted capacity building sessions for procurement professionals on key external sustainability programs. Furthermore, Pfizer played a leadership role in the first Pharmaceutical Supply Chain Initiative (PSCI) Supplier Decarbonization Summit, a two-day, industry-wide virtual event designed to help amplify collective action. The summit underscored the growing momentum of supplier decarbonization and emphasized that meaningful progress requires strong partnerships and shared accountability between buyers and suppliers. To further accelerate supplier-driven innovation, our approach is shifting from traditional requests for proposal to requests for solution. In 2025, we piloted the external application of our 4I innovation methodology—Identify, Insight, Idea, and Impact—with suppliers, inviting them to propose solutions to reduce emissions and scale sustainable impact.*

#### (5.11.7.10) Engagement is helping your tier 1 suppliers meet an environmental requirement related to this environmental issue

Select from:

☒ Yes, please specify the environmental requirement :Setting a science-based emission reduction target

#### (5.11.7.11) Engagement is helping your tier 1 suppliers engage with their own suppliers on the selected action

Select from:

☒ Yes

### Water

#### (5.11.7.2) Action driven by supplier engagement

Select from:

☒ Other, please specify :Antibiotic discharge reductions

### (5.11.7.3) Type and details of engagement

Capacity building

☒ Provide training, support and best practices on how to mitigate environmental impact

### (5.11.7.4) Upstream value chain coverage

Select all that apply

☒ Tier 1 suppliers

### (5.11.7.5) % of tier 1 suppliers by procurement spend covered by engagement

Select from:

☒ 1-25%

### (5.11.7.7) % tier 1 suppliers with substantive impacts and/or dependencies related to this environmental issue covered by engagement

Select from:

☒ 100%

### (5.11.7.9) Describe the engagement and explain the effect of your engagement on the selected environmental action

*Pharmaceuticals in the environment (PiE) and antimicrobial resistance (AMR) continue to be important environmental issues for our industry. Pharmaceutical residues enter the environment from a range of sources. Proactively managing PiE and AMR helps protect the environment, safeguard patient trust, and improve the sustainability of our medicines and vaccines. We remain dedicated to limiting discharge of active pharmaceutical ingredient (API) to wastewater from our manufacturing processes following the responsible manufacturing practices set out in the AMR Industry Alliance (AMRIA) Antibiotic Manufacturing Standard (AMR Standard). Pfizer maintains a leadership role within AMRIA, where we currently chair the manufacturing working group's science team. In 2025, Pfizer substantially advanced our PiE program, building on certifications achieved in prior years and demonstrating continued progress against the AMR Standard across our dynamic global supply chain. Since its launch in 2023, four of our suppliers have achieved the independent third-party British Standards Institution Kitemark for Minimized Risk of Antimicrobial Resistance certification for certain antibiotic APIs and drug products (DPs). Pfizer continues to pursue opportunities with our internal API and DP network and external suppliers to implement certification of our antibiotic products, underscoring our long-term commitment to responsible antibiotic manufacturing. Pfizer has made significant progress toward our goal of achieving industry-published Predicted No Effect Concentrations (PNECs) for antibiotics by 2025 through*

sustained investment in environmental risk assessment, controls, and governance across our manufacturing network. As of 2025, Pfizer's supplier governance framework and assessment processes confirmed that PNECs were met across all antibiotics produced by our current supplier network, reinforcing our commitment to responsible sourcing.

#### **(5.11.7.10) Engagement is helping your tier 1 suppliers meet an environmental requirement related to this environmental issue**

Select from:

☒ Yes, please specify the environmental requirement :Setting and monitoring water pollution-related targets

#### **(5.11.7.11) Engagement is helping your tier 1 suppliers engage with their own suppliers on the selected action**

Select from:

☒ Yes

[Add row]

### **(5.11.9) Provide details of any environmental engagement activity with other stakeholders in the value chain.**

#### **Climate change**

##### **(5.11.9.1) Type of stakeholder**

Select from:

☒ Customers

##### **(5.11.9.2) Type and details of engagement**

Education/Information sharing

☒ Share information about your products and relevant certification schemes

Innovation and collaboration

☒ Align your organization's goals to support customers' targets and ambitions

☒ Engage with stakeholders to advocate for policy or regulatory change

### (5.11.9.3) % of stakeholder type engaged

Select from:

☒ 100%

### (5.11.9.4) % stakeholder-associated scope 3 emissions

Select from:

☒ 100%

### (5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

*Pfizer recognizes that environmental sustainability issues are increasingly a priority for certain stakeholders, including our customers and shareholders. We proactively share information on our climate change performance and strategy with current and prospective customers through our annual Impact Report, postings on our Pfizer.com website, press releases, and social media posts. We frequently respond to requests from our customers for details of our environmental sustainability program and performance data and in 2025 provided information to support Scope 3 reporting for customers representing over \$160M in revenue. We are committed to continuing to collaborate with our customers to identify opportunities to reduce emissions. Pfizer is also working with our peers in the pharma industry, many of which are also our customers, to identify opportunities to drive emissions reductions in the pharmaceutical supply chain. Pfizer is proud to be part of Energize, a first-of-its-kind collaboration launched in November 2021 between 10 global pharmaceutical companies to engage suppliers in decarbonization of the pharmaceutical value chain through renewable energy procurement. The program, which is designed and delivered by Schneider Electric, enables pharmaceutical suppliers to learn more about renewable energy adoption and contracting. This offers suppliers which may not otherwise have the internal resources or expertise available the opportunity to participate in the market for PPAs. Furthermore, Pfizer is a founding member and active participant in the Pharmaceutical Supply Chain Initiative (PSCI). Pfizer colleagues currently sit on PSCI's board and several working committees. Pfizer played a leadership role in the first Pharmaceutical Supply Chain Initiative (PSCI) Supplier Decarbonization Summit, a two-day, industry-wide virtual event designed to help amplify collective action. The summit underscored the growing momentum of supplier decarbonization and emphasized that meaningful progress requires strong partnerships and shared accountability between buyers and suppliers. The percentage of stakeholder-associated Scope 3 emissions was calculated based on downstream transportation emissions.*

### (5.11.9.6) Effect of engagement and measures of success

*Pfizer shares climate-related information through our annual Impact Report, CDP Climate Change Response, and Pfizer.com. In 2025 we provided information to support Scope 3 reporting for customers representing over \$160M in revenue. As of the end of 2025, over 300 suppliers invited to participate by Pfizer have registered with Energize.*

## Water

### (5.11.9.1) Type of stakeholder

Select from:

☒ Customers

### (5.11.9.2) Type and details of engagement

Innovation and collaboration

☒ Collaborate with stakeholders on innovations to reduce environmental impacts in products and services

### (5.11.9.3) % of stakeholder type engaged

Select from:

☒ Less than 1%

### (5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

*Pharmaceuticals in the environment and antimicrobial resistance (AMR) continue to be priority environmental issues for our industry. Pfizer is committed to limiting discharge of active pharmaceutical ingredients to wastewater from our manufacturing processes, using environmental risk assessment methodologies and emission control practices and technologies. As a founding member of the AMR Industry Alliance Manufacturing Working Group, Pfizer has partnered with peer companies, many of whom are also our customers, and key stakeholders to establish and implement a common framework for managing antibiotic discharge. As a result, the AMR Industry Alliance first published its Antibiotic Manufacturing Standard: "Minimizing risk of developing antibiotic resistance and aquatic ecotoxicity in the environment resulting from the manufacturing of human antibiotics" in June 2022 and updated it in May 2025.*

### (5.11.9.6) Effect of engagement and measures of success

*Pfizer engages customers, such as government tender bodies and peer customers, on antibiotic and active pharmaceutical ingredient (API) emissions by sharing environmental risk data upon request to support transparency and alignment on responsible manufacturing practices. As a founding member of the AMR Industry Alliance Manufacturing Working Group, Pfizer collaborated with other pharmaceutical companies—many of whom are also our customers—to develop the Antibiotic Manufacturing Standard. This standard aims to minimize the risk of antimicrobial resistance and aquatic toxicity from antibiotic production. Pfizer maintains a leadership role within AMRIA, where we currently chair the manufacturing working group's science team. In 2025, Pfizer substantially advanced our PiE program, building on certifications achieved in prior years and demonstrating continued progress against the AMR Standard across our dynamic global supply chain. The effectiveness of our engagement is measured by customer uptake of data, participation in joint initiatives, and progress toward meeting discharge targets across the value chain.*

## Climate change

### (5.11.9.1) Type of stakeholder

Select from:

☒ Investors and shareholders

### (5.11.9.2) Type and details of engagement

Education/Information sharing

☒ Share information on environmental initiatives, progress and achievements

### (5.11.9.3) % of stakeholder type engaged

Select from:

☒ 1-25%

### (5.11.9.4) % stakeholder-associated scope 3 emissions

Select from:

☒ None

### (5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

*We engage investors on relevant issues, such as corporate strategy, board composition, risk oversight, patient access and affordability, executive compensation, human capital, environmental goals, corporate political spending and lobbying activities through ongoing one-on-one conversations, targeted communications, content in our annual Impact Report, and on our Responsible Business webpage (<https://www.pfizer.com/about/responsibility/responsible-business>).*

### (5.11.9.6) Effect of engagement and measures of success

*Pfizer engages investors on climate-related topics through a structured and proactive outreach strategy. Investors have expressed appreciation for our transparency, particularly around KPIs, and encouraged further action on renewable energy access and Scope 3 emissions reduction. As a result of this feedback, Pfizer participated in the pilot of the Science Based Targets initiative's (SBTi) revised Net-Zero Standard in 2025 and provided feedback to help inform its development. While measuring success is inherently qualitative, the absence of shareholder proposals related to our climate strategy and the positive feedback received during engagements are indicators of effective alignment and responsiveness to investor expectations.*

## Climate change

### (5.11.9.1) Type of stakeholder

Select from:

- ☒ Other value chain stakeholder, please specify :Employees

### (5.11.9.2) Type and details of engagement

Education/Information sharing

- ☒ Educate and work with stakeholders on understanding and measuring exposure to environmental risks
- ☒ Share information on environmental initiatives, progress and achievements

### (5.11.9.3) % of stakeholder type engaged

Select from:

- ☒ 100%

### (5.11.9.4) % stakeholder-associated scope 3 emissions

Select from:

- ☒ 100%

### (5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

*Pfizer recognizes that addressing climate change requires collective action across the value chain, including the active engagement of colleagues. As part of our goal to achieve Net-Zero greenhouse gas (GHG) emissions across our value chain by 2040, we engage colleagues globally to support climate-related initiatives that reduce emissions, build resilience, and foster a culture of environmental responsibility. Colleagues are central to Pfizer's climate strategy. Their decisions—ranging from energy use and travel to procurement and logistics—directly influence our Scope 1, 2, and 3 emissions. Engaging colleagues empowers them to contribute to our climate goals and supports alignment with Pfizer's Purpose Blueprint and values. Pfizer fosters a network of sustainability-focused groups and champions who lead climate-related initiatives, share best practices, and promote awareness across functions and geographies. This engagement model helps ensure that colleagues are not only informed but also equipped and motivated to drive climate action in their daily work. Colleagues are encouraged to identify and implement energy-saving projects at manufacturing and R&D sites. These initiatives are supported by site-level master plans and capital investment processes. The percentage of stakeholder-associated Scope 3 emissions was calculated based on business travel and employee commuting emissions.*

### (5.11.9.6) Effect of engagement and measures of success

*Pfizer integrates climate awareness and action into colleague engagement through a variety of initiatives that help colleagues make informed decisions, build sustainability capabilities, and recognize environmental leadership. To support more sustainable business travel, Pfizer has implemented tools and digital platforms that help colleagues limit travel where appropriate and select preferred carriers aligned with greenhouse gas (GHG) reduction goals. These efforts contributed to Pfizer achieving its 2025 target for reducing travel-related GHG emissions, with emissions remaining 58% below the 2019 baseline—significantly exceeding the company's 25% reduction goal. In 2025, Pfizer also developed the Net-Zero by Design Sustainability Playbook to help integrate sustainability considerations into product development and commercialization. As the playbook is rolled out in 2026, Pfizer is educating colleagues through targeted communications and engagement activities to build awareness, capability, and consistent application of sustainability principles. Additionally, Pfizer fosters colleague engagement through its Safety and Sustainability STAR Awards program, which recognizes projects that advance environmental performance. In 2025, the program received 155 nominations, including several focused on GHG reductions. Winning teams were recognized during a virtual Earth Day event, reinforcing a culture of shared learning, collaboration, and recognition.*

## Water

### (5.11.9.1) Type of stakeholder

Select from:

☒ Other value chain stakeholder, please specify :Employees

### (5.11.9.2) Type and details of engagement

Education/Information sharing

☒ Educate and work with stakeholders on understanding and measuring exposure to environmental risks

☒ Share information on environmental initiatives, progress and achievements

### (5.11.9.3) % of stakeholder type engaged

Select from:

☒ 100%

### (5.11.9.5) Rationale for engaging these stakeholders and scope of engagement

*Pfizer recognizes access to clean and safe water as a fundamental human right and a critical component of environmental stewardship. We remain committed to conserving this natural resource, with particular attention in water-stressed areas. We engage colleagues across the organization as key stakeholders in advancing our water stewardship goals, aligning with our Water Stewardship Position Statement and broader environmental strategy. The rationale for engaging colleagues stems from their integral role in implementing Pfizer's water conservation and quality initiatives. Colleagues not only are responsible for executing site-level water*

management practices but also serve as champions of sustainability within their local communities and work environments. Their engagement helps ensure that water-related risks and opportunities are addressed through both operational excellence and cultural alignment. The scope of engagement includes awareness, training, and action. Colleagues receive resource conservation training and are encouraged to identify and implement water-saving initiatives in their daily tasks and processes. Additionally, Pfizer promotes collective action and community involvement through local sustainability groups and initiatives, where colleagues collaborate on water-related projects and share best practices. These efforts are supported by Pfizer's internal environmental standards, which require sites to evaluate water usage, assess local water stress, and develop mitigation plans. Action plans developed from site-level water risk assessments often include colleague-led initiatives. By empowering colleagues to take ownership of water stewardship, Pfizer fosters a culture of environmental responsibility that extends beyond compliance—driving innovation, resilience, and long-term impact across our value chain.

**(5.11.9.6) Effect of engagement and measures of success**

Pfizer engages colleagues in water stewardship by promoting awareness, accountability, and innovation across its global operations. Our comprehensive water management strategy includes quantifying water use, implementing mitigation plans, establishing water conservation targets, protecting water quality, improving wastewater treatment where necessary, evaluating recycling practices, and engaging with surrounding communities. To further drive engagement, Pfizer's annual Safety and Sustainability STAR Awards program recognized projects that advanced environmental performance, including water conservation. Of the 155 nominations received in 2025, several focused on strategies such as optimizing cooling tower operations, implementing closed-loop systems, and reducing process water use. These efforts supported Pfizer's sustainability goals while fostering a culture of innovation and accountability. Winning teams were recognized during Earth Week and shared their approaches with the Environmental, Health, and Safety (EHS) community, reinforcing Pfizer's commitment to continuous improvement and peer learning.

[Add row]

**(5.13) Has your organization already implemented any mutually beneficial environmental initiatives due to CDP Supply Chain member engagement?**

|  | Environmental initiatives implemented due to CDP Supply Chain member engagement                         | Primary reason for not implementing environmental initiatives                                                                                               | Explain why your organization has not implemented any environmental initiatives  |
|--|---------------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------|
|  | Select from:<br><input checked="" type="checkbox"/> No, and we do not plan to within the next two years | Select from:<br><input checked="" type="checkbox"/> Other, please specify :Pfizer already engages with pharma peers on beneficial environmental initiatives | Pfizer already engages with pharma peers on beneficial environmental initiatives |

[Fixed row]

## C6. Environmental performance - Consolidation approach

(6.1) Provide details on your chosen consolidation approach for the calculation of environmental performance data.

### Climate change

#### (6.1.1) Consolidation approach used

Select from:

☒ Operational control

#### (6.1.2) Provide the rationale for the choice of consolidation approach

*The operational control boundary best represents sites and activities over which Pfizer has full authority to introduce and implement operating policies and can therefore drive reductions in emissions.*

### Water

#### (6.1.1) Consolidation approach used

Select from:

☒ Operational control

#### (6.1.2) Provide the rationale for the choice of consolidation approach

*The operational control boundary best represents sites and activities over which Pfizer has full authority to introduce and implement operating policies and can therefore best manage water use and wastewater discharge quality.*

[Fixed row]

## C7. Environmental performance - Climate change

### (7.1) Is this your first year of reporting emissions data to CDP?

Select from:

☒ No

### (7.1.1) Has your organization undergone any structural changes in the reporting year, or are any previous structural changes being accounted for in this disclosure of emissions data?

#### (7.1.1.1) Has there been a structural change?

Select all that apply

☒ Yes, a divestment

☒ Yes, other structural change, please specify :Changes to sites within Operational Control

#### (7.1.1.2) Name of organization(s) acquired, divested from, or merged with

*In December 2025, Pfizer transferred our joint venture shares in the Tunis, Tunisia site to Oleander Pharmaceuticals Pte Limited, a wholly owned subsidiary of Tenshi Pharmaceutical Private Limited (India).*

#### (7.1.1.3) Details of structural change(s), including completion dates

*In 2025, the expansion of Pfizer's Commercial offices in Paris, France and Thessaloniki, Greece resulted in these sites meeting our definition of operational control; accordingly, their emissions have been reclassified from Scope 3 to Scopes 1 and 2. In December 2025, changes at the Wuhan Biolake office resulted in the site no longer meeting our definition of operational control; accordingly, its emissions have been reclassified from Scopes 1 and 2 to Scope 3. In October 2025, Pfizer transitioned from a smaller Scope 3 office to a newly leased office in Shanghai that meets our definition of operational control; accordingly, emissions from this site are reported under Scopes 1 and 2.*

*[Fixed row]*

## **(7.1.2) Has your emissions accounting methodology, boundary, and/or reporting year definition changed in the reporting year?**

### **(7.1.2.1) Change(s) in methodology, boundary, and/or reporting year definition?**

Select all that apply

☒ Yes, a change in methodology

### **(7.1.2.2) Details of methodology, boundary, and/or reporting year definition change(s)**

*For Scope 3 Categories 1 and 2 (Purchased Goods and Services and Capital Goods), to better capture emissions at the supplier level, 2025 emissions were calculated using an updated hybrid methodology that applies supplier-specific emission factors where available, or industry-average emission factors based on each supplier's sector, covering suppliers representing over 90% of total spend. Supplier-specific emission factors are derived from the latest publicly reported emissions and financial data, identified and compiled using artificial intelligence tools. The remaining spend (less than 10%) is aggregated by material categories and groups and mapped to industry-average emission factors. For Scope 3 Category 9 (Downstream Transportation and Distribution), emissions for 2025 reflect a significant update to the calculation methodology, incorporating improved activity data and emission factors to better represent downstream logistics emissions. In addition, the scope of reporting has been expanded to include downstream transportation of final products across all regions globally, whereas prior years were primarily limited to the United States and Europe. As a result of these methodological changes and expanded coverage, 2025 emissions are not directly comparable to prior years, and the increase observed compared to 2024 is primarily attributable to the updated methodology rather than underlying changes in operational activity.*

[Fixed row]

## **(7.1.3) Have your organization's base year emissions and past years' emissions been recalculated as a result of any changes or errors reported in 7.1.1 and/or 7.1.2?**

### **(7.1.3.1) Base year recalculation**

Select from:

☒ Yes

### **(7.1.3.2) Scopes recalculated**

Select all that apply

- ☒ Scope 1
- ☒ Scope 2, location-based
- ☒ Scope 2, market-based

#### **(7.1.3.4) Base year emissions recalculation policy, including significance threshold**

*Pfizer's base year emissions are reviewed at least annually and adjusted for any changes to footprint, including acquisitions, divestitures, and closures. Emission factors for Scope 1&2 are updated annually to reflect any changes from issuing bodies and are applied retroactively from the effective date which may impact the baseline year. These adjustments are applied for all changes regardless of significance. Additionally, base year emissions, including Scope 3 emissions, may be recalculated to reflect changes in methodology if the change increases or decreases emissions by 5% or more by category.*

#### **(7.1.3.5) Past years' recalculation**

Select from:

- ☒ Yes

[Fixed row]

### **(7.2) Select the name of the standard, protocol, or methodology you have used to collect activity data and calculate emissions.**

Select all that apply

- ☒ The Greenhouse Gas Protocol: A Corporate Accounting and Reporting Standard (Revised Edition)
- ☒ The Greenhouse Gas Protocol: Scope 2 Guidance

### **(7.3) Describe your organization's approach to reporting Scope 2 emissions.**

|  | Scope 2, location-based                                                                                      | Scope 2, market-based                                                                                      | Comment                                                 |
|--|--------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------|---------------------------------------------------------|
|  | <i>Select from:</i><br><input checked="" type="checkbox"/> We are reporting a Scope 2, location-based figure | <i>Select from:</i><br><input checked="" type="checkbox"/> We are reporting a Scope 2, market-based figure | <i>We report both location and market-based figures</i> |

[Fixed row]

#### **(7.4) Are there any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1, Scope 2 or Scope 3 emissions that are excluded from your disclosure of climate-related data?**

*Select from:*

☒ Yes

##### **(7.4.1) Provide details of the sources of Scope 1, Scope 2, or Scope 3 emissions which are not included in your disclosure.**

###### **Row 1**

###### **(7.4.1.1) Source of excluded emissions**

*Emissions associated with market logistics outside of the US and the operation of third-party logistics centers.*

###### **(7.4.1.2) Scope(s) or Scope 3 category(ies)**

*Select all that apply*

☒ Scope 3: Upstream transportation and distribution

###### **(7.4.1.6) Relevance of Scope 3 emissions from this source**

*Select from:*

☒ Emissions are not relevant

#### **(7.4.1.9) Estimated percentage of total Scope 3 emissions this excluded source represents**

1

#### **(7.4.1.10) Explain why this source is excluded**

*Emissions from in-market local transportation globally (excluding the U.S.) and third-party logistics centers have historically been difficult to quantify due to limited data availability. Because these emissions do not contribute significantly to Pfizer's overall Scope 3 footprint, they have previously been excluded from reporting in accordance with the GHG Protocol. For 2025, Pfizer quantified these emissions using enhanced data obtained from transportation and logistics providers, improving the completeness of the inventory. These results are currently undergoing third-party verification. To maintain consistency in measuring performance against Pfizer's 2025 emissions targets and baseline, these newly quantified emissions have not been incorporated into the current disclosure. Consistent methodologies and boundaries throughout the target period support the comparability of reported performance over time. Following the completion of third-party verification, Pfizer intends to incorporate these emissions into future disclosures beginning with the 2026 Impact Report, aligned with future targets and baseline years as applicable. Expanding data coverage and strengthening data quality reflect Pfizer's ongoing commitment to enhancing the completeness, accuracy, and transparency of its Scope 3 emissions inventory. Inclusion of these emissions is not expected to materially affect Pfizer's total Scope 3 results or related decision-making.*

#### **(7.4.1.11) Explain how you estimated the percentage of emissions this excluded source represents**

*The percentage of emissions represented by these excluded sources was estimated using the results of emissions quantified using enhanced data; these updated results are currently undergoing third-party verification. For third-party logistics centers (warehousing), primary data were collected directly from third-party operators for over 90% of sites, specifically energy consumption data, which were used to calculate associated emissions. For the remaining sites where primary data were not available, emissions were estimated using a proxy approach based on the number of pallets handled, applying an emission factor derived from sites with available energy data. For in-market transportation, emissions were calculated using shipment-level activity data, including weight, distance, and mode of transportation, consistent with the methodology applied for Pfizer's global logistics (Category 4) emissions. The resulting emissions from these calculations were compared to Pfizer's total Scope 3 inventory to estimate their relative contribution.*

*[Add row]*

### **(7.5) Provide your base year and base year emissions.**

#### **Scope 1**

##### **(7.5.1) Base year end**

12/31/2019

##### **(7.5.2) Base year emissions (metric tons CO2e)**

### (7.5.3) Methodological details

*Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: [https://cdn.pfizer.com/pfizercom/GHG\\_Calculation\\_Methodology\\_For\\_Publication\\_JUL2026.pdf](https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_For_Publication_JUL2026.pdf).*

## Scope 2 (location-based)

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO<sub>2</sub>e)

558111

### (7.5.3) Methodological details

*Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: [https://cdn.pfizer.com/pfizercom/GHG\\_Calculation\\_Methodology\\_For\\_Publication\\_JUL2026.pdf](https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_For_Publication_JUL2026.pdf).*

## Scope 2 (market-based)

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO<sub>2</sub>e)

570388

### (7.5.3) Methodological details

*Pfizer's organizational boundaries for GHG reporting include all owned sites and leased facilities where Pfizer has operational control. Data are baseline adjusted to reflect acquisitions and divestitures, reported absolute, using boundaries per the World Resources Institute (WRI) Greenhouse Gas (GHG) Protocol, and include certain estimates and assumptions. Additional information on Pfizer's GHG emissions calculation methodology can be found on our website: [https://cdn.pfizer.com/pfizercom/GHG\\_Calculation\\_Methodology\\_For\\_Publication\\_JUL2026.pdf](https://cdn.pfizer.com/pfizercom/GHG_Calculation_Methodology_For_Publication_JUL2026.pdf).*

## Scope 3 category 1: Purchased goods and services

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO2e)

1900504

### (7.5.3) Methodological details

*Emissions were calculated based on 2019 spend data after removing spend from divested business units to the extent possible. Cradle-to-grave emissions for purchased goods and services are estimated based on spend using secondary emission factors. Spend data is extracted from Pfizer's accounting systems (i.e., SAP) by material category and material group (e.g., material category: IT Hardware, Supplies & Software; material group: Software and Licenses) and uploaded into Pfizer's Category 1&2 GHG emissions calculation tool. Spend associated with purchased goods and services with an associated GHG footprint is multiplied by the most appropriate emission factor to estimate emissions (CO2e). Spend not considered to have a significant Scope 3 GHG footprint (e.g., colleague wages, customer rebates, taxes, etc.) is excluded from the calculation. US EPA Supply Chain Greenhouse Gas Emission Factors v1.2 by NAICS6 adjusted for inflation are used to estimate emissions. Inflation adjustments are based on data from the US Bureau of Labor Statistics.*

## Scope 3 category 2: Capital goods

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO2e)

101679

### (7.5.3) Methodological details

*Emissions were calculated based on 2019 spend data after removing spend from divested business units to the extent possible. Cradle-to-grave emissions for capital goods are estimated based on spend using secondary emission factors. Spend data is extracted from Pfizer's accounting systems (i.e., SAP) by material category and material group and uploaded into Pfizer's Category 1&2 GHG emissions calculation tool. Spend associated with capital goods is multiplied by the most appropriate emission factor to estimate emissions (CO2e). US EPA Supply Chain Greenhouse Gas Emission Factors v1.2 by NAICS6 adjusted for inflation are used. Inflation adjustments are based on data from the US Bureau of Labor Statistics.*

### Scope 3 category 3: Fuel-and-energy-related activities (not included in Scope 1 or 2)

#### (7.5.1) Base year end

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

252909

### (7.5.3) Methodological details

*Emissions were calculated using electricity, heat, and steam as well as stationary and mobile fuels consumption reported by operations within Pfizer's control. For fuels, consumption by fuel type (in MWh) was multiplied by the appropriate emission factors to determine GHG emissions. Emissions from UK sources calculated using UK Government GHG Conversion Factors for Company Reporting (2020) and include CO2, CH4 and N2O (CO2e). For electricity, heat and steam, WTT emissions globally were calculated using UK Government Conversion Factors for Company Reporting. Emissions associated with transportation and distribution losses for the UK were calculated using UK factors for sites in the UK and using IEA CO2 emissions from fuel combustion 2017 for the rest of the world. T&D losses calculated using IEA factors include CO2 emissions only. T&D losses associated with chilled water were excluded due to unavailability of an emission factor but are anticipated to be <0.1% of total.*

### Scope 3 category 4: Upstream transportation and distribution

#### (7.5.1) Base year end

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

200873

### (7.5.3) Methodological details

*Emissions estimates related to upstream transportation include international transportation and market transportation within the US. 1. Emissions associated with international transportation and distribution services are calculated by our Global Logistics (GL) team using transportation mode, distance, shipment weight, and average emission factors from the GLEC Framework from Smart Freight Center. Primary operational data from our Enterprise Resource Planning tools are leveraged by the GL&NS team to obtain origin, destination, and shipment weight data. 2. Emissions data for US market transportation is obtained directly from our main vendors (FedEx-Parcel, UPS-Parcel). Additionally, for other US vendors, fuel surcharge data is used to estimate gallons of diesel fuel consumed by full truckload shipments, and GLEC v3 emission factors are applied to estimate GHG emissions. Due to lack of access to accurate 2019 US in-market data, we used 2020 data instead. Emissions associated with the transportation of goods purchased from our Tier 1 suppliers (e.g., raw materials, packaging materials) are excluded as they are included in Category 1, Purchased Goods and Services. Additionally, emissions associated with market logistics outside the US and emissions associated with the operations of third-party logistics centers are not included in the calculation. Historical upstream transportation and distribution emissions have been recalculated as the result of improvements in our methodology accounting for logistics and tertiary packaging material weights.*

## Scope 3 category 5: Waste generated in operations

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO2e)

9512

### (7.5.3) Methodological details

*Emissions (CO2e) were calculated using waste disposal and wastewater discharge data reported by operations within Pfizer's control and UK Government GHG Conversion Factors for Company Reporting (2020). Emission factors include collection, transportation and landfill emissions ('gate to grave') for waste sent to landfill. For combustion and recycling, the factors consider transport to an energy recovery or material reclamation facility only. Because most of the waste reported by sites as "other disposal" by Pfizer locations was sent to wastewater treatment, the wastewater treatment emission factor was used to estimate emissions for all waste reported in this category.*

## Scope 3 category 6: Business travel

### (7.5.1) Base year end

12/31/2019

## (7.5.2) Base year emissions (metric tons CO2e)

421399

## (7.5.3) Methodological details

*Emissions associated with air travel, hotel stays, car use (rental and personal), and rail travel booked within Pfizer's travel system are calculated by Pfizer's travel partner using detailed primary data such as distance, aircraft type, cabin class, etc. plus secondary data when primary data is not available. Air travel emission factors include radiative force. Personal and rental car travel emissions include WTT emissions. Emissions associated with personal car by the field force in the US are calculated using data from the company's reimbursement service provider and US EPA emission factors. Air travel booked outside Pfizer's travel system is estimated using spend data, and leakage rates for other forms of travel are estimated based on industry averages as reported in the paper "Data Dive: How 2021 Priorities Can Be Guided by Leakage Data" by Emburse. Emissions associated with this travel are estimated by Pfizer's travel partner.*

## Scope 3 category 7: Employee commuting

### (7.5.1) Base year end

12/31/2019

## (7.5.2) Base year emissions (metric tons CO2e)

60645

## (7.5.3) Methodological details

*Emissions were estimated based on Pfizer's employee headcount as of June 30, 2019. Commuting distance for all colleagues estimated based on data published by NationMaster using the median distance per region to estimate for countries not covered by the source data. Commuting methods for North American colleagues estimated based on a study published by Bloomberg in 2019. Commuting method assumptions for colleagues outside North America were made based on general knowledge of the region. Emissions associated with employee commuting in North America were calculated using US EPA Climate Leaders GHG 2020 emission factors. Emissions for all other regions were calculated using DEFRA emission factors (average car, unknown fuel type; national rail; light rail and tram; and average local bus).*

## Scope 3 category 8: Upstream leased assets

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO2e)

36273

### (7.5.3) Methodological details

*Leased facility square footage for sites not within Pfizer's operational control derived from Pfizer's corporate real estate database. Emissions estimated using the Greenhouse Gas Protocol/Quantis Scope 3 Evaluator.*

## Scope 3 category 9: Downstream transportation and distribution

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO2e)

99576

### (7.5.3) Methodological details

*Emissions estimated based on number of products sold and average distance of travel to medical offices, pharmacies and retailers in the US only using DEFRA emission factors.*

## Scope 3 category 10: Processing of sold products

### (7.5.1) Base year end

12/31/2019

### (7.5.2) Base year emissions (metric tons CO2e)

0

### (7.5.3) Methodological details

*Not Applicable*

### **Scope 3 category 11: Use of sold products**

#### **(7.5.1) Base year end**

12/31/2019

#### **(7.5.2) Base year emissions (metric tons CO2e)**

0

#### **(7.5.3) Methodological details**

*Not Applicable*

### **Scope 3 category 12: End of life treatment of sold products**

#### **(7.5.1) Base year end**

12/31/2019

#### **(7.5.2) Base year emissions (metric tons CO2e)**

0

#### **(7.5.3) Methodological details**

*Not Applicable*

### **Scope 3 category 13: Downstream leased assets**

#### **(7.5.1) Base year end**

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

0

#### (7.5.3) Methodological details

*Not Applicable*

### Scope 3 category 14: Franchises

#### (7.5.1) Base year end

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

0

#### (7.5.3) Methodological details

*Not Applicable*

### Scope 3 category 15: Investments

#### (7.5.1) Base year end

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

33892

#### (7.5.3) Methodological details

*Emissions data provided by Pfizer's joint venture operations where we had influence and/or operational control.*

### Scope 3: Other (upstream)

#### (7.5.1) Base year end

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

0

#### (7.5.3) Methodological details

*Not Applicable*

### Scope 3: Other (downstream)

#### (7.5.1) Base year end

12/31/2019

#### (7.5.2) Base year emissions (metric tons CO2e)

0

#### (7.5.3) Methodological details

*Not Applicable*

*[Fixed row]*

### (7.6) What were your organization's gross global Scope 1 emissions in metric tons CO2e?

|                | Gross global Scope 1 emissions (metric tons CO2e) | Methodological details                                                                                    |
|----------------|---------------------------------------------------|-----------------------------------------------------------------------------------------------------------|
| Reporting year | 614274                                            | <i>Emission factors for Scope 1 have been updated to reflect the latest releases from issuing bodies.</i> |

[Fixed row]

## (7.7) What were your organization's gross global Scope 2 emissions in metric tons CO2e?

|                | Gross global Scope 2, location-based emissions (metric tons CO2e) | Gross global Scope 2, market-based emissions (metric tons CO2e) | Methodological details                                                                                   |
|----------------|-------------------------------------------------------------------|-----------------------------------------------------------------|----------------------------------------------------------------------------------------------------------|
| Reporting year | 422876                                                            | 134232                                                          | <i>Emission factors for Scope 2 have been updated to reflect the latest releases from issuing bodies</i> |

[Fixed row]

## (7.8) Account for your organization's gross global Scope 3 emissions, disclosing and explaining any exclusions.

### Purchased goods and services

#### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

#### (7.8.2) Emissions in reporting year (metric tons CO2e)

2647407

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Hybrid method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

45

### (7.8.6) Please explain

*Pfizer estimates cradle-to-gate GHG emissions for purchased goods and services and capital goods using a hybrid spend based methodology in accordance with GHG Protocol Scope 3 Calculation Guidance, applying supplier-specific emission factors where available and industry average emission factors otherwise. Spend data are extracted from Pfizer's accounting systems (SAP) at the supplier level and categorized by material category and material group. A supplier mapping tool is used to align individual suppliers to their respective parent entities to support the application of parent-level emissions data where appropriate. The enriched spend dataset is submitted to a third-party platform. The platform uses artificial intelligence-supported models to estimate supplier-specific emission factors based on publicly available information, including reported GHG emissions and revenue data. The platform applies defined quality criteria to assess whether supplier published emissions data are sufficiently complete and robust to support the calculation of a supplier-specific emission factor. Where supplier-specific emission factors cannot be calculated due to insufficient or unavailable data, suppliers are mapped to industry average emission factors. This process is applied to over 1000 suppliers, representing more than 90% of Pfizer's total spend in Categories 1 and 2. The remaining spend—covering approximately 20,000 suppliers and representing less than 10% of total spend—is allocated based on SAP material categories and material groups and mapped to the relevant industry average emission factors. Industry average emission factors are derived from the latest available environmentally extended input-output (EEIO) datasets developed by environmental researchers and government agencies (e.g., U.S. EPA USEEIO) and are assigned at the supplier level using third-party sector classification data, supplemented by Pfizer inputs where needed. Industry emission factors are adjusted to align with the reporting year using relevant economic inflation indices (e.g., U.S. Bureau of Economic Analysis price indices) to ensure consistency between emission factors and current year spend data. In addition, geographic adjustments are applied, where relevant, to reflect differences in regional electricity grid intensity and other location-specific emission characteristics.*

### Capital goods

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

164066

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Hybrid method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

30

### (7.8.6) Please explain

*Pfizer estimates cradle-to-gate GHG emissions for purchased goods and services and capital goods using a hybrid spend based methodology that applies supplier-specific emission factors where available and industry average emission factors otherwise. Spend data are extracted from Pfizer's accounting systems (SAP) at the supplier level and categorized by material category and material group. A supplier mapping tool is used to align individual suppliers to their respective parent entities to support the application of parent-level emissions data where appropriate. The enriched spend dataset is submitted to a third-party platform. The platform uses artificial intelligence-supported models to estimate supplier-specific emission factors based on publicly available information, including reported GHG emissions and revenue data. The platform applies defined quality criteria to assess whether supplier published emissions data are sufficiently complete and robust to support the calculation of a supplier-specific emission factor. Where supplier-specific emission factors cannot be calculated due to insufficient or unavailable data, suppliers are mapped to industry average emission factors. This process is applied to over 1000 suppliers, representing more than 90% of Pfizer's total spend in Categories 1 and 2. The remaining spend—covering approximately 20,000 suppliers and representing less than 10% of total spend—is allocated based on SAP material categories and material groups and mapped to the relevant industry average emission factors. Industry average emission factors are derived from the latest available environmentally extended input-output (EEIO) datasets developed by environmental researchers and government agencies (e.g., U.S. EPA USEEIO) and are assigned at the supplier level using third-party sector classification data, supplemented by Pfizer inputs where needed. Industry emission factors are adjusted to align with the reporting year using relevant economic inflation indices (e.g., U.S. Bureau of Economic Analysis price indices) to ensure consistency between emission factors and current year spend data. In addition, geographic adjustments are applied, where relevant, to reflect differences in regional electricity grid intensity and other location-specific emission characteristics.*

### Fuel-and-energy-related activities (not included in Scope 1 or 2)

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

231527

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Average data method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

### (7.8.6) Please explain

*Emissions are calculated using Pfizer's GHG reporting tool and include: a. Production of Stationary and Mobile Fuels: Emissions are calculated by multiplying fuel consumption (in MWh, gross calorific value) by fuel-specific emission factors from the UK Government GHG Conversion Factors for Company Reporting (current year); b. Electricity Production: WTT-Generation and WTT-Transmission & Distribution (T&D) – for UK operations, emissions are calculated using current-year UK Government GHG Conversion Factors; for non-UK operations, emissions are calculated using IEA Emission Factors (latest publication). T&D Losses – UK: calculated using current-year UK Government factors; non-UK: calculated using IEA Emission Factors (latest publication); c. Heat and Steam Production (i.e., WTT-Generation and WTT-T&D) and T&D Losses: Emissions are calculated globally using current-year UK Government Conversion Factors; d. Chilled Water T&D Losses: These emissions are excluded due to the lack of an available emission factor. However, they are estimated to contribute less than 0.1% of total emissions in this category.*

## Upstream transportation and distribution

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

110146

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Distance-based method

☒ Fuel-based method

## (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

16

### (7.8.6) Please explain

*Pfizer's emissions estimates for upstream transportation and distribution include international transportation; domestic (U.S. market) transportation, Pfizer's largest market; and dry ice use related to global COVID-19 vaccine distribution. a. International Transportation and Distribution Emissions for all international transportation and distribution services are calculated by Pfizer's Global Logistics (GL) team using transportation mode, distance, shipment weight and average emission factors from the GLEC Framework by the Smart Freight Center. Primary operational data from our Enterprise Resource Planning tools are leveraged by the GL team to obtain origin, destination, and shipment weight data. Emissions are reduced through the application of certificates provided by logistics suppliers using low emissions fuels, ensuring that the claimed reductions do not surpass the calculated maximum allowable limit. Emissions associated with the transportation of goods purchased from our Tier 1 suppliers (e.g., raw materials, packaging materials) are excluded as they are included in Category 1, Purchased Goods and Services. b. U.S. Domestic Transportation Emissions from domestic transportation in the U.S. are obtained directly from Pfizer's three primary logistics providers. Additionally, for full truckload providers, fuel surcharge data is used to estimate gallons of diesel fuel consumed and GLEC emission factors are applied to estimate GHG emissions. For less-than-truckload shipments, emissions are estimated using shipment weight, average distance per shipment, and GLEC average freight emission factors. Activity data is provided by the U.S. market logistics team. c. Dry Ice and Liquid CO<sub>2</sub> Use: Pfizer sites report purchases of liquid CO<sub>2</sub> and dry ice through the GHG tracking tool. Emissions from these materials are calculated using emission factors developed by an external engineering consulting firm.*

## Waste generated in operations

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO<sub>2</sub>e)

4433

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Waste-type-specific method

## (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

### (7.8.6) Please explain

*Emissions from this category are calculated using Pfizer's GHG reporting tool. These include CO2e emissions associated with the routine disposal of waste and wastewater generated by operations under Pfizer's control. Calculations are based on data reported by sites in accordance with Pfizer's Environmental Impact Reduction and Waste and Surplus Material Management standards and use the current-year UK Government GHG Conversion Factors for Company Reporting. Emissions associated with the disposal of non-routine wastes - those generated only under special circumstances and not commonly disposed of (e.g., construction debris, remediation waste) - are not considered relevant and are not included in reporting. Included waste types: Recycled; Incinerated; Heat recovery/fuel blending; Landfilled; Other treatment. Emission factor coverage: Landfill - includes collection, transportation, and disposal ("gate to grave"); Combustion (with energy recovery) and recycling - includes transport to energy recovery or material reclamation facilities; Other treatment - as the majority of waste reported in this category is sent to wastewater treatment, the wastewater treatment emission factor is applied to all waste in this category.*

## Business travel

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

175200

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Distance-based method

☒ Fuel-based method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

94

### (7.8.6) Please explain

U.S. Emissions from business travel are calculated using a combination of primary and secondary data, depending on how the trip was booked: a. Travel Booked Within Pfizer's Travel System: Emissions from air travel, hotel stays, car use (rental and personal), and rail travel are calculated by Pfizer's travel agency consulting partner. Calculations are based on detailed primary data such as travel distance, aircraft type, cabin class, and other relevant factors. When primary data is unavailable, secondary data is used. Air travel emission factors include radiative forcing. Air, car, and rail travel include well-to-wheel (WTW) emissions. b. Personal Car Use by U.S. Field Force: Emissions are calculated by Pfizer's reimbursement service provider using vehicle type and U.S. EPA vehicle emission ratings. c. Travel Booked Outside Pfizer's Travel System: Emissions from air travel and hotel stays are estimated using spend data. If the air travel leakage rate for the reporting year is unavailable, the previous year's rate is used. Leakage rates for other travel types are estimated by Pfizer's travel agency consulting firm using industry averages, as referenced in the Emburse report: "Data Dive: How 2021 Priorities Can Be Guided By Leakage Data."

## Employee commuting

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

18953

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Average data method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

### (7.8.6) Please explain

Emissions from employee commuting are estimated using the average method outlined in the GHG Protocol Scope 3 Technical Guidance. Estimates are based on Pfizer's year-end employee headcount, as reported in the corporate headcount report. This report identifies: Employees working onsite full time; Employees commuting approximately 50% of the working year; Employees assigned to work remotely full time. Commuting assumptions: Onsite employees are assumed to commute 200 days per year; Flexible workers are assumed to commute 100 days per year (based on an average of 2.5 days per week); Remote workers are excluded from the commuting emissions estimate. Country specific median commuting distance estimates were sourced from NationMaster, with regional averages applied where data gaps existed. Commuting methods: For North America, commuting mode shares are based on a 2019 Bloomberg study; For other regions,

assumptions are made based on general regional knowledge. Emission factors: North America: U.S. EPA GHG Emission Factors Hub (Table 10 – passenger car, commuter rail, transit rail, and bus); Other regions: DEFRA emission factors (average car, unknown fuel type; national rail; light rail and tram; and average local bus). Note: There may be some double counting of emissions from employees using company-owned vehicles, which are already reported under Scope 1. Pfizer is actively working to refine and improve its commuting emissions methodology.

## Upstream leased assets

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO<sub>2</sub>e)

12982

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Asset-specific method

☒ Average data method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

52

### (7.8.6) Please explain

*In line with the GHG Protocol Corporate Value Chain (Scope 3) Standard and Category 8 Technical Guidance, Pfizer calculates upstream leased asset emissions using a combination of asset-specific data reported within Pfizer's GHG reporting tool and estimation methods based on square footage data from Pfizer's corporate real estate database, depending on data availability and site function. • For leased properties where site-specific energy data is available, emissions are estimated using data reported through Pfizer's GHG reporting tool. • For leased offices, laboratories, warehouses, distribution centers, data centers, and other leased spaces where site-specific energy data is unavailable, emissions are estimated using a GHG Protocol hybrid method. The approach combines square footage or other asset-specific activity data with emission factors developed from comparable Pfizer-defined Scope 1 and Scope 2 sites (i.e., operationally controlled sites) and applies those factors to Category 8 leased sites with similar characteristics. For data centers, a specialized asset-based approach is used that leverages average UPS load data and representative Pfizer-operated data centers to develop emission factors when actual energy consumption data is unavailable.*

## Downstream transportation and distribution

### (7.8.1) Evaluation status

Select from:

☒ Relevant, calculated

### (7.8.2) Emissions in reporting year (metric tons CO2e)

37626

### (7.8.3) Emissions calculation methodology

Select all that apply

☒ Distance-based method

### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

0

### (7.8.6) Please explain

*Emissions from downstream transportation and distribution are estimated using an activity-based approach, in which downstream operational activities are modelled. The model covers downstream transportation activities across one or two legs: from Pfizer sites to distributors, and from distributors to their customers, as well as storage activities across up to two warehousing nodes: warehousing by distributors where applicable, and warehousing by retailers or any patient serving facilities. The downstream transportation and distribution emissions model applied does not include the following activities: 1. Movements of goods not related to downstream distribution, like transfers across Pfizer sites or goods returns, 2. Transportation activities paid for by Pfizer to deliver products to downstream customers or any other Transportation already reported within our Category 4 - Upstream Transportation section and 3. Activities occurring beyond the retail level directly serving patients. Product volumes, expressed as weights, are used with modelled distances to calculate tonne-kilometer (tkm) activity, to which emission factors sourced from the GLEC Framework are applied to quantify emissions.*

## Processing of sold products

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

#### (7.8.5) Reason for this category not being relevant

Select from:

☒ Emissions estimated to be insignificant

#### (7.8.6) Please explain

*Not relevant. Pfizer products are not typically subjected to further processing.*

### Use of sold products

#### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

#### (7.8.5) Reason for this category not being relevant

Select from:

☒ Emissions estimated to be insignificant

#### (7.8.6) Please explain

*Not relevant. Pfizer products are not likely to create significant emissions in normal use.*

### End of life treatment of sold products

#### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

#### (7.8.5) Reason for this category not being relevant

Select from:

☒ Emissions estimated to be insignificant

### (7.8.6) Please explain

*Not relevant. GHG emissions associated with the normal use of Pfizer products are negligible. Products returned to Pfizer for destruction by Pfizer are accounted for in the waste treatment estimate.*

## Downstream leased assets

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Reason for this category not being relevant

Select from:

☒ Emissions covered under scope 1 or 2

### (7.8.6) Please explain

*Not relevant. Pfizer is not a significant lessor of real estate. Emissions from real estate assets within Pfizer sites that are leased to third parties are included in Scope 1 and 2 emissions and are therefore not reported under Scope 3.*

## Franchises

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Reason for this category not being relevant

Select from:

☒ Not applicable to our organization's activities

#### (7.8.6) Please explain

*Not relevant. Pfizer does not operate franchises.*

### Investments

#### (7.8.1) Evaluation status

*Select from:*

☒ Relevant, calculated

#### (7.8.2) Emissions in reporting year (metric tons CO2e)

6605

#### (7.8.3) Emissions calculation methodology

*Select all that apply*

☒ Investment-specific method

#### (7.8.4) Percentage of emissions calculated using data obtained from suppliers or value chain partners

100

#### (7.8.6) Please explain

*Pfizer holds an interest in a joint venture, ZHOPL, located in India. This site reports its energy consumption directly into Pfizer's GHG tracking tool, which is then used to calculate its Scopes 1 and 2 emissions. Pfizer's Category 15 emissions inventory includes only those equity method investments—such as joint ventures—that have operational activities and are not already reflected in the company's Scopes 1 and 2 emissions. Other equity method investments were evaluated and determined not to generate material GHG emissions*

### Other (upstream)

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Reason for this category not being relevant

Select from:

☒ Not applicable to our organization's activities

### (7.8.6) Please explain

*Pfizer does not have other upstream emissions.*

### Other (downstream)

### (7.8.1) Evaluation status

Select from:

☒ Not relevant, explanation provided

### (7.8.5) Reason for this category not being relevant

Select from:

☒ Not applicable to our organization's activities

### (7.8.6) Please explain

*Pfizer does not have other downstream emissions.*

*[Fixed row]*

### (7.9) Indicate the verification/assurance status that applies to your reported emissions.

|                                          | Verification/assurance status                                                                                     |
|------------------------------------------|-------------------------------------------------------------------------------------------------------------------|
| Scope 1                                  | <i>Select from:</i><br><input checked="" type="checkbox"/> Third-party verification or assurance process in place |
| Scope 2 (location-based or market-based) | <i>Select from:</i><br><input checked="" type="checkbox"/> Third-party verification or assurance process in place |
| Scope 3                                  | <i>Select from:</i><br><input checked="" type="checkbox"/> Third-party verification or assurance process in place |

[Fixed row]

**(7.9.1) Provide further details of the verification/assurance undertaken for your Scope 1 emissions, and attach the relevant statements.**

## Row 1

### (7.9.1.1) Verification or assurance cycle in place

*Select from:*

☒ Annual process

### (7.9.1.2) Status in the current reporting year

*Select from:*

☒ Complete

### (7.9.1.3) Type of verification or assurance

*Select from:*

☒ Reasonable assurance

#### (7.9.1.4) Attach the statement

*ERM CVS - Limited and Reasonable Assurance Report for Pfizer 2025 CDP [FINAL].pdf*

#### (7.9.1.5) Page/section reference

*Full document*

#### (7.9.1.6) Relevant standard

*Select all that apply*

☒ ISAE3000

#### (7.9.1.7) Proportion of reported emissions verified (%)

*100*

*[Add row]*

**(7.9.2) Provide further details of the verification/assurance undertaken for your Scope 2 emissions and attach the relevant statements.**

#### **Row 1**

#### (7.9.2.1) Scope 2 approach

*Select from:*

☒ Scope 2 location-based

#### (7.9.2.2) Verification or assurance cycle in place

*Select from:*

☒ Annual process

#### (7.9.2.3) Status in the current reporting year

Select from:

☒ Complete

#### (7.9.2.4) Type of verification or assurance

Select from:

☒ Reasonable assurance

#### (7.9.2.5) Attach the statement

*ERM CVS - Limited and Reasonable Assurance Report for Pfizer 2025 CDP [FINAL].pdf*

#### (7.9.2.6) Page/ section reference

*Full document*

#### (7.9.2.7) Relevant standard

Select all that apply

☒ ISAE3000

#### (7.9.2.8) Proportion of reported emissions verified (%)

100

### Row 2

#### (7.9.2.1) Scope 2 approach

Select from:

☒ Scope 2 market-based

#### (7.9.2.2) Verification or assurance cycle in place

Select from:

☒ Annual process

#### (7.9.2.3) Status in the current reporting year

Select from:

☒ Complete

#### (7.9.2.4) Type of verification or assurance

Select from:

☒ Reasonable assurance

#### (7.9.2.5) Attach the statement

*ERM CVS - Limited and Reasonable Assurance Report for Pfizer 2025 CDP [FINAL].pdf*

#### (7.9.2.6) Page/ section reference

*Full document*

#### (7.9.2.7) Relevant standard

Select all that apply

☒ ISAE3000

#### (7.9.2.8) Proportion of reported emissions verified (%)

100

[Add row]

**(7.9.3) Provide further details of the verification/assurance undertaken for your Scope 3 emissions and attach the relevant statements.**

**Row 1**

### (7.9.3.1) Scope 3 category

Select all that apply

- ☒ Scope 3: Investments
- ☒ Scope 3: Capital goods
- ☒ Scope 3: Business travel
- ☒ Scope 3: Employee commuting
- ☒ Scope 3: Upstream leased assets
- ☒ Scope 3: Purchased goods and services
- ☒ Scope 3: Waste generated in operations
- ☒ Scope 3: Upstream transportation and distribution
- ☒ Scope 3: Downstream transportation and distribution
- ☒ Scope 3: Fuel and energy-related activities (not included in Scopes 1 or 2)

### (7.9.3.2) Verification or assurance cycle in place

Select from:

- ☒ Annual process

### (7.9.3.3) Status in the current reporting year

Select from:

- ☒ Complete

### (7.9.3.4) Type of verification or assurance

Select from:

- ☒ Limited assurance

### (7.9.3.5) Attach the statement

*ERM CVS - Limited and Reasonable Assurance Report for Pfizer 2025 CDP [FINAL].pdf*

### (7.9.3.6) Page/section reference

*Full document*

### (7.9.3.7) Relevant standard

Select all that apply

☒ ISAE3000

#### (7.9.3.8) Proportion of selected emissions categories verified (%)

100

#### (7.9.3.9) Proportion of total reported scope 3 emissions verified (%)

100

[Add row]

**(7.10) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year?**

Select from:

☒ Decreased

**(7.10.1) Identify the reasons for any change in your gross global emissions (Scope 1 and 2 combined), and for each of them specify how your emissions compare to the previous year.**

**Change in renewable energy consumption**

#### (7.10.1.1) Change in emissions (metric tons CO2e)

376725

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

#### (7.10.1.3) Emissions value (percentage)

50.33

#### (7.10.1.4) Please explain calculation

*Change in emissions divided by total scope 1 & scope 2 MB emissions in reporting year, multiplied by 100  $((-376,725/748,506)*100)$*

### Other emissions reduction activities

#### (7.10.1.1) Change in emissions (metric tons CO<sub>2</sub>e)

35931

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

#### (7.10.1.3) Emissions value (percentage)

4.8

#### (7.10.1.4) Please explain calculation

*Change in emissions divided by total scope 1 & scope 2 MB emissions in reporting year, multiplied by 100  $((-32,292/748,506)*100)$*

### Divestment

#### (7.10.1.1) Change in emissions (metric tons CO<sub>2</sub>e)

231

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ Decreased

#### (7.10.1.3) Emissions value (percentage)

0.03

#### (7.10.1.4) Please explain calculation

*Change in emissions divided by total scope 1 & scope 2 MB emissions in reporting year, multiplied by 100  $((-231/748,506)*100)$*

### Acquisitions

#### (7.10.1.1) Change in emissions (metric tons CO<sub>2</sub>e)

0

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ No change

#### (7.10.1.3) Emissions value (percentage)

0

#### (7.10.1.4) Please explain calculation

*Not applicable*

### Mergers

#### (7.10.1.1) Change in emissions (metric tons CO<sub>2</sub>e)

0

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ No change

#### (7.10.1.3) Emissions value (percentage)

0

#### (7.10.1.4) Please explain calculation

*Not applicable*

### Change in output

#### (7.10.1.1) Change in emissions (metric tons CO<sub>2</sub>e)

31026

#### (7.10.1.2) Direction of change in emissions

*Select from:*

☒ Increased

#### (7.10.1.3) Emissions value (percentage)

4.15

#### (7.10.1.4) Please explain calculation

*Change in emissions divided by total scope 1 & scope 2 MB emissions in reporting year, multiplied by 100 ((31026/748506)\*100)*

### Change in methodology

#### (7.10.1.1) Change in emissions (metric tons CO<sub>2</sub>e)

0

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ No change

#### (7.10.1.3) Emissions value (percentage)

0

#### (7.10.1.4) Please explain calculation

Not applicable

#### Change in boundary

#### (7.10.1.1) Change in emissions (metric tons CO2e)

0

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ No change

#### (7.10.1.3) Emissions value (percentage)

0

#### (7.10.1.4) Please explain calculation

Not applicable

#### Change in physical operating conditions

#### (7.10.1.1) Change in emissions (metric tons CO2e)

0

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ No change

#### (7.10.1.3) Emissions value (percentage)

0

#### (7.10.1.4) Please explain calculation

*Not applicable*

### Unidentified

#### (7.10.1.1) Change in emissions (metric tons CO<sub>2</sub>e)

0

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ No change

#### (7.10.1.3) Emissions value (percentage)

0

#### (7.10.1.4) Please explain calculation

*Not applicable*

### Other

#### (7.10.1.1) Change in emissions (metric tons CO2e)

0

#### (7.10.1.2) Direction of change in emissions

Select from:

☒ No change

#### (7.10.1.3) Emissions value (percentage)

0

#### (7.10.1.4) Please explain calculation

Not applicable

[Fixed row]

**(7.10.2) Are your emissions performance calculations in 7.10 and 7.10.1 based on a location-based Scope 2 emissions figure or a market-based Scope 2 emissions figure?**

Select from:

☒ Market-based

**(7.12) Does your organization have significant land sector activities in its operations or value chain?**

#### (7.12.1) Agriculture, forestry or other land sector activities

Select from:

☒ No, explanation provided

#### (7.12.3) Specify the reason for no significant activities

Select from:

☒ Relevant activities identified but evaluated to be below the significance threshold

**(7.12.4) Significance threshold**

*Pfizer's approved science-based target boundary includes biogenic emissions and removals associated with bioenergy feedstocks. While these emissions are therefore relevant to our greenhouse gas inventory and targets, land-related emissions are not significant to Pfizer's operations. Pfizer reports a small amount of biogenic carbon emissions associated with biomass fuel use at two manufacturing facilities: wood pellets at our Freiburg, Germany facility and wood chips at our Sanford, USA facility. These biogenic emissions represented approximately 2% of total Scope 1 emissions in the reporting year. The total biogenic emissions for 2025 were 13,796.46 metric tons CO2. This resulted from wood chips, wood pellets, biodiesel 100 and Ethanol E-100 from fleet (mobile).*  
[Fixed row]

**(7.13) Does your organization choose to account for and report technological CO2 removals or captured CO2 with geologic storage, or have you done so in previous years?**

|  | Technological CO2 removals or captured CO2 with geologic storage in the reporting year | Specify the reason for no technological CO2 removals or captured CO2 with geological storage in the reporting year | Technological CO2 removals or captured CO2 with geologic storage were accounted for and reported in previous years |
|--|----------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------|
|  | Select from:<br><input checked="" type="checkbox"/> No, explanation provided           | Select from:<br><input checked="" type="checkbox"/> No relevant activities identified                              | Select from:<br><input checked="" type="checkbox"/> No                                                             |

[Fixed row]

**(7.15) Does your organization break down its Scope 1 and/or Scope 2 emissions by greenhouse gas type?**

**(7.15.1) Emissions breakdown by greenhouse gas type**

Select from:  
☒ Yes, Scope 1 emissions only  
[Fixed row]

**(7.15.1) Break down your total gross global Scope 1 and Scope 2 emissions by greenhouse gas type and provide the source of each used global warming potential (GWP).**

**Row 1**

**(7.15.1.1) Greenhouse gas**

Select from:

☒ CO2

**(7.15.1.2) Scope 1 emissions (metric tons of selected gas)**

576886

**(7.15.1.3) Scope 1 emissions (metric tons of CO2e)**

576886

**(7.15.1.8) GWP Reference**

Select from:

☒ IPCC Sixth Assessment Report (AR6 - 100 year)

**Row 2**

**(7.15.1.1) Greenhouse gas**

Select from:

☒ CH4

**(7.15.1.2) Scope 1 emissions (metric tons of selected gas)**

12

### (7.15.1.3) Scope 1 emissions (metric tons of CO2e)

332

### (7.15.1.8) GWP Reference

Select from:

☒ IPCC Sixth Assessment Report (AR6 - 100 year)

### Row 3

### (7.15.1.1) Greenhouse gas

Select from:

☒ N2O

### (7.15.1.2) Scope 1 emissions (metric tons of selected gas)

5

### (7.15.1.3) Scope 1 emissions (metric tons of CO2e)

1250

### (7.15.1.8) GWP Reference

Select from:

☒ IPCC Sixth Assessment Report (AR6 - 100 year)

### Row 4

### (7.15.1.1) Greenhouse gas

Select from:

☒ HFCs

#### (7.15.1.2) Scope 1 emissions (metric tons of selected gas)

27

#### (7.15.1.3) Scope 1 emissions (metric tons of CO<sub>2</sub>e)

39013

#### (7.15.1.8) GWP Reference

Select from:

☒ IPCC Sixth Assessment Report (AR6 - 100 year)

[\[Add row\]](#)

### (7.16) Break down your total gross global Scope 1 and 2 emissions by country/area.

#### Algeria

#### (7.16.1) Scope 1 emissions (metric tons CO<sub>2</sub>e)

467

#### (7.16.2) Scope 2, location-based (metric tons CO<sub>2</sub>e)

1530

#### (7.16.3) Scope 2, market-based (metric tons CO<sub>2</sub>e)

1530

#### Argentina

#### (7.16.1) Scope 1 emissions (metric tons CO<sub>2</sub>e)

1585

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

2170

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

2170

**Australia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

3129

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

7779

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

7779

**Austria**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

272

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

2569

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

1848

## Belarus

### (7.16.1) Scope 1 emissions (metric tons CO2e)

32

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Belgium

### (7.16.1) Scope 1 emissions (metric tons CO2e)

25271

### (7.16.2) Scope 2, location-based (metric tons CO2e)

10800

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Brazil

### (7.16.1) Scope 1 emissions (metric tons CO2e)

4672

### (7.16.2) Scope 2, location-based (metric tons CO2e)

959

(7.16.3) Scope 2, market-based (metric tons CO2e)

87

## Bulgaria

(7.16.1) Scope 1 emissions (metric tons CO2e)

153

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Canada

(7.16.1) Scope 1 emissions (metric tons CO2e)

9545

(7.16.2) Scope 2, location-based (metric tons CO2e)

30

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Chile

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

208

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

7

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

7

**China**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

18

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

4776

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

4776

**Colombia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

471

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

55

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

46

**Costa Rica**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

565

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Croatia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

2786

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

1541

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Czechia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Denmark****(7.16.1) Scope 1 emissions (metric tons CO2e)**

117

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Ecuador****(7.16.1) Scope 1 emissions (metric tons CO2e)**

6

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

## Egypt

(7.16.1) Scope 1 emissions (metric tons CO2e)

631

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Estonia

(7.16.1) Scope 1 emissions (metric tons CO2e)

43

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Finland

(7.16.1) Scope 1 emissions (metric tons CO2e)

170

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

318

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

278

**France**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

2047

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

10

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Germany**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

11273

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

9544

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

18

## Greece

### (7.16.1) Scope 1 emissions (metric tons CO2e)

825

### (7.16.2) Scope 2, location-based (metric tons CO2e)

622

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Hungary

### (7.16.1) Scope 1 emissions (metric tons CO2e)

275

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## India

### (7.16.1) Scope 1 emissions (metric tons CO2e)

5546

### (7.16.2) Scope 2, location-based (metric tons CO2e)

35298

(7.16.3) Scope 2, market-based (metric tons CO2e)

35298

Indonesia

(7.16.1) Scope 1 emissions (metric tons CO2e)

472

(7.16.2) Scope 2, location-based (metric tons CO2e)

3732

(7.16.3) Scope 2, market-based (metric tons CO2e)

3732

Ireland

(7.16.1) Scope 1 emissions (metric tons CO2e)

66407

(7.16.2) Scope 2, location-based (metric tons CO2e)

23686

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

Israel

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

479

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Italy**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

25937

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

4228

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Japan**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

7156

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

14163

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

13100

**Kazakhstan**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

71

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Korea (The Republic of)**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

12

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Latvia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

36

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Lithuania

(7.16.1) Scope 1 emissions (metric tons CO2e)

115

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Luxembourg

(7.16.1) Scope 1 emissions (metric tons CO2e)

36

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Mexico

(7.16.1) Scope 1 emissions (metric tons CO2e)

3307

(7.16.2) Scope 2, location-based (metric tons CO2e)

3194

(7.16.3) Scope 2, market-based (metric tons CO2e)

3295

## Morocco

(7.16.1) Scope 1 emissions (metric tons CO2e)

530

(7.16.2) Scope 2, location-based (metric tons CO2e)

1177

(7.16.3) Scope 2, market-based (metric tons CO2e)

1177

## Netherlands

(7.16.1) Scope 1 emissions (metric tons CO2e)

452

(7.16.2) Scope 2, location-based (metric tons CO2e)

79

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## New Zealand

(7.16.1) Scope 1 emissions (metric tons CO2e)

6

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Norway

(7.16.1) Scope 1 emissions (metric tons CO2e)

9

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Pakistan

### (7.16.1) Scope 1 emissions (metric tons CO2e)

126

### (7.16.2) Scope 2, location-based (metric tons CO2e)

4050

### (7.16.3) Scope 2, market-based (metric tons CO2e)

4050

## Peru

### (7.16.1) Scope 1 emissions (metric tons CO2e)

145

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Philippines

### (7.16.1) Scope 1 emissions (metric tons CO2e)

752

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Poland

(7.16.1) Scope 1 emissions (metric tons CO2e)

809

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Portugal

(7.16.1) Scope 1 emissions (metric tons CO2e)

681

(7.16.2) Scope 2, location-based (metric tons CO2e)

105

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Romania

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

451

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Russian Federation**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

1385

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Saudi Arabia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

658

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

3880

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

3880

**Serbia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

120

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Singapore**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

33958

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

15630

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

15630

**Slovakia**

**(7.16.1) Scope 1 emissions (metric tons CO2e)**

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**South Africa****(7.16.1) Scope 1 emissions (metric tons CO2e)**

21

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

0

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

**Spain****(7.16.1) Scope 1 emissions (metric tons CO2e)**

4569

**(7.16.2) Scope 2, location-based (metric tons CO2e)**

1386

**(7.16.3) Scope 2, market-based (metric tons CO2e)**

0

## Sweden

(7.16.1) Scope 1 emissions (metric tons CO2e)

291

(7.16.2) Scope 2, location-based (metric tons CO2e)

520

(7.16.3) Scope 2, market-based (metric tons CO2e)

417

## Switzerland

(7.16.1) Scope 1 emissions (metric tons CO2e)

297

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Taiwan, China

(7.16.1) Scope 1 emissions (metric tons CO2e)

693

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Thailand

(7.16.1) Scope 1 emissions (metric tons CO2e)

38

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Tunisia

(7.16.1) Scope 1 emissions (metric tons CO2e)

346

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Türkiye

### (7.16.1) Scope 1 emissions (metric tons CO2e)

2388

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## Ukraine

### (7.16.1) Scope 1 emissions (metric tons CO2e)

210

### (7.16.2) Scope 2, location-based (metric tons CO2e)

0

### (7.16.3) Scope 2, market-based (metric tons CO2e)

0

## United Kingdom

### (7.16.1) Scope 1 emissions (metric tons CO2e)

1314

### (7.16.2) Scope 2, location-based (metric tons CO2e)

1093

(7.16.3) Scope 2, market-based (metric tons CO2e)

95

United States of America

(7.16.1) Scope 1 emissions (metric tons CO2e)

389258

(7.16.2) Scope 2, location-based (metric tons CO2e)

267946

(7.16.3) Scope 2, market-based (metric tons CO2e)

35021

Uruguay

(7.16.1) Scope 1 emissions (metric tons CO2e)

15

(7.16.2) Scope 2, location-based (metric tons CO2e)

0

(7.16.3) Scope 2, market-based (metric tons CO2e)

0

[Fixed row]

(7.17) Indicate which gross global Scope 1 emissions breakdowns you are able to provide.

Select all that apply  
☒ By business division

(7.17.1) Break down your total gross global Scope 1 emissions by business division.

|       | Business division                    | Scope 1 emissions (metric ton CO2e) |
|-------|--------------------------------------|-------------------------------------|
| Row 1 | Pfizer Global Supply (Manufacturing) | 408691                              |
| Row 2 | Research and Development             | 129081                              |
| Row 3 | Fleet                                | 67926                               |
| Row 4 | Logistics                            | 3131                                |
| Row 5 | Other Sites                          | 17                                  |
| Row 6 | Commercial Offices                   | 5428                                |

[Add row]

(7.20) Indicate which gross global Scope 2 emissions breakdowns you are able to provide.

Select all that apply  
☒ By business division

(7.20.1) Break down your total gross global Scope 2 emissions by business division.

|       | Business division                           | Scope 2, location-based (metric tons CO2e) | Scope 2, market-based (metric tons CO2e) |
|-------|---------------------------------------------|--------------------------------------------|------------------------------------------|
| Row 1 | <i>Pfizer Global Supply (Manufacturing)</i> | 347530                                     | 92036                                    |
| Row 2 | <i>Commercial Offices</i>                   | 15875                                      | 4349                                     |
| Row 3 | <i>Logistics</i>                            | 8021                                       | 2887                                     |
| Row 4 | <i>Other Sites</i>                          | 1                                          | 0                                        |
| Row 5 | <i>Research and Development</i>             | 51359                                      | 34871                                    |
| Row 6 | <i>Historical Sites</i>                     | 90                                         | 90                                       |

[Add row]

**(7.22) Break down your gross Scope 1 and Scope 2 emissions between your consolidated accounting group and other entities included in your response.**

### Consolidated accounting group

#### (7.22.1) Scope 1 emissions (metric tons CO2e)

614274

#### (7.22.2) Scope 2, location-based emissions (metric tons CO2e)

422876

#### (7.22.3) Scope 2, market-based emissions (metric tons CO2e)

134233

#### (7.22.4) Please explain

All business units for each scope are included as Pfizer Inc.

## All other entities

### (7.22.1) Scope 1 emissions (metric tons CO2e)

0

### (7.22.2) Scope 2, location-based emissions (metric tons CO2e)

0

### (7.22.3) Scope 2, market-based emissions (metric tons CO2e)

0

### (7.22.4) Please explain

Not applicable  
[Fixed row]

## (7.23) Is your organization able to break down your emissions data for any of the subsidiaries included in your CDP response?

Select from:

☒ Not relevant as we do not have any subsidiaries

## (7.26) Allocate your emissions to your customers listed below according to the goods or services you have sold them in this reporting period.

### Row 1

### (7.26.1) Requesting member

Select from:

☒ Medtronic PLC

### (7.26.2) Scope of emissions

Select from:

☒ Scope 1

### (7.26.4) Allocation level

Select from:

☒ Company wide

### (7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

### (7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

### (7.26.8) Market value or quantity of goods/services supplied to the requesting member

787293.13

### (7.26.9) Emissions in metric tonnes of CO<sub>2</sub>e

322

### (7.26.10) Uncertainty (±%)

5

### (7.26.11) Major sources of emissions

*Fuel used to support manufacturing, R&D and Commercial operation.*

### (7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

### (7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

*GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.*

### (7.26.14) Where published information has been used, please provide a reference

*Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report ([https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).*

## Row 2

### (7.26.1) Requesting member

Select from:

☒ Medtronic PLC

### (7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

### (7.26.4) Allocation level

Select from:

☒ Company wide

#### (7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

#### (7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

#### (7.26.8) Market value or quantity of goods/services supplied to the requesting member

787293.13

#### (7.26.9) Emissions in metric tonnes of CO<sub>2</sub>e

70

#### (7.26.10) Uncertainty (±%)

5

#### (7.26.11) Major sources of emissions

*Purchased electricity, steam and heat for manufacturing, R&D and Commercial.*

#### (7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

#### (7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.

#### (7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report ([https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

### Row 3

#### (7.26.1) Requesting member

Select from:

☒ Novartis

#### (7.26.2) Scope of emissions

Select from:

☒ Scope 1

#### (7.26.4) Allocation level

Select from:

☒ Company wide

#### (7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

#### (7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

#### (7.26.8) Market value or quantity of goods/services supplied to the requesting member

2852172.49

#### (7.26.9) Emissions in metric tonnes of CO<sub>2</sub>e

652

#### (7.26.10) Uncertainty (±%)

5

#### (7.26.11) Major sources of emissions

*Fuel used to support manufacturing, R&D and Commercial operation.*

#### (7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

#### (7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

*GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.*

#### (7.26.14) Where published information has been used, please provide a reference

*Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report ([https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).*

#### Row 4

#### (7.26.1) Requesting member

Select from:

☒ Novartis

## (7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

## (7.26.4) Allocation level

Select from:

☒ Company wide

## (7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

## (7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

## (7.26.8) Market value or quantity of goods/services supplied to the requesting member

2852172.49

## (7.26.9) Emissions in metric tonnes of CO<sub>2</sub>e

144

## (7.26.10) Uncertainty (±%)

5

### (7.26.11) Major sources of emissions

*Purchased electricity, steam and heat for manufacturing, R&D and Commercial.*

### (7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

### (7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

*GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.*

### (7.26.14) Where published information has been used, please provide a reference

*Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report ([https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).*

## Row 5

### (7.26.1) Requesting member

Select from:

☒ Bristol-Myers Squibb

### (7.26.2) Scope of emissions

Select from:

☒ Scope 1

### (7.26.4) Allocation level

Select from:

☒ Company wide

#### (7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

#### (7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

#### (7.26.8) Market value or quantity of goods/services supplied to the requesting member

7033685.83

#### (7.26.9) Emissions in metric tonnes of CO<sub>2</sub>e

725

#### (7.26.10) Uncertainty (±%)

5

#### (7.26.11) Major sources of emissions

*Fuel used to support manufacturing, R&D and Commercial operation.*

#### (7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

#### (7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.

#### (7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report ([https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

### Row 6

#### (7.26.1) Requesting member

Select from:

☒ Bristol-Myers Squibb

#### (7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

#### (7.26.4) Allocation level

Select from:

☒ Company wide

#### (7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

#### (7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

**(7.26.8) Market value or quantity of goods/services supplied to the requesting member**

7033685.83

**(7.26.9) Emissions in metric tonnes of CO2e**

158

**(7.26.10) Uncertainty (±%)**

5

**(7.26.11) Major sources of emissions**

*Purchased electricity, steam and heat for manufacturing, R&D and Commercial.*

**(7.26.12) Allocation verified by a third party?**

Select from:

☒ Yes

**(7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made**

*GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.*

**(7.26.14) Where published information has been used, please provide a reference**

*Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report ([https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).*

**Row 7**

**(7.26.1) Requesting member**

Select from:

☒ Zoetis Inc

### (7.26.2) Scope of emissions

Select from:

☒ Scope 1

### (7.26.4) Allocation level

Select from:

☒ Company wide

### (7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

### (7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

### (7.26.8) Market value or quantity of goods/services supplied to the requesting member

130043465.5

### (7.26.9) Emissions in metric tonnes of CO<sub>2</sub>e

62378

### (7.26.10) Uncertainty (±%)

5

### (7.26.11) Major sources of emissions

*Fuel used to support manufacturing, R&D and Commercial operation.*

### (7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

### (7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

*GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.*

### (7.26.14) Where published information has been used, please provide a reference

*Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report ([https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).*

## Row 8

### (7.26.1) Requesting member

Select from:

☒ Zoetis Inc

### (7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

### (7.26.4) Allocation level

Select from:

☒ Company wide

#### (7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

#### (7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

#### (7.26.8) Market value or quantity of goods/services supplied to the requesting member

130043465.5

#### (7.26.9) Emissions in metric tonnes of CO<sub>2</sub>e

13631

#### (7.26.10) Uncertainty (±%)

5

#### (7.26.11) Major sources of emissions

*Purchased electricity, steam and heat for manufacturing, R&D and Commercial.*

#### (7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

#### (7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.

#### (7.26.14) Where published information has been used, please provide a reference

Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report ([https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).

#### Row 9

#### (7.26.1) Requesting member

Select from:

☒ AstraZeneca

#### (7.26.2) Scope of emissions

Select from:

☒ Scope 1

#### (7.26.4) Allocation level

Select from:

☒ Company wide

#### (7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

#### (7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

#### (7.26.8) Market value or quantity of goods/services supplied to the requesting member

21985195

#### (7.26.9) Emissions in metric tonnes of CO2e

9003

#### (7.26.10) Uncertainty (±%)

5

#### (7.26.11) Major sources of emissions

*Fuel used to support manufacturing, R&D and Commercial operation.*

#### (7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

#### (7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

*GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.*

#### (7.26.14) Where published information has been used, please provide a reference

*Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report ([https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).*

#### Row 10

#### (7.26.1) Requesting member

Select from:

☒ AstraZeneca

## (7.26.2) Scope of emissions

Select from:

☒ Scope 2: market-based

## (7.26.4) Allocation level

Select from:

☒ Company wide

## (7.26.6) Allocation method

Select from:

☒ Allocation based on the market value of products purchased

## (7.26.7) Unit for market value or quantity of goods/services supplied

Select from:

☒ Currency

## (7.26.8) Market value or quantity of goods/services supplied to the requesting member

21985195

## (7.26.9) Emissions in metric tonnes of CO<sub>2</sub>e

1967

## (7.26.10) Uncertainty (±%)

5

### (7.26.11) Major sources of emissions

*Purchased electricity, steam and heat for manufacturing, R&D and Commercial.*

### (7.26.12) Allocation verified by a third party?

Select from:

☒ Yes

### (7.26.13) Please explain how you have identified the GHG source, including major limitations to this process and assumptions made

*GHG emissions calculated using market-based emission factors and energy consumption data reported by sites within Pfizer's operational control.*

### (7.26.14) Where published information has been used, please provide a reference

*Pfizer discloses corporate-level GHG emissions and other climate-related data in our annual Impact Report ([https://cdn.pfizer.com/pfizercom/Pfizer\\_2025\\_Impact\\_Report\\_02JUN2026.pdf](https://cdn.pfizer.com/pfizercom/Pfizer_2025_Impact_Report_02JUN2026.pdf)) and KPI Table (<https://www.pfizer.com/about/responsibility/ehs-key-performance-indicators>).*

*[Add row]*

## (7.27) What are the challenges in allocating emissions to different customers, and what would help you to overcome these challenges?

### Row 1

#### (7.27.1) Allocation challenges

Select from:

☒ Other, please specify :Lack of customer-specific information

#### (7.27.2) Please explain what would help you overcome these challenges

Many of our customers, especially in the United States, purchase Pfizer products through wholesalers. We therefore do not have access to data to enable us to allocate emissions.

[Add row]

## (7.28) Do you plan to develop your capabilities to allocate emissions to your customers in the future?

|  | Do you plan to develop your capabilities to allocate emissions to your customers in the future? | Describe how you plan to develop your capabilities                                                                                                    |
|--|-------------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------|
|  | Select from:<br><input checked="" type="checkbox"/> Yes                                         | We are working to develop product-specific environmental footprint data that will enable us to more accurately allocate emissions for some customers. |

[Fixed row]

## (7.29) What percentage of your total operational spend in the reporting year was on energy?

Select from:

☒ More than 0% but less than or equal to 5%

## (7.30) Select which energy-related activities your organization has undertaken.

|                                                  | Indicate whether your organization undertook this energy-related activity in the reporting year |
|--------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Consumption of fuel (excluding feedstocks)       | Select from:<br><input checked="" type="checkbox"/> Yes                                         |
| Consumption of purchased or acquired electricity | Select from:<br><input checked="" type="checkbox"/> Yes                                         |

|                                                    | Indicate whether your organization undertook this energy-related activity in the reporting year |
|----------------------------------------------------|-------------------------------------------------------------------------------------------------|
| Consumption of purchased or acquired heat          | Select from:<br><input checked="" type="checkbox"/> Yes                                         |
| Consumption of purchased or acquired steam         | Select from:<br><input checked="" type="checkbox"/> Yes                                         |
| Consumption of purchased or acquired cooling       | Select from:<br><input checked="" type="checkbox"/> Yes                                         |
| Generation of electricity, heat, steam, or cooling | Select from:<br><input checked="" type="checkbox"/> Yes                                         |

[Fixed row]

### (7.30.1) Report your organization's energy consumption totals (excluding feedstocks) in MWh.

#### Consumption of fuel (excluding feedstock)

##### (7.30.1.1) Heating value

Select from:

☒ HHV (higher heating value)

##### (7.30.1.2) MWh from renewable sources

43537

##### (7.30.1.3) MWh from non-renewable sources

2919696

**(7.30.1.5) Total (renewable + non-renewable) MWh**

2963233.00

**Consumption of purchased or acquired electricity**

**(7.30.1.2) MWh from renewable sources**

963291

**(7.30.1.3) MWh from non-renewable sources**

176657

**(7.30.1.4) MWh from non-renewable zero or near-zero emission sources**

0

**(7.30.1.5) Total (renewable + non-renewable) MWh**

1139948.00

**Consumption of purchased or acquired heat**

**(7.30.1.2) MWh from renewable sources**

0

**(7.30.1.3) MWh from non-renewable sources**

5431

**(7.30.1.5) Total (renewable + non-renewable) MWh**

5431.00

## Consumption of purchased or acquired steam

### (7.30.1.2) MWh from renewable sources

0

### (7.30.1.3) MWh from non-renewable sources

108123

### (7.30.1.5) Total (renewable + non-renewable) MWh

108123.00

## Consumption of purchased or acquired cooling

### (7.30.1.2) MWh from renewable sources

0

### (7.30.1.3) MWh from non-renewable sources

70190

### (7.30.1.5) Total (renewable + non-renewable) MWh

70190.00

## Consumption of self-generated non-fuel renewable energy

### (7.30.1.2) MWh from renewable sources

29667

### (7.30.1.5) Total (renewable + non-renewable) MWh

29667.00

Total energy consumption

(7.30.1.2) MWh from renewable sources

1036495

(7.30.1.3) MWh from non-renewable sources

3280097

(7.30.1.4) MWh from non-renewable zero or near-zero emission sources

0

(7.30.1.5) Total (renewable + non-renewable) MWh

4316592.00  
[Fixed row]

(7.30.6) Select the applications of your organization’s consumption of fuel.

|                                                       | Indicate whether your organization undertakes this fuel application |
|-------------------------------------------------------|---------------------------------------------------------------------|
| Consumption of fuel for the generation of electricity | Select from:<br><input checked="" type="checkbox"/> Yes             |
| Consumption of fuel for the generation of heat        | Select from:<br><input checked="" type="checkbox"/> No              |

|                                                         |                                                                     |
|---------------------------------------------------------|---------------------------------------------------------------------|
|                                                         | Indicate whether your organization undertakes this fuel application |
| Consumption of fuel for the generation of steam         | Select from:<br><input checked="" type="checkbox"/> Yes             |
| Consumption of fuel for the generation of cooling       | Select from:<br><input checked="" type="checkbox"/> No              |
| Consumption of fuel for co-generation or tri-generation | Select from:<br><input checked="" type="checkbox"/> Yes             |

[Fixed row]

**(7.30.7) State how much fuel in MWh your organization has consumed (excluding feedstocks) by fuel type.**

### **Sustainable biomass**

#### **(7.30.7.1) Total fuel MWh consumed by the organization**

0

#### **(7.30.7.2) MWh fuel consumed for self-generation of electricity**

0

#### **(7.30.7.3) MWh fuel consumed for self-generation of heat**

0

#### **(7.30.7.4) MWh fuel consumed for self-generation of steam**

0

**(7.30.7.6) MWh fuel consumed for self- cogeneration or self-trigeneration**

0

**(7.30.7.7) Comment**

*No certificates for Biomass*

**Other biomass**

**(7.30.7.1) Total fuel MWh consumed by the organization**

42871

**(7.30.7.2) MWh fuel consumed for self-generation of electricity**

0

**(7.30.7.3) MWh fuel consumed for self-generation of heat**

0

**(7.30.7.4) MWh fuel consumed for self-generation of steam**

42871

**(7.30.7.6) MWh fuel consumed for self- cogeneration or self-trigeneration**

0

**(7.30.7.7) Comment**

*N/A*

**Other renewable fuels (e.g. renewable hydrogen)**

**(7.30.7.1) Total fuel MWh consumed by the organization**

317

**(7.30.7.2) MWh fuel consumed for self-generation of electricity**

0

**(7.30.7.3) MWh fuel consumed for self-generation of heat**

0

**(7.30.7.4) MWh fuel consumed for self-generation of steam**

0

**(7.30.7.6) MWh fuel consumed for self- cogeneration or self-trigeneration**

0

**(7.30.7.7) Comment**

N/A

**Coal**

**(7.30.7.1) Total fuel MWh consumed by the organization**

0

**(7.30.7.2) MWh fuel consumed for self-generation of electricity**

0

**(7.30.7.3) MWh fuel consumed for self-generation of heat**

0

(7.30.7.4) MWh fuel consumed for self-generation of steam

0

(7.30.7.6) MWh fuel consumed for self- cogeneration or self-trigeneration

0

(7.30.7.7) Comment

*No coal used at any Pfizer site*

## Oil

(7.30.7.1) Total fuel MWh consumed by the organization

114992

(7.30.7.2) MWh fuel consumed for self-generation of electricity

18023

(7.30.7.3) MWh fuel consumed for self-generation of heat

0

(7.30.7.4) MWh fuel consumed for self-generation of steam

50029

(7.30.7.6) MWh fuel consumed for self- cogeneration or self-trigeneration

0

**(7.30.7.7) Comment**

N/A

**Gas**

**(7.30.7.1) Total fuel MWh consumed by the organization**

2603735

**(7.30.7.2) MWh fuel consumed for self-generation of electricity**

0

**(7.30.7.3) MWh fuel consumed for self-generation of heat**

0

**(7.30.7.4) MWh fuel consumed for self-generation of steam**

2604029

**(7.30.7.6) MWh fuel consumed for self- cogeneration or self-trigeneration**

251759

**(7.30.7.7) Comment**

N/A

**Other non-renewable fuels (e.g. non-renewable hydrogen)**

**(7.30.7.1) Total fuel MWh consumed by the organization**

201317

**(7.30.7.2) MWh fuel consumed for self-generation of electricity**

0

**(7.30.7.3) MWh fuel consumed for self-generation of heat**

0

**(7.30.7.4) MWh fuel consumed for self-generation of steam**

0

**(7.30.7.6) MWh fuel consumed for self- cogeneration or self-trigeneration**

0

**(7.30.7.7) Comment**

N/A

**Total fuel**

**(7.30.7.1) Total fuel MWh consumed by the organization**

2963233

**(7.30.7.2) MWh fuel consumed for self-generation of electricity**

18023

**(7.30.7.3) MWh fuel consumed for self-generation of heat**

0

**(7.30.7.4) MWh fuel consumed for self-generation of steam**

2696929

**(7.30.7.6) MWh fuel consumed for self- cogeneration or self-trigeneration**

0

**(7.30.7.7) Comment**

N/A  
[Fixed row]

**(7.30.9) Provide details on the electricity, heat, steam, and cooling your organization has generated and consumed in the reporting year.**

**Electricity**

**(7.30.9.1) Total Gross generation (MWh)**

318592

**(7.30.9.2) Generation that is consumed by the organization (MWh)**

305769

**(7.30.9.3) Gross generation from renewable sources (MWh)**

30447

**(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)**

29667

**Heat**

**(7.30.9.1) Total Gross generation (MWh)**

0

**(7.30.9.2) Generation that is consumed by the organization (MWh)**

0

**(7.30.9.3) Gross generation from renewable sources (MWh)**

0

**(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)**

0

## **Steam**

**(7.30.9.1) Total Gross generation (MWh)**

0

**(7.30.9.2) Generation that is consumed by the organization (MWh)**

0

**(7.30.9.3) Gross generation from renewable sources (MWh)**

0

**(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)**

0

## **Cooling**

**(7.30.9.1) Total Gross generation (MWh)**

0

**(7.30.9.2) Generation that is consumed by the organization (MWh)**

0

**(7.30.9.3) Gross generation from renewable sources (MWh)**

0

**(7.30.9.4) Generation from renewable sources that is consumed by the organization (MWh)**

0

*[Fixed row]*

**(7.30.14) Provide a breakdown by country/area of your electricity/heat/steam/cooling consumption in the reporting year.**

**Algeria**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

3055

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Argentina**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

8395

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Australia**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

13283

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

123

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Austria**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

7167

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

61

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

8157

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

## Belarus

### (7.30.14.1) Consumption of purchased electricity (MWh)

0

### (7.30.14.2) Consumption of self-generated electricity (MWh)

0

### (7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

### (7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

### (7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

### (7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

### (7.30.14.7) Provide details of the electricity consumption excluded

Not applicable

## Belgium

### (7.30.14.1) Consumption of purchased electricity (MWh)

75984

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

23354

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Brazil**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

14552

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

1473

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Bulgaria**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Canada**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

13386

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Chile**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

30

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**China**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

6400

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

4352

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Colombia**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

260

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

88

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Costa Rica**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Croatia**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

10360

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Czechia**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Denmark**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Ecuador**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.14.7) Provide details of the electricity consumption excluded

*Not applicable*

**Egypt**

(7.30.14.1) Consumption of purchased electricity (MWh)

0

(7.30.14.2) Consumption of self-generated electricity (MWh)

0

(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

*Select from:*

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Estonia**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Finland**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

943

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

1230

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**France**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

245

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Germany**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

28603

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

249

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

54

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

## **Greece**

### **(7.30.14.1) Consumption of purchased electricity (MWh)**

2105

### **(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

### **(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

### **(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

### **(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

## **Hungary**

### **(7.30.14.1) Consumption of purchased electricity (MWh)**

0

### **(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

### **(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.14.7) Provide details of the electricity consumption excluded

*Not applicable*

**India**

(7.30.14.1) Consumption of purchased electricity (MWh)

43262

(7.30.14.2) Consumption of self-generated electricity (MWh)

1883

(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

3750

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Indonesia**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

4926

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Ireland**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

97698

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

57257

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Israel**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.14.7) Provide details of the electricity consumption excluded

*Not applicable*

## Italy

(7.30.14.1) Consumption of purchased electricity (MWh)

16360

(7.30.14.2) Consumption of self-generated electricity (MWh)

34043

(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

*Select from:*

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.14.7) Provide details of the electricity consumption excluded

*Not applicable*

## Japan

(7.30.14.1) Consumption of purchased electricity (MWh)

27032

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

2740

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

8780

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Kazakhstan**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Korea (The Republic of)**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Latvia**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

## **Lithuania**

### **(7.30.14.1) Consumption of purchased electricity (MWh)**

0

### **(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

### **(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

### **(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

### **(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

### **(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

### **(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

## **Luxembourg**

### **(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Mexico**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

7576

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Morocco**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

1736

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

231

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

## Netherlands

### (7.30.14.1) Consumption of purchased electricity (MWh)

339

### (7.30.14.2) Consumption of self-generated electricity (MWh)

0

### (7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

### (7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

### (7.30.14.7) Provide details of the electricity consumption excluded

Not applicable

## New Zealand

### (7.30.14.1) Consumption of purchased electricity (MWh)

0

### (7.30.14.2) Consumption of self-generated electricity (MWh)

0

### (7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.14.7) Provide details of the electricity consumption excluded

*Not applicable*

## Norway

(7.30.14.1) Consumption of purchased electricity (MWh)

0

(7.30.14.2) Consumption of self-generated electricity (MWh)

0

(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

*Select from:*

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Pakistan**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

11659

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Peru**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Philippines**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

## **Poland**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.14.7) Provide details of the electricity consumption excluded

*Not applicable*

## Portugal

(7.30.14.1) Consumption of purchased electricity (MWh)

999

(7.30.14.2) Consumption of self-generated electricity (MWh)

0

(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

*Select from:*

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Romania**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Russian Federation**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Saudi Arabia**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

6488

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Serbia**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.14.7) Provide details of the electricity consumption excluded

*Not applicable*

**Singapore**

(7.30.14.1) Consumption of purchased electricity (MWh)

41233

(7.30.14.2) Consumption of self-generated electricity (MWh)

33392

(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

*Select from:*

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.14.7) Provide details of the electricity consumption excluded

*Not applicable*

**Slovakia**

(7.30.14.1) Consumption of purchased electricity (MWh)

0

(7.30.14.2) Consumption of self-generated electricity (MWh)

0

(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.14.7) Provide details of the electricity consumption excluded

Not applicable

**South Africa**

(7.30.14.1) Consumption of purchased electricity (MWh)

0

(7.30.14.2) Consumption of self-generated electricity (MWh)

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Spain**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

10387

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

1924

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Sweden**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

10391

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

15906

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Switzerland**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Taiwan, China**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

(7.30.14.7) Provide details of the electricity consumption excluded

*Not applicable*

**Thailand**

(7.30.14.1) Consumption of purchased electricity (MWh)

0

(7.30.14.2) Consumption of self-generated electricity (MWh)

0

(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Tunisia**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**Türkiye**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

*Select from:*

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded**

Not applicable

## Ukraine

### (7.30.14.1) Consumption of purchased electricity (MWh)

0

### (7.30.14.2) Consumption of self-generated electricity (MWh)

0

### (7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?

Select from:

☒ No

### (7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)

0

### (7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)

0

### (7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)

0.00

### (7.30.14.7) Provide details of the electricity consumption excluded

Not applicable

## United Kingdom

### (7.30.14.1) Consumption of purchased electricity (MWh)

5639

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

1780

**(7.30.14.7) Provide details of the electricity consumption excluded**

*Not applicable*

**United States of America**

**(7.30.14.1) Consumption of purchased electricity (MWh)**

669455

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

148951

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?**

Select from:

☒ No

**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

**(7.30.14.7) Provide details of the electricity consumption excluded***Not applicable***Uruguay****(7.30.14.1) Consumption of purchased electricity (MWh)**

0

**(7.30.14.2) Consumption of self-generated electricity (MWh)**

0

**(7.30.14.3) Is some or all of this electricity consumption excluded from your RE100 commitment?***Select from:*☒ No**(7.30.14.4) Consumption of purchased heat, steam, and cooling (MWh)**

0

**(7.30.14.5) Consumption of self-generated heat, steam, and cooling (MWh)**

0

**(7.30.14.6) Total electricity/heat/steam/cooling energy consumption (MWh)**

0.00

**(7.30.14.7) Provide details of the electricity consumption excluded***Not applicable*

[Fixed row]

**(7.30.15) Provide details on the electricity purchases that were accounted for at a zero or near-zero emission factor in the reporting year.**

**Row 1**

**(7.30.15.1) Country/area of electricity consumption**

Select from:

☒ Austria

**(7.30.15.2) Sourcing method**

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

**(7.30.15.3) Low-carbon technology type**

Select from:

☒ Solar

**(7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)**

7167

**(7.30.15.6) Energy attribute certificate (EAC) tracking system used**

Select from:

☒ GO [Europe]

**(7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute**

Select from:

☒ Spain

**(7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?**

Select from:

☒ Yes

**(7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)**

2025

**(7.30.15.10) Time matching basis**

Select from:

☒ Annual volumetric matching

**(7.30.15.11) Supply arrangement start year**

2025

**(7.30.15.12) Supply agreement length**

Select from:

☒ Longer than 10 years and less than or equal to 15 years

**(7.30.15.13) Ecolabel associated with purchased renewable electricity**

Select from:

☒ Green-e Certified(R) Renewable Energy

**(7.30.15.14) Comment**

None

**Row 2**

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ Belgium

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

#### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

#### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

75984

#### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ GO [Europe]

#### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ Spain

#### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ Yes

#### (7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2025

#### (7.30.15.10) Time matching basis

Select from:

☒ Annual volumetric matching

#### (7.30.15.11) Supply arrangement start year

2025

#### (7.30.15.12) Supply agreement length

Select from:

☒ Longer than 10 years and less than or equal to 15 years

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ Green-e Certified(R) Renewable Energy

#### (7.30.15.14) Comment

None

### Row 3

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ Croatia

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

10360

### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ GO [Europe]

### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ Spain

### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ Yes

### (7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2025

### (7.30.15.10) Time matching basis

Select from:

☒ Annual volumetric matching

#### (7.30.15.11) Supply arrangement start year

2025

#### (7.30.15.12) Supply agreement length

Select from:

☒ Longer than 10 years and less than or equal to 15 years

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ Green-e Certified(R) Renewable Energy

#### (7.30.15.14) Comment

None

### Row 4

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ Finland

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

#### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

**(7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)**

943

**(7.30.15.6) Energy attribute certificate (EAC) tracking system used**

Select from:

☒ GO [Europe]

**(7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute**

Select from:

☒ Spain

**(7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?**

Select from:

☒ Yes

**(7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)**

2025

**(7.30.15.10) Time matching basis**

Select from:

☒ Annual volumetric matching

**(7.30.15.11) Supply arrangement start year**

2025

**(7.30.15.12) Supply agreement length**

Select from:

☒ Longer than 10 years and less than or equal to 15 years

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ Green-e Certified(R) Renewable Energy

#### (7.30.15.14) Comment

None

### Row 5

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ France

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

#### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

#### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

245

#### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ GO [Europe]

#### **(7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute**

Select from:

☒ Spain

#### **(7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?**

Select from:

☒ Yes

#### **(7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)**

2025

#### **(7.30.15.10) Time matching basis**

Select from:

☒ Annual volumetric matching

#### **(7.30.15.11) Supply arrangement start year**

2025

#### **(7.30.15.12) Supply agreement length**

Select from:

☒ Longer than 10 years and less than or equal to 15 years

#### **(7.30.15.13) Ecolabel associated with purchased renewable electricity**

Select from:

☒ Green-e Certified(R) Renewable Energy

#### (7.30.15.14) Comment

None

#### Row 6

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ Germany

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

#### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

#### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

28603

#### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ GO [Europe]

#### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ Spain

**(7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?**

Select from:

☒ Yes

**(7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)**

2025

**(7.30.15.10) Time matching basis**

Select from:

☒ Annual volumetric matching

**(7.30.15.11) Supply arrangement start year**

2025

**(7.30.15.12) Supply agreement length**

Select from:

☒ Longer than 10 years and less than or equal to 15 years

**(7.30.15.13) Ecolabel associated with purchased renewable electricity**

Select from:

☒ Green-e Certified(R) Renewable Energy

**(7.30.15.14) Comment**

None

**Row 7**

**(7.30.15.1) Country/area of electricity consumption**

Select from:

☒ Greece

### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

2105

### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ GO [Europe]

### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ Spain

### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ Yes

### (7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2025

#### (7.30.15.10) Time matching basis

Select from:

☒ Annual volumetric matching

#### (7.30.15.11) Supply arrangement start year

2025

#### (7.30.15.12) Supply agreement length

Select from:

☒ Longer than 10 years and less than or equal to 15 years

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ Green-e Certified(R) Renewable Energy

#### (7.30.15.14) Comment

None

### Row 8

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ Ireland

#### (7.30.15.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

### (7.30.15.3) Low-carbon technology type

Select from:

☒ Renewable electricity mix, please specify :Unknown mix

### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

97698

### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ GO [Europe]

### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ Ireland

### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ No

### (7.30.15.10) Time matching basis

Select from:

☒ Annual volumetric matching

### (7.30.15.11) Supply arrangement start year

2023

### (7.30.15.12) Supply agreement length

Select from:

☒ Year long contract

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ No additional, voluntary label

#### (7.30.15.14) Comment

*Sourced from European Union*

### Row 9

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ Italy

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

#### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

#### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

16359

#### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ GO [Europe]

#### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ Spain

#### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ Yes

#### (7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2025

#### (7.30.15.10) Time matching basis

Select from:

☒ Annual volumetric matching

#### (7.30.15.11) Supply arrangement start year

2025

#### (7.30.15.12) Supply agreement length

Select from:

☒ Longer than 10 years and less than or equal to 15 years

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ Green-e Certified(R) Renewable Energy

#### (7.30.15.14) Comment

None

#### Row 10

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ Netherlands

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

#### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

#### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

339

#### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ No EACs redeemed, retired, or cancelled by your organization or on its behalf

#### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ Spain

**(7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?**

Select from:

☒ Yes

**(7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)**

2025

**(7.30.15.10) Time matching basis**

Select from:

☒ Annual volumetric matching

**(7.30.15.11) Supply arrangement start year**

2025

**(7.30.15.12) Supply agreement length**

Select from:

☒ Longer than 10 years and less than or equal to 15 years

**(7.30.15.13) Ecolabel associated with purchased renewable electricity**

Select from:

☒ Green-e Certified(R) Renewable Energy

**(7.30.15.14) Comment**

None

**Row 11**

**(7.30.15.1) Country/area of electricity consumption**

Select from:

☒ Portugal

### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

999

### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ GO [Europe]

### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ Spain

### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ Yes

### (7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2025

#### (7.30.15.10) Time matching basis

Select from:

☒ Annual volumetric matching

#### (7.30.15.11) Supply arrangement start year

2025

#### (7.30.15.12) Supply agreement length

Select from:

☒ Longer than 10 years and less than or equal to 15 years

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ Green-e Certified(R) Renewable Energy

#### (7.30.15.14) Comment

None

### Row 12

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ Spain

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

10388

### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ GO [Europe]

### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ Spain

### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ Yes

### (7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2025

### (7.30.15.10) Time matching basis

Select from:

☒ Annual volumetric matching

### (7.30.15.11) Supply arrangement start year

2025

#### (7.30.15.12) Supply agreement length

Select from:

☒ Longer than 10 years and less than or equal to 15 years

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ Green-e Certified(R) Renewable Energy

#### (7.30.15.14) Comment

None

### Row 13

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ Sweden

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

#### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

#### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

**(7.30.15.6) Energy attribute certificate (EAC) tracking system used**

Select from:

☒ GO [Europe]

**(7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute**

Select from:

☒ Spain

**(7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?**

Select from:

☒ Yes

**(7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)**

2025

**(7.30.15.10) Time matching basis**

Select from:

☒ Annual volumetric matching

**(7.30.15.11) Supply arrangement start year**

2025

**(7.30.15.12) Supply agreement length**

Select from:

☒ Longer than 10 years and less than or equal to 15 years

### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ Green-e Certified(R) Renewable Energy

### (7.30.15.14) Comment

None

## Row 14

### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ United Kingdom

### (7.30.15.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

### (7.30.15.3) Low-carbon technology type

Select from:

☒ Renewable electricity mix, please specify :Unknown Mix

### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

2911

### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ REGO [UK]

#### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ United Kingdom

#### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ Yes

#### (7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2018

#### (7.30.15.10) Time matching basis

Select from:

☒ Annual volumetric matching

#### (7.30.15.11) Supply arrangement start year

2023

#### (7.30.15.12) Supply agreement length

Select from:

☒ Year long contract

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ No additional, voluntary label

#### (7.30.15.14) Comment

None

## Row 15

### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ Brazil

### (7.30.15.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

### (7.30.15.3) Low-carbon technology type

Select from:

☒ Hydropower (capacity unknown)

### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

13230

### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ I-REC [International]

### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ Brazil

### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ Yes

**(7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)**

2016

**(7.30.15.10) Time matching basis**

Select from:

☒ Annual volumetric matching

**(7.30.15.11) Supply arrangement start year**

2016

**(7.30.15.12) Supply agreement length**

Select from:

☒ Year long contract

**(7.30.15.13) Ecolabel associated with purchased renewable electricity**

Select from:

☒ Green-e Certified(R) Renewable Energy

**(7.30.15.14) Comment**

None

**Row 16**

**(7.30.15.1) Country/area of electricity consumption**

Select from:

☒ Canada

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

#### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

#### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

13387

#### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ REC [US and Canada]

#### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ United States of America

#### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ Yes

#### (7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2025

#### (7.30.15.10) Time matching basis

Select from:

☒ Annual volumetric matching

#### (7.30.15.11) Supply arrangement start year

2025

#### (7.30.15.12) Supply agreement length

Select from:

☒ Longer than 10 years and less than or equal to 15 years

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ Green-e Certified(R) Renewable Energy

#### (7.30.15.14) Comment

None

### Row 17

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ United States of America

#### (7.30.15.2) Sourcing method

Select from:

☒ Financial (virtual) power purchase agreement (VPPA)

### (7.30.15.3) Low-carbon technology type

Select from:

☒ Solar

### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

669454

### (7.30.15.6) Energy attribute certificate (EAC) tracking system used

Select from:

☒ REC [US and Canada]

### (7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute

Select from:

☒ United States of America

### (7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?

Select from:

☒ Yes

### (7.30.15.9) Commissioning year of the energy generation facility (e.g. date of first commercial operation or repowering)

2025

### (7.30.15.10) Time matching basis

Select from:

☒ Annual volumetric matching

### (7.30.15.11) Supply arrangement start year

2025

#### (7.30.15.12) Supply agreement length

Select from:

☒ Longer than 10 years and less than or equal to 15 years

#### (7.30.15.13) Ecolabel associated with purchased renewable electricity

Select from:

☒ Green-e Certified(R) Renewable Energy

#### (7.30.15.14) Comment

None

### Row 18

#### (7.30.15.1) Country/area of electricity consumption

Select from:

☒ United Kingdom

#### (7.30.15.2) Sourcing method

Select from:

☒ Retail supply contract with an electricity supplier (retail green electricity)

#### (7.30.15.3) Low-carbon technology type

Select from:

☒ Renewable electricity mix, please specify :Unknown Mix

#### (7.30.15.5) Low-carbon electricity consumed via selected sourcing method in the reporting year (MWh)

**(7.30.15.6) Energy attribute certificate (EAC) tracking system used***Select from:*☒ REGO [UK]**(7.30.15.7) Country/area of origin (generation) of the low-carbon electricity or energy attribute***Select from:*☒ United Kingdom**(7.30.15.8) Are you able to report the commissioning or re-powering year of the electricity generation facility?***Select from:*☒ No**(7.30.15.10) Time matching basis***Select from:*☒ Annual volumetric matching**(7.30.15.11) Supply arrangement start year**

2024

**(7.30.15.12) Supply agreement length***Select from:*☒ Longer than 1 year and less than or equal to 5 years**(7.30.15.13) Ecolabel associated with purchased renewable electricity***Select from:*☒ No additional, voluntary label

#### (7.30.15.14) Comment

*The supply agreement is a 2 year long contract*  
[Add row]

**(7.30.18) Provide details of your organization's renewable electricity generation by country/area in the reporting year.**

**Row 1**

#### (7.30.18.1) Country/area of generation

*Select from:*

☒ Australia

#### (7.30.18.2) Renewable electricity technology type

*Select from:*

☒ Solar

#### (7.30.18.3) Facility capacity (MW)

0.48

#### (7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)

123

#### (7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

123

#### (7.30.18.6) Energy attribute certificates issued for this generation

*Select from:*

☒ No

#### (7.30.18.8) Comment

None

#### Row 2

#### (7.30.18.1) Country/area of generation

Select from:

☒ Austria

#### (7.30.18.2) Renewable electricity technology type

Select from:

☒ Solar

#### (7.30.18.3) Facility capacity (MW)

0.11

#### (7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)

61

#### (7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

61

#### (7.30.18.6) Energy attribute certificates issued for this generation

Select from:

☒ No

### (7.30.18.8) Comment

None

### Row 3

### (7.30.18.1) Country/area of generation

Select from:

☒ Belgium

### (7.30.18.2) Renewable electricity technology type

Select from:

☒ Solar

### (7.30.18.3) Facility capacity (MW)

4.6

### (7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)

472

### (7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

472

### (7.30.18.6) Energy attribute certificates issued for this generation

Select from:

☒ No

### (7.30.18.8) Comment

None

#### Row 4

##### (7.30.18.1) Country/area of generation

Select from:

☒ Belgium

##### (7.30.18.2) Renewable electricity technology type

Select from:

☒ Wind

##### (7.30.18.3) Facility capacity (MW)

0.47

##### (7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)

6673

##### (7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

6673

##### (7.30.18.6) Energy attribute certificates issued for this generation

Select from:

☒ No

##### (7.30.18.8) Comment

None

Row 5

(7.30.18.1) Country/area of generation

Select from:

☒ Brazil

(7.30.18.2) Renewable electricity technology type

Select from:

☒ Solar

(7.30.18.3) Facility capacity (MW)

1.21

(7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)

1473

(7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

1473

(7.30.18.6) Energy attribute certificates issued for this generation

Select from:

☒ No

(7.30.18.8) Comment

None

Row 6

#### (7.30.18.1) Country/area of generation

Select from:

☒ Colombia

#### (7.30.18.2) Renewable electricity technology type

Select from:

☒ Solar

#### (7.30.18.3) Facility capacity (MW)

0.2

#### (7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)

97

#### (7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

88

#### (7.30.18.6) Energy attribute certificates issued for this generation

Select from:

☒ No

#### (7.30.18.8) Comment

None

#### Row 7

#### (7.30.18.1) Country/area of generation

Select from:

☒ Germany

#### (7.30.18.2) Renewable electricity technology type

Select from:

☒ Solar

#### (7.30.18.3) Facility capacity (MW)

0.11

#### (7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)

14

#### (7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

0

#### (7.30.18.6) Energy attribute certificates issued for this generation

Select from:

☒ No

#### (7.30.18.8) Comment

None

### Row 8

#### (7.30.18.1) Country/area of generation

Select from:

☒ Germany

#### (7.30.18.2) Renewable electricity technology type

Select from:

☒ Renewable electricity mix, please specify :Solar Thermal

#### (7.30.18.3) Facility capacity (MW)

0.1

#### (7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)

73

#### (7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

73

#### (7.30.18.6) Energy attribute certificates issued for this generation

Select from:

☒ No

#### (7.30.18.8) Comment

None

#### Row 9

#### (7.30.18.1) Country/area of generation

Select from:

☒ Germany

#### (7.30.18.2) Renewable electricity technology type

Select from:

☒ Geothermal

**(7.30.18.3) Facility capacity (MW)**

0.11

**(7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

176

**(7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

176

**(7.30.18.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.18.8) Comment**

None

**Row 10**

**(7.30.18.1) Country/area of generation**

Select from:

☒ India

**(7.30.18.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.18.3) Facility capacity (MW)**

0.24

**(7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

2609

**(7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

1852

**(7.30.18.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.18.8) Comment**

None

**Row 11**

**(7.30.18.1) Country/area of generation**

Select from:

☒ Ireland

**(7.30.18.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.18.3) Facility capacity (MW)**

0.19

**(7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

115

**(7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

115

**(7.30.18.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.18.8) Comment**

None

**Row 12**

**(7.30.18.1) Country/area of generation**

Select from:

☒ Italy

**(7.30.18.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.18.3) Facility capacity (MW)**

1.6

**(7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

2858

**(7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

2858

**(7.30.18.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.18.8) Comment**

None

**Row 13**

**(7.30.18.1) Country/area of generation**

Select from:

☒ Japan

**(7.30.18.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.18.3) Facility capacity (MW)**

0.24

**(7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

2740

**(7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

2740

**(7.30.18.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.18.8) Comment**

None

**Row 14**

**(7.30.18.1) Country/area of generation**

Select from:

☒ Morocco

**(7.30.18.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.18.3) Facility capacity (MW)**

0.21

**(7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

231

**(7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

231

**(7.30.18.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.18.8) Comment**

None

**Row 15**

**(7.30.18.1) Country/area of generation**

Select from:

☒ Singapore

**(7.30.18.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.18.3) Facility capacity (MW)**

1

**(7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

1959

**(7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

1959

**(7.30.18.6) Energy attribute certificates issued for this generation**

Select from:

☒ No

**(7.30.18.8) Comment**

None

**Row 16**

**(7.30.18.1) Country/area of generation**

Select from:

☒ Spain

**(7.30.18.2) Renewable electricity technology type**

Select from:

☒ Solar

**(7.30.18.3) Facility capacity (MW)**

140

**(7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)**

1924

**(7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)**

1924

#### (7.30.18.6) Energy attribute certificates issued for this generation

Select from:

☒ No

#### (7.30.18.8) Comment

None

### Row 17

#### (7.30.18.1) Country/area of generation

Select from:

☒ United States of America

#### (7.30.18.2) Renewable electricity technology type

Select from:

☒ Solar

#### (7.30.18.3) Facility capacity (MW)

0.24

#### (7.30.18.4) Total renewable electricity generated by this facility in the reporting year (MWh)

8849

#### (7.30.18.5) Renewable electricity consumed by your organization from this facility in the reporting year (MWh)

8849

#### (7.30.18.6) Energy attribute certificates issued for this generation

Select from:

☒ No

### (7.30.18.8) Comment

None

[Add row]

### (7.30.19) Describe how your organization's renewable electricity sourcing strategy directly or indirectly contributes to bringing new capacity into the grid in the countries/areas in which you operate.

*Pfizer continues to advance efforts to reduce GHG emissions from our facilities by procuring low-carbon and renewable energy across our global portfolio. Facility-level actions are complemented by Pfizer's investments in no- and low-carbon technologies and our use of virtual power purchase agreements (VPPAs) that enable sourcing of renewable energy. VPPAs supporting solar projects in Spain and the United States that became operational in 2025 generate RECs that cover 100% of Pfizer's purchased electricity in North America and the European Union, representing approximately 59% of our global electricity consumption. Pfizer continues to explore and advance country- and market specific solutions to source renewable electricity across the remainder of our global operations, taking into account local market structures, availability, and regulatory requirements.*

### (7.30.20) In the reporting year, has your organization faced barriers or challenges to sourcing renewable electricity?

|  | Challenges to sourcing renewable electricity                                                             | Challenges faced by your organization which were not country/area-specific                                                             |
|--|----------------------------------------------------------------------------------------------------------|----------------------------------------------------------------------------------------------------------------------------------------|
|  | Select from:<br><input checked="" type="checkbox"/> Yes, both in specific countries/areas and in general | <i>There is a limited supply of renewable electricity across all markets and the cost of VPPAs in many markets can be prohibitive.</i> |

[Fixed row]

### (7.30.21) Provide details of the country/area-specific challenges to sourcing renewable electricity faced by your organization in the reporting year.

## Row 1

### (7.30.21.1) Country/area

Select from:

☒ Singapore

### (7.30.21.2) Reason why it was challenging to source renewable electricity within selected country/area

Select all that apply

☒ Limited supply of renewable electricity in the market

### (7.30.21.3) Provide additional details of the barriers faced within this country/area

Limited land availability for the development of new renewable energy infrastructure.

[Add row]

**(7.45) Describe your gross global combined Scope 1 and 2 emissions for the reporting year in metric tons CO2e per unit currency total revenue and provide any additional intensity metrics that are appropriate to your business operations.**

## Row 1

### (7.45.1) Intensity figure

0.000012

### (7.45.2) Metric numerator (Gross global combined Scope 1 and 2 emissions, metric tons CO2e)

748506

### (7.45.3) Metric denominator

Select from:

☒ unit total revenue

#### (7.45.4) Metric denominator: Unit total

62579000000

#### (7.45.5) Scope 2 figure used

Select from:

☒ Market-based

#### (7.45.6) % change from previous year

33

#### (7.45.7) Direction of change

Select from:

☒ Decreased

#### (7.45.8) Reasons for change

Select all that apply

☒ Change in renewable energy consumption

#### (7.45.9) Please explain

Scope 1 and 2 GHG emissions were 33.8% lower in 2025 than in 2024, driven primarily by the commencement of renewable electricity sourcing through virtual power purchase agreements (VPPAs) in North America and Europe.

[Add row]

#### (7.52) Provide any additional climate-related metrics relevant to your business.

##### Row 1

##### (7.52.1) Description

Select from:

☒ Energy usage

#### (7.52.2) Metric value

4319018

#### (7.52.3) Metric numerator

*megawatt hours (MWh)*

#### (7.52.5) % change from previous year

2

#### (7.52.6) Direction of change

Select from:

☒ Decreased

#### (7.52.7) Please explain

*Pfizer is committed to reducing greenhouse gas (GHG) emissions by implementing targeted energy efficiency initiatives across our operations. Each of our manufacturing sites establishes annual energy reduction goals and actively pursues projects to achieve them. Progress is tracked through a structured operational excellence framework, ensuring continuous improvement and accountability.*

### Row 2

#### (7.52.1) Description

Select from:

☒ Waste

#### (7.52.2) Metric value

110631

### (7.52.3) Metric numerator

metric tons

### (7.52.5) % change from previous year

3

### (7.52.6) Direction of change

Select from:

☒ Decreased

### (7.52.7) Please explain

*Waste minimization is a core element of Pfizer's commitment to sustainable medicines. Our waste management strategy follows a hierarchy of control—avoid, reduce, reuse, recycle, and dispose—that emphasizes waste prevention, resource efficiency, and the safe, compliant management of waste across our operations. Manufacturing sites set annual targets to reduce waste sent to landfill, and performance is tracked through our operational excellence framework using internal metrics aligned with these waste hierarchy principles, supporting ongoing improvements in waste management practices.*

[Add row]

## (7.53) Did you have an emissions target that was active in the reporting year?

Select all that apply

☒ Absolute target

### (7.53.1) Provide details of your absolute emissions targets and progress made against those targets.

#### Row 1

#### (7.53.1.1) Target reference number

Select from:

☒ Abs 3

### (7.53.1.2) Is this a science-based target?

Select from:

- ☒ Yes, and this target has been approved by the Science Based Targets initiative

### (7.53.1.3) Science Based Targets initiative official validation letter

PFIZ-USA-002-OFF\_ApprovalLetter\_V4.1.pdf

### (7.53.1.4) Target ambition

Select from:

- ☒ 1.5°C aligned

### (7.53.1.5) Date target was set

11/23/2020

### (7.53.1.6) Target coverage

Select from:

- ☒ Organization-wide

### (7.53.1.7) Greenhouse gases covered by target

Select all that apply

- ☒ Carbon dioxide (CO2)  
☒ Methane (CH4)  
☒ Nitrous oxide (N2O)  
☒ Hydrofluorocarbons (HFCs)  
☒ Sulphur hexafluoride (SF6)

### (7.53.1.8) Scopes

Select all that apply

☒ Scope 1

☒ Scope 2

#### (7.53.1.9) Scope 2 accounting method

Select from:

☒ Market-based

#### (7.53.1.11) End date of base year

12/31/2019

#### (7.53.1.12) Base year Scope 1 emissions covered by target (metric tons CO2e)

695107

#### (7.53.1.13) Base year Scope 2 emissions covered by target (metric tons CO2e)

570388

#### (7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)

0.000

#### (7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)

1265495.000

#### (7.53.1.33) Base year Scope 1 emissions covered by target as % of total base year emissions in Scope 1

100

#### (7.53.1.34) Base year Scope 2 emissions covered by target as % of total base year emissions in Scope 2

100

**(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes**

100

**(7.53.1.54) End date of target**

12/31/2030

**(7.53.1.55) Targeted reduction from base year (%)**

46

**(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)**

683367.300

**(7.53.1.57) Scope 1 emissions in reporting year covered by target (metric tons CO2e)**

614274

**(7.53.1.58) Scope 2 emissions in reporting year covered by target (metric tons CO2e)**

134232

**(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)**

748506.000

**(7.53.1.78) Land-related emissions covered by target**

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

**(7.53.1.79) % of target achieved relative to base year**

**(7.53.1.80) Target status in reporting year**

Select from:

☒ Underway**(7.53.1.82) Explain target coverage and identify any exclusions**

*Pfizer's near-term Scope 1 and 2 GHG emissions reduction goal is company-wide, covering all owned sites and leased sites where Pfizer has operational control, and includes biogenic emissions and removals from bioenergy feedstocks. Pfizer's biogenic emissions are limited to the burning of wood pellets and chips at two of our manufacturing facilities and comprise approximately 1% of our Scope 1 and 2 footprint.*

**(7.53.1.83) Target objective**

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.*

**(7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year**

*Pfizer made significant progress toward our near-term climate goal in 2025, driven largely by the successful implementation of renewable electricity sourcing initiatives, including Virtual Power Purchase Agreements (VPPAs) that substantially reduced our Scope 2 emissions. Our manufacturing and R&D sites maintain long-term environmental sustainability master plans that identify opportunities to reduce environmental impacts through initiatives of varying scale and complexity. These efforts include designing new facilities and major renovations to minimize energy consumption, water use, and waste generation; investing in low- and no-carbon technologies; securing renewable electricity through contractual agreements; and improving manufacturing processes to reduce resource consumption and increase efficiency. In 2025, VPPAs supporting solar projects in Spain and the United States became operational and began generating renewable energy certificates (RECs) to cover approximately 100% of Pfizer's purchased electricity needs in North America and Europe. As a result, Pfizer reduced Scope 2 market based greenhouse gas emissions by 77% compared with our 2019 baseline. We are also advancing country-specific renewable electricity projects in other regions to further reduce our global emissions footprint. As of the end of 2025, Pfizer had achieved a 41% reduction in combined Scope 1 and 2 greenhouse gas emissions compared with our 2019 baseline.*

**(7.53.1.85) Target derived using a sectoral decarbonization approach**

Select from:

☒ No

## Row 2

### (7.53.1.1) Target reference number

Select from:

☒ Abs 4

### (7.53.1.2) Is this a science-based target?

Select from:

☒ Yes, and this target has been approved by the Science Based Targets initiative

### (7.53.1.3) Science Based Targets initiative official validation letter

PFIZ-USA-002-OFF\_ApprovalLetter\_V4.1.pdf

### (7.53.1.4) Target ambition

Select from:

☒ Well-below 2°C aligned

### (7.53.1.5) Date target was set

11/23/2020

### (7.53.1.6) Target coverage

Select from:

☒ Organization-wide

### (7.53.1.7) Greenhouse gases covered by target

Select all that apply

☒ Carbon dioxide (CO2)

☒ Methane (CH4)

- ☒ Nitrous oxide (N2O)
- ☒ Hydrofluorocarbons (HFCs)
- ☒ Sulphur hexafluoride (SF6)

#### (7.53.1.8) Scopes

*Select all that apply*

- ☒ Scope 3

#### (7.53.1.10) Scope 3 categories

*Select all that apply*

- ☒ Scope 3, Category 4 – Upstream transportation and distribution

#### (7.53.1.11) End date of base year

12/31/2019

#### (7.53.1.17) Base year Scope 3, Category 4: Upstream transportation and distribution emissions covered by target (metric tons CO2e)

200873

#### (7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)

200873.000

#### (7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)

200873.000

#### (7.53.1.38) Base year Scope 3, Category 4: Upstream transportation and distribution covered by target as % of total base year emissions in Scope 3, Category 4: Upstream transportation and distribution (metric tons CO2e)

100

**(7.53.1.52) Base year total Scope 3 emissions covered by target as % of total base year emissions in Scope 3 (in all Scope 3 categories)**

6.4

**(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes**

6.4

**(7.53.1.54) End date of target**

12/31/2025

**(7.53.1.55) Targeted reduction from base year (%)**

10

**(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)**

180785.700

**(7.53.1.62) Scope 3, Category 4: Upstream transportation and distribution emissions in reporting year covered by target (metric tons CO2e)**

110146

**(7.53.1.76) Total Scope 3 emissions in reporting year covered by target (metric tons CO2e)**

110146.000

**(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)**

110146.000

### (7.53.1.78) Land-related emissions covered by target

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

### (7.53.1.79) % of target achieved relative to base year

451.66

### (7.53.1.80) Target status in reporting year

Select from:

☒ Achieved

### (7.53.1.82) Explain target coverage and identify any exclusions

*Upstream transportation and distribution emissions were Pfizer's second largest source of Scope 3 emissions at the time the target was set. Target coverage includes Pfizer-paid transportation and distribution of Pfizer products.*

### (7.53.1.83) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.*

### (7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

### (7.53.1.86) List the emissions reduction initiatives which contributed most to achieving this target

*- Expansion of the Air-to-Ocean/Ocean Program, increasing use of lower-carbon ocean freight in place of air transport where feasible. - Increased use of low-emission fuels through emissions insetting and book-and-claim programs with logistics providers. - Collaboration with carriers and logistics partners to improve route efficiency and implement lower-emission transportation solutions*

### Row 3

#### (7.53.1.1) Target reference number

Select from:

☒ Abs 5

#### (7.53.1.2) Is this a science-based target?

Select from:

☒ Yes, and this target has been approved by the Science Based Targets initiative

#### (7.53.1.3) Science Based Targets initiative official validation letter

PFIZ-USA-002-OFF\_ApprovalLetter\_V4.1.pdf

#### (7.53.1.4) Target ambition

Select from:

☒ Well-below 2°C aligned

#### (7.53.1.5) Date target was set

11/23/2020

#### (7.53.1.6) Target coverage

Select from:

☒ Organization-wide

#### (7.53.1.7) Greenhouse gases covered by target

Select all that apply

☒ Carbon dioxide (CO2)

☒ Methane (CH4)

- ☒ Nitrous oxide (N2O)
- ☒ Hydrofluorocarbons (HFCs)
- ☒ Sulphur hexafluoride (SF6)

#### (7.53.1.8) Scopes

*Select all that apply*

- ☒ Scope 3

#### (7.53.1.10) Scope 3 categories

*Select all that apply*

- ☒ Scope 3, Category 6 – Business travel

#### (7.53.1.11) End date of base year

12/31/2019

#### (7.53.1.19) Base year Scope 3, Category 6: Business travel emissions covered by target (metric tons CO2e)

421399

#### (7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)

421399.000

#### (7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)

421399.000

#### (7.53.1.40) Base year Scope 3, Category 6: Business travel emissions covered by target as % of total base year emissions in Scope 3, Category 6: Business travel (metric tons CO2e)

100.0

**(7.53.1.52) Base year total Scope 3 emissions covered by target as % of total base year emissions in Scope 3 (in all Scope 3 categories)**

13.5

**(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes**

13.5

**(7.53.1.54) End date of target**

12/31/2025

**(7.53.1.55) Targeted reduction from base year (%)**

25

**(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)**

316049.250

**(7.53.1.64) Scope 3, Category 6: Business travel emissions in reporting year covered by target (metric tons CO2e)**

175200

**(7.53.1.76) Total Scope 3 emissions in reporting year covered by target (metric tons CO2e)**

175200.000

**(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)**

175200.000

**(7.53.1.78) Land-related emissions covered by target**

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

#### (7.53.1.79) % of target achieved relative to base year

233.70

#### (7.53.1.80) Target status in reporting year

Select from:

☒ Achieved

#### (7.53.1.82) Explain target coverage and identify any exclusions

*Business travel has historically represented approximately 6% of Pfizer's Scope 3 footprint. The target covers emissions from air travel, hotel stays, automobile use (rental as well as business use of personal vehicles), and rail transportation associated with Pfizer business.*

#### (7.53.1.83) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.*

#### (7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

#### (7.53.1.86) List the emissions reduction initiatives which contributed most to achieving this target

*- Expanded use of virtual meeting and collaboration technologies to reduce business travel demand. - Continued emphasis on preferred airlines and other travel providers that have established emissions-reduction programs and climate commitments. - Ongoing management of travel demand through hybrid ways of working and virtual engagement where appropriate.*

**Row 4**

### (7.53.1.1) Target reference number

Select from:

☒ Abs 6

### (7.53.1.2) Is this a science-based target?

Select from:

☒ No, but we are reporting another target that is science-based

### (7.53.1.5) Date target was set

06/30/2022

### (7.53.1.6) Target coverage

Select from:

☒ Organization-wide

### (7.53.1.7) Greenhouse gases covered by target

Select all that apply

☒ Carbon dioxide (CO<sub>2</sub>)

☒ Methane (CH<sub>4</sub>)

☒ Nitrous oxide (N<sub>2</sub>O)

☒ Hydrofluorocarbons (HFCs)

☒ Sulphur hexafluoride (SF<sub>6</sub>)

### (7.53.1.8) Scopes

Select all that apply

☒ Scope 1

☒ Scope 2

### **(7.53.1.9) Scope 2 accounting method**

Select from:

☒ Market-based

### **(7.53.1.11) End date of base year**

12/31/2019

### **(7.53.1.12) Base year Scope 1 emissions covered by target (metric tons CO2e)**

695107

### **(7.53.1.13) Base year Scope 2 emissions covered by target (metric tons CO2e)**

570388

### **(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)**

0.000

### **(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)**

1265495.000

### **(7.53.1.33) Base year Scope 1 emissions covered by target as % of total base year emissions in Scope 1**

100

### **(7.53.1.34) Base year Scope 2 emissions covered by target as % of total base year emissions in Scope 2**

100

### **(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes**

**(7.53.1.54) End date of target**

12/31/2040

**(7.53.1.55) Targeted reduction from base year (%)**

95

**(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)**

63274.750

**(7.53.1.57) Scope 1 emissions in reporting year covered by target (metric tons CO2e)**

614274

**(7.53.1.58) Scope 2 emissions in reporting year covered by target (metric tons CO2e)**

134232

**(7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)**

748506.000

**(7.53.1.78) Land-related emissions covered by target***Select from:*☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)**(7.53.1.79) % of target achieved relative to base year**

43.00

**(7.53.1.80) Target status in reporting year**

Select from:

☒ Underway

#### (7.53.1.82) Explain target coverage and identify any exclusions

*Pfizer's long-term Scope 1 and 2 GHG emissions reduction goal is company-wide, covering all owned sites and leased sites where Pfizer has operational control, and includes biogenic emissions and removals from bioenergy feedstocks. Pfizer's biogenic emissions are limited to the burning of wood pellets and chips at two of our manufacturing facilities and comprise approximately 1% of our Scope 1 and 2 footprint.*

#### (7.53.1.83) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.*

#### (7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

*Pfizer's path to Net-Zero is centered on reducing emissions across our operations and value chain through renewable electricity procurement, energy efficiency projects, fleet electrification, transportation and logistics decarbonization, business travel reduction, supplier engagement, and the integration of sustainability considerations into product design and lifecycle management. Emissions for 2025 were 41% lower than the 2019 baseline.*

#### (7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

### Row 5

#### (7.53.1.1) Target reference number

Select from:

☒ Abs 7

#### (7.53.1.2) Is this a science-based target?

Select from:

- ☒ No, but we are reporting another target that is science-based

#### (7.53.1.5) Date target was set

06/30/2022

#### (7.53.1.6) Target coverage

Select from:

- ☒ Organization-wide

#### (7.53.1.7) Greenhouse gases covered by target

Select all that apply

- ☒ Carbon dioxide (CO2)

#### (7.53.1.8) Scopes

Select all that apply

- ☒ Scope 3

#### (7.53.1.10) Scope 3 categories

Select all that apply

- |                                                                                                   |                                                                                                                 |
|---------------------------------------------------------------------------------------------------|-----------------------------------------------------------------------------------------------------------------|
| <input checked="" type="checkbox"/> Scope 3, Category 15 – Investments                            | <input checked="" type="checkbox"/> Scope 3, Category 1 – Purchased goods and services                          |
| <input checked="" type="checkbox"/> Scope 3, Category 2 – Capital goods                           | <input checked="" type="checkbox"/> Scope 3, Category 5 – Waste generated in operations                         |
| <input checked="" type="checkbox"/> Scope 3, Category 6 – Business travel                         | <input checked="" type="checkbox"/> Scope 3, Category 4 – Upstream transportation and distribution              |
| <input checked="" type="checkbox"/> Scope 3, Category 7 – Employee commuting                      | <input checked="" type="checkbox"/> Scope 3, Category 9 – Downstream transportation and distribution            |
| <input checked="" type="checkbox"/> Scope 3, Category 8 - Upstream leased assets<br>Scope 1 or 2) | <input checked="" type="checkbox"/> Scope 3, Category 3 – Fuel- and energy- related activities (not included in |

#### (7.53.1.11) End date of base year

12/31/2019

**(7.53.1.14) Base year Scope 3, Category 1: Purchased goods and services emissions covered by target (metric tons CO2e)**

1900504

**(7.53.1.15) Base year Scope 3, Category 2: Capital goods emissions covered by target (metric tons CO2e)**

101679

**(7.53.1.16) Base year Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) emissions covered by target (metric tons CO2e)**

252909

**(7.53.1.17) Base year Scope 3, Category 4: Upstream transportation and distribution emissions covered by target (metric tons CO2e)**

200873

**(7.53.1.18) Base year Scope 3, Category 5: Waste generated in operations emissions covered by target (metric tons CO2e)**

9512

**(7.53.1.19) Base year Scope 3, Category 6: Business travel emissions covered by target (metric tons CO2e)**

421399

**(7.53.1.20) Base year Scope 3, Category 7: Employee commuting emissions covered by target (metric tons CO2e)**

60645

**(7.53.1.21) Base year Scope 3, Category 8: Upstream leased assets emissions covered by target (metric tons CO2e)**

36273

**(7.53.1.22) Base year Scope 3, Category 9: Downstream transportation and distribution emissions covered by target (metric tons CO2e)**

99576

**(7.53.1.28) Base year Scope 3, Category 15: Investments emissions covered by target (metric tons CO2e)**

33892

**(7.53.1.31) Base year total Scope 3 emissions covered by target (metric tons CO2e)**

3117262.000

**(7.53.1.32) Total base year emissions covered by target in all selected Scopes (metric tons CO2e)**

3117262.000

**(7.53.1.35) Base year Scope 3, Category 1: Purchased goods and services emissions covered by target as % of total base year emissions in Scope 3, Category 1: Purchased goods and services (metric tons CO2e)**

100

**(7.53.1.36) Base year Scope 3, Category 2: Capital goods emissions covered by target as % of total base year emissions in Scope 3, Category 2: Capital goods (metric tons CO2e)**

100

**(7.53.1.37) Base year Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) emissions covered by target as % of total base year emissions in Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) (metric tons CO2e)**

100

**(7.53.1.38) Base year Scope 3, Category 4: Upstream transportation and distribution covered by target as % of total base year emissions in Scope 3, Category 4: Upstream transportation and distribution (metric tons CO2e)**

100

**(7.53.1.39) Base year Scope 3, Category 5: Waste generated in operations emissions covered by target as % of total base year emissions in Scope 3, Category 5: Waste generated in operations (metric tons CO2e)**

100

**(7.53.1.40) Base year Scope 3, Category 6: Business travel emissions covered by target as % of total base year emissions in Scope 3, Category 6: Business travel (metric tons CO2e)**

100

**(7.53.1.41) Base year Scope 3, Category 7: Employee commuting covered by target as % of total base year emissions in Scope 3, Category 7: Employee commuting (metric tons CO2e)**

100

**(7.53.1.42) Base year Scope 3, Category 8: Upstream leased assets emissions covered by target as % of total base year emissions in Scope 3, Category 8: Upstream leased assets (metric tons CO2e)**

100

**(7.53.1.43) Base year Scope 3, Category 9: Downstream transportation and distribution emissions covered by target as % of total base year emissions in Scope 3, Category 9: Downstream transportation and distribution (metric tons CO2e)**

100

**(7.53.1.49) Base year Scope 3, Category 15: Investments emissions covered by target as % of total base year emissions in Scope 3, Category 15: Investments (metric tons CO2e)**

100

**(7.53.1.52) Base year total Scope 3 emissions covered by target as % of total base year emissions in Scope 3 (in all Scope 3 categories)**

100

**(7.53.1.53) Base year emissions covered by target in all selected Scopes as % of total base year emissions in all selected Scopes**

100

**(7.53.1.54) End date of target**

12/31/2040

**(7.53.1.55) Targeted reduction from base year (%)**

90

**(7.53.1.56) Total emissions at end date of target covered by target in all selected Scopes (metric tons CO2e)**

311726.200

**(7.53.1.59) Scope 3, Category 1: Purchased goods and services emissions in reporting year covered by target (metric tons CO2e)**

2647407

**(7.53.1.60) Scope 3, Category 2: Capital goods emissions in reporting year covered by target (metric tons CO2e)**

164066

**(7.53.1.61) Scope 3, Category 3: Fuel-and-energy-related activities (not included in Scopes 1 or 2) emissions in reporting year covered by target (metric tons CO2e)**

231527

**(7.53.1.62) Scope 3, Category 4: Upstream transportation and distribution emissions in reporting year covered by target (metric tons CO2e)**

110146

**(7.53.1.63) Scope 3, Category 5: Waste generated in operations emissions in reporting year covered by target (metric tons CO2e)**

4433

**(7.53.1.64) Scope 3, Category 6: Business travel emissions in reporting year covered by target (metric tons CO2e)**

175200

**(7.53.1.65) Scope 3, Category 7: Employee commuting emissions in reporting year covered by target (metric tons CO2e)**

18953

**(7.53.1.66) Scope 3, Category 8: Upstream leased assets emissions in reporting year covered by target (metric tons CO2e)**

12982

**(7.53.1.67) Scope 3, Category 9: Downstream transportation and distribution emissions in reporting year covered by target (metric tons CO2e)**

37626

**(7.53.1.73) Scope 3, Category 15: Investments emissions in reporting year covered by target (metric tons CO2e)**

6605

**(7.53.1.76) Total Scope 3 emissions in reporting year covered by target (metric tons CO2e)**

3408945.000

#### (7.53.1.77) Total emissions in reporting year covered by target in all selected scopes (metric tons CO2e)

3408945.000

#### (7.53.1.78) Land-related emissions covered by target

Select from:

☒ No, it does not cover any land-related emissions (e.g. non-FLAG SBT)

#### (7.53.1.79) % of target achieved relative to base year

-10.40

#### (7.53.1.80) Target status in reporting year

Select from:

☒ Underway

#### (7.53.1.82) Explain target coverage and identify any exclusions

*Pfizer's long-term Scope 3 GHG emissions reduction target is company-wide, covering all Scope 3 emissions relevant to Pfizer's operations.*

#### (7.53.1.83) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.*

#### (7.53.1.84) Plan for achieving target, and progress made to the end of the reporting year

*Pfizer's strategy for achieving its Net-Zero Scope 3 target is centered on working with suppliers, logistics providers, and other value chain partners to reduce emissions across the categories that comprise the majority of its Scope 3 footprint. A key element of this approach is supplier engagement, including encouraging suppliers to measure and disclose emissions, establish science-based targets, and implement decarbonization initiatives within their own operations. Pfizer complements these efforts through targeted actions to reduce transportation and distribution emissions, lower business travel emissions, and incorporate sustainability considerations into product development and lifecycle management. As of the end of 2025, Pfizer had made meaningful progress toward its Scope 3*

objectives. The company achieved its 2025 upstream transportation and distribution emissions reduction target through transportation mode optimization, expanded use of ocean freight, and increased adoption of lower-emission fuels and logistics solutions. Pfizer also exceeded its business travel emissions reduction target, with emissions remaining substantially below the 2019 baseline due to continued use of digital collaboration tools and engagement with travel providers advancing emissions-reduction efforts. These achievements, together with continued supplier engagement and the rollout of the Net-Zero by Design Sustainability Playbook, position Pfizer to drive further emissions reductions across its value chain on the path to Net-Zero.

#### (7.53.1.85) Target derived using a sectoral decarbonization approach

Select from:

☒ No

[Add row]

#### (7.54) Did you have any other climate-related targets that were active in the reporting year?

Select all that apply

☒ Targets to increase or maintain low-carbon energy consumption or production

☒ Net-zero targets

☒ Other climate-related targets

#### (7.54.1) Provide details of your targets to increase or maintain low-carbon energy consumption or production.

##### Row 1

#### (7.54.1.1) Target reference number

Select from:

☒ Low 1

#### (7.54.1.2) Date target was set

11/23/2020

#### (7.54.1.3) Target coverage

Select from:

☒ Organization-wide

#### (7.54.1.4) Target type: energy carrier

Select from:

☒ Electricity

#### (7.54.1.5) Target type: activity

Select from:

☒ Consumption

#### (7.54.1.6) Target type: energy source

Select from:

☒ Renewable energy source(s) only

#### (7.54.1.7) End date of base year

12/31/2019

#### (7.54.1.8) Consumption or production of selected energy carrier in base year (MWh)

1448363

#### (7.54.1.9) % share of low-carbon or renewable energy in base year

9.5

#### (7.54.1.10) End date of target

12/31/2030

#### (7.54.1.11) % share of low-carbon or renewable energy at end date of target

**(7.54.1.12) % share of low-carbon or renewable energy in reporting year**

68.7

**(7.54.1.13) % of target achieved relative to base year**

65.41

**(7.54.1.14) Target status in reporting year***Select from:*☒ Underway**(7.54.1.16) Is this target part of an emissions target?***Yes, Pfizer's commitment to 100% renewable electricity is a component of our Scope 1 and 2 emissions reduction target (Abs 3).***(7.54.1.17) Is this target part of an overarching initiative?***Select all that apply*☒ RE100☒ Science Based Targets initiative**(7.54.1.18) Science Based Targets initiative official validation letter***PFIZ-USA-002-OFF\_ApprovalLetter\_V4.1 (1).pdf***(7.54.1.19) Explain target coverage and identify any exclusions***This target is company-wide with no exclusions.***(7.54.1.20) Target objective***The sourcing of renewable electricity is a key component of Pfizer's decarbonization strategy.*

#### (7.54.1.21) Plan for achieving target, and progress made to the end of the reporting year

*Pfizer's virtual power purchase agreements (VPPAs) covering North America and the EU came online in 2025 and generate renewable energy credits (RECs) sufficient to cover approximately 100% of Pfizer's purchased electricity needs in these jurisdictions. The projects contributed to a 77% reduction in Scope 2 market based emissions from the 2019 baseline by the end of 2025. Pfizer continues to advance country-specific renewable electricity projects to address electricity consumption outside of North America and Europe.*

[Add row]

#### (7.54.2) Provide details of any other climate-related targets, including methane reduction targets.

##### Row 1

#### (7.54.2.1) Target reference number

Select from:

☒ Oth 1

#### (7.54.2.2) Date target was set

11/23/2020

#### (7.54.2.3) Target coverage

Select from:

☒ Organization-wide

#### (7.54.2.4) Target type: absolute or intensity

Select from:

☒ Intensity

#### (7.54.2.5) Target type: category & metric (target numerator if reporting an intensity target)

Engagement with suppliers

☒ Percentage of suppliers (by procurement spend) with a science-based target

**(7.54.2.6) Target denominator (intensity targets only)**

Select from:

☒ Other, please specify :Total procurement spend

**(7.54.2.7) End date of base year**

12/31/2019

**(7.54.2.8) Figure or percentage in base year**

0

**(7.54.2.9) End date of target**

12/31/2025

**(7.54.2.10) Figure or percentage at end of date of target**

64

**(7.54.2.11) Figure or percentage in reporting year**

72

**(7.54.2.12) % of target achieved relative to base year**

112.5000000000

**(7.54.2.13) Target status in reporting year**

Select from:

☒ Achieved

#### (7.54.2.15) Is this target part of an emissions target?

No

#### (7.54.2.16) Is this target part of an overarching initiative?

Select all that apply

☒ Science Based Targets initiative – approved supplier engagement target

#### (7.54.2.17) Science Based Targets initiative official validation letter

PFIZ-USA-002-OFF\_ApprovalLetter\_V4.1 (1).pdf

#### (7.54.2.18) Please explain target coverage and identify any exclusions

*Pfizer currently estimates GHG emissions associated with purchased goods and services based on spend and aligned with the GHG Protocol Corporate Value Chain (Scope 3) Accounting and Reporting Standard. Estimated emissions for this category currently represent 78% of Pfizer's Scope 3 footprint. Pfizer is committed to accelerating change across our supply chain and established a target to drive 64% of our suppliers of goods and services by spend to set their own science-based emission reduction goals by 2025. Emissions associated with purchased goods and services are calculated using spend-based emission factors.*

#### (7.54.2.19) Target objective

*Procurement of goods and services, which are essential to producing medicines and vaccines, is the most significant contributor to our scope 3 emissions. We therefore expect all our suppliers to commit to ambitious, science-based GHG reduction targets and have integrated environmental criteria in our supplier sourcing, contracting, and performance management processes.*

#### (7.54.2.21) List the actions which contributed most to achieving this target

*The actions that contributed most to achieving Pfizer's supplier engagement target included integrating climate and sustainability considerations into supplier sourcing, contracting, and performance management processes; conducting focused engagement with priority suppliers; and providing capacity-building opportunities to support suppliers in setting science-based emissions reduction targets. Pfizer also advanced supplier decarbonization through initiatives such as the Supplier Summit, the Energize renewable energy education program, and sponsorship of the Activate program for pharmaceutical suppliers. As a result of these engagement efforts, 72% of suppliers by spend had committed to science-based emissions reduction targets by the end of 2025, exceeding our target of 64%.*

[Add row]

### (7.54.3) Provide details of your net-zero target(s).

#### Row 1

##### (7.54.3.1) Target reference number

Select from:

☒ NZ1

##### (7.54.3.2) Date target was set

06/30/2022

##### (7.54.3.3) Target Coverage

Select from:

☒ Organization-wide

##### (7.54.3.4) Targets linked to this net zero target

Select all that apply

☒ Abs3

☒ Abs4

☒ Abs5

☒ Low1

##### (7.54.3.5) End date of target for achieving net zero

12/31/2040

##### (7.54.3.6) Is this a science-based target?

Select from:

☒ Yes, we consider this a science-based target, and we have committed to seek validation of this target by the Science Based Targets initiative in the next two years

### (7.54.3.8) Scopes

*Select all that apply*

- ☒ Scope 1
- ☒ Scope 2
- ☒ Scope 3

### (7.54.3.9) Greenhouse gases covered by target

*Select all that apply*

- ☒ Carbon dioxide (CO<sub>2</sub>)
- ☒ Methane (CH<sub>4</sub>)
- ☒ Nitrous oxide (N<sub>2</sub>O)
- ☒ Hydrofluorocarbons (HFCs)
- ☒ Sulphur hexafluoride (SF<sub>6</sub>)

### (7.54.3.10) Explain target coverage and identify any exclusions

*Pfizer's Net-Zero target covers at least 95% of total scope 1 and 2 emissions and at least 90% of total scope 3 emissions.*

### (7.54.3.11) Target objective

*Pfizer recognizes global climate change as one of the defining issues of our time, requiring collective action to mitigate the potential risks it poses. Such risks include the potential for increased adverse impacts on human health and decreased access to critical medicines and vaccines due to disruptions in value chains caused by the greater frequency of severe weather. Mitigation of the risks posed by a changing climate is a sustainability priority for Pfizer and is connected to our corporate purpose and strategy.*

### (7.54.3.12) Do you intend to neutralize any residual emissions with permanent carbon removals at the end of the target?

*Select from:*

- ☒ Yes

### (7.54.3.13) Do you plan to mitigate emissions beyond your value chain?

Select from:

☒ No, and we do not plan to within the next two years

### (7.54.3.14) Do you intend to purchase and cancel carbon credits for neutralization and/or beyond value chain mitigation?

Select all that apply

☒ No, we do not plan to purchase and cancel carbon credits for neutralization and/or beyond value chain mitigation

### (7.54.3.15) Planned milestones and/or near-term investments for neutralization at the end of the target

*While Pfizer's focus is driving absolute GHG reductions, we anticipate that a carbon removal strategy may be necessary to address hard-to-abate emissions as we progress towards the target end dates.*

### (7.54.3.17) Target status in reporting year

Select from:

☒ Underway

### (7.54.3.19) Process for reviewing target

*Environmental sustainability has been integrated into the overarching Pfizer strategy and GHG emissions reduction is monitored as a key performance indicator (KPI). Performance against targets is monitored throughout the year by the PGS Executive Leadership Team.*

*[Add row]*

**(7.55) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases.**

|  |                                                                            |
|--|----------------------------------------------------------------------------|
|  | Emissions reduction initiatives that were active within the reporting year |
|  | Select from:<br><input checked="" type="checkbox"/> Yes                    |

[Fixed row]

**(7.55.1) Identify the total number of initiatives at each stage of development, and for those in the implementation stages, the estimated CO2e savings.**

|                          | Number of initiatives | Total estimated annual CO2e savings in metric tonnes CO2e |
|--------------------------|-----------------------|-----------------------------------------------------------|
| Under investigation      | 46                    |                                                           |
| To be implemented        | 0                     | 0                                                         |
| Implementation commenced | 17                    | 2262                                                      |
| Implemented              | 301                   | 35861                                                     |
| Not to be implemented    | 71                    |                                                           |

[Fixed row]

**(7.55.2) Provide details on the initiatives implemented in the reporting year in the table below.**

**Row 1**

**(7.55.2.1) Initiative category & Initiative type**

Other

☒ Other, please specify :Energy efficiency in buildings

#### (7.55.2.2) Estimated annual CO<sub>2</sub>e savings (metric tonnes CO<sub>2</sub>e)

35861

#### (7.55.2.3) Scope(s) or Scope 3 category(ies) where emissions savings occur

*Select all that apply*

☒ Scope 1

☒ Scope 2 (location-based)

☒ Scope 2 (market-based)

#### (7.55.2.4) Voluntary/Mandatory

*Select from:*

☒ Voluntary

#### (7.55.2.5) Annual monetary savings (unit currency – as specified in 1.2)

11659977

#### (7.55.2.6) Investment required (unit currency – as specified in 1.2)

95808632

#### (7.55.2.7) Payback period

*Select from:*

☒ 4-10 years

#### (7.55.2.8) Estimated lifetime of the initiative

Select from:

☒ 6-10 years

### (7.55.2.9) Comment

*Multiple initiatives across Pfizer*

*[Add row]*

## (7.55.3) What methods do you use to drive investment in emissions reduction activities?

### Row 1

#### (7.55.3.1) Method

Select from:

☒ Internal incentives/recognition programs

#### (7.55.3.2) Comment

*Pfizer's internal "Safety and Sustainability STAR Awards" program recognizes projects advanced by colleagues across Pfizer related to driving sustainability improvements including GHG reductions and innovations in sustainable medicines. These awards encourage sites to implement sustainability initiatives. In 2025, 75 emissions reduction projects and 10 sustainable medicines projects were nominated for STAR award consideration, with two projects in each category ultimately recognized for their contributions.*

### Row 2

#### (7.55.3.1) Method

Select from:

☒ Lower return on investment (ROI) specification

#### (7.55.3.2) Comment

*Projects with environmental benefits may be approved for funding despite not meeting internally established financial hurdle rates.*

### Row 3

#### (7.55.3.1) Method

Select from:

☒ Compliance with regulatory requirements/standards

#### (7.55.3.2) Comment

*Pfizer prioritizes funding for projects that reduce energy demand and GHG emissions associated with regulatory compliance requirements.*

[Add row]

### (7.73) Are you providing product level data for your organization's goods or services?

Select from:

☒ No, I am not providing data

### (7.74) Do you classify any of your existing goods and/or services as low-carbon products?

Select from:

☒ Yes

#### (7.74.1) Provide details of your products and/or services that you classify as low-carbon products.

### Row 1

#### (7.74.1.1) Level of aggregation

Select from:

☒ Product or service

#### (7.74.1.2) Taxonomy used to classify product(s) or service(s) as low-carbon

Select from:

☒ Other, please specify :Life Cycle Assessment (LCA) using in-house collaborative tools

#### (7.74.1.3) Type of product(s) or service(s)

Chemicals and plastics

☒ Other chemicals and plastics, please specify :Elimination of materials used in manufacturing of product

#### (7.74.1.4) Description of product(s) or service(s)

*The product, Enviero® progesterone, is now synthesized using a plant sterols pathway which uses fewer natural resources (than the original synthesis pathway) during its manufacture, reducing waste, GHG emissions, and use of hazardous solvents. The product can be used as a final active pharmaceutical ingredient or as an intermediate for more advanced steroidal products based on the customers intentions.*

#### (7.74.1.5) Have you estimated the avoided emissions of this low-carbon product(s) or service(s)

Select from:

☒ Yes

#### (7.74.1.6) Methodology used to calculate avoided emissions

Select from:

☒ Other, please specify :Performed in-house using a collaborative LCA tool created by the American Chemical Society Green Chemistry Institute Pharmaceutical Roundtable (ACS GCIPR). The tool is underpinned with Life Cycle Inventory (LCI) from the Ecoinvent database.

#### (7.74.1.7) Life cycle stage(s) covered for the low-carbon product(s) or services(s)

Select from:

☒ Cradle-to-gate

#### (7.74.1.8) Functional unit used

*kg of progesterone product sold in its primary form (i.e., not with excipients or in solution, etc.)*

#### (7.74.1.9) Reference product/service or baseline scenario used

The original and historical longer chemical synthesis route used to manufacture progesterone

**(7.74.1.10) Life cycle stage(s) covered for the reference product/service or baseline scenario**

Select from:

☒ Cradle-to-gate

**(7.74.1.11) Estimated avoided emissions (metric tons CO<sub>2</sub>e per functional unit) compared to reference product/service or baseline scenario**

0.18

**(7.74.1.12) Explain your calculation of avoided emissions, including any assumptions**

*The emissions (in kg CO<sub>2</sub>e) are determined from the manufacturing process via a cradle to gate LCA using Ecoinvent Life Cycle Inventory (LCI) databases. Based on LCA calculations, the historical chemical synthesis manufacturing process generated approximately 256 kg CO<sub>2</sub>e per kg of progesterone produced. The new process, based on plant sterols, generated approximately 72 kg CO<sub>2</sub>e per kg of progesterone produced, a reduction of approximately 184 kg CO<sub>2</sub>e per kg of progesterone. This equates to a 72% reduction. Key assumptions: 1) Where compound-specific LCIs were not available, analogous proxies have been used (or built) within the same tools. 2) The lifecycle tool used (ACS GCIPR PMI-LCA tool) does not include energy for processing. This will lead to a conservative estimate of benefit as the new process is largely at room temperature conditions whereas the original route used several heating and cooling steps. Likewise, the new route is half the number of internal processing steps as the original route. Previous studies show that the GHG emissions associated with energy consumption in chemical synthesis commonly represent 15 to 25% of the carbon footprint when compared to bill of materials.*

**(7.74.1.13) Revenue generated from low-carbon product(s) or service(s) as % of total revenue in the reporting year**

0.01

[Add row]

**(7.79) Has your organization retired any project-based carbon credits within the reporting year?**

Select from:

☒ No

## C9. Environmental performance - Water security

### (9.1) Are there any exclusions from your disclosure of water-related data?

Select from:

☒ Yes

#### (9.1.1) Provide details on these exclusions.

##### Row 1

##### (9.1.1.1) Exclusion

Select from:

☒ Facilities

##### (9.1.1.2) Description of exclusion

*Withdrawals and discharges of water from sites outside of Pfizer's Operational Control. This includes leased offices and logistics centers under 100,000 sq ft and R&D facilities under 50,000 sq ft.*

##### (9.1.1.3) Reason for exclusion

Select from:

☒ Water used for internal WASH services

##### (9.1.1.4) Primary reason why data is not collected and/or reported

Select from:

☒ Challenges associated with data collection and/or quality

##### (9.1.1.7) Country/area and river basin of exclusion

China

☒ Yangtze River (Chang Jiang)

#### (9.1.1.8) Estimated volume of water the exclusion represents (megaliters)

4.22

#### (9.1.1.9) Estimated % of total water

0.2

#### (9.1.1.10) Please explain

*Withdrawals and discharges from sites outside of Pfizer's Operational Control are not measured, as they are considered de minimis. These sites include leased offices and logistics centers under 100,000 sq ft and R&D facilities under 50,000 sq ft. The total contribution of these excluded sites is estimated to represent approximately 0.2% of Pfizer's global water withdrawals, consumption, and discharges. As such, their exclusion does not materially impact the overall assessment of water use or associated risks. The estimated volume of these excluded sites is 42.16 megaliters (withdrawal), 37.94 megaliters (wastewater discharge) and 4.22 megaliters (consumption). Where data is not directly measured, estimates are derived using intensity factors based on comparable facilities within Pfizer's Operational Control and applied to sites with similar characteristics. The Yangtze River basin has been identified as the primary excluded river basin, as it serves the largest excluded site located in Wuhan, China. This basin therefore represents the most relevant geographic area where minor exclusions occur, although the associated water volumes remain immaterial.*

[Add row]

### (9.2) Across all your operations, what proportion of the following water aspects are regularly measured and monitored?

#### Water withdrawals – total volumes

##### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

##### (9.2.2) Frequency of measurement

Select from:

☒ At least once a month

### (9.2.3) Method of measurement

*Water withdrawal volumes are measured and monitored at the site level through a combination of municipal and internal flow meters and are reported centrally via our internal global environmental reporting system.*

### (9.2.4) Please explain

*Pfizer collects and reports water withdrawal for all locations where we maintain operational control. Sites report monthly withdrawal data (with a few exceptions where water data is only available quarterly). Total water withdrawal is reported annually in our Impact Report.*

## Water withdrawals – volumes by source

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ At least once a month

### (9.2.3) Method of measurement

*Water withdrawal volumes are measured and monitored at the site level and are reported centrally by source. Volume data is obtained in a variety of ways depending on site specific factors: purchased water through utility providers' invoices; ground water and fresh water through municipal and internal flow meters; and rainwater through actual measurement with local mechanical flow meters.*

### (9.2.4) Please explain

*Pfizer collects and reports water withdrawal by source for all locations where we maintain operational control. Sites report monthly withdrawal data by source (with a few exceptions where water data is only available quarterly).*

## Water withdrawals quality

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ At least once a month

### (9.2.3) Method of measurement

*Water withdrawal quality is monitored through sampling and is tested onsite and by external labs analysis and includes all parameters related to the local regulations for potable water.*

### (9.2.4) Please explain

*Water quality is monitored at the site level as required by regulation (local potable water standards) and as necessary to help ensure conformance with quality standards for manufacturing by all locations where Pfizer maintains operational control. Water is purified as necessary to support manufacturing and R&D operations.*

## Water discharges – total volumes

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ At least once a month

### (9.2.3) Method of measurement

*Total volume data is obtained through utility invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed periodically. See Pfizer's website for our calculation methodology.*  
[https://cdn.pfizer.com/pfizercom/Waste\\_and\\_Water\\_Methodology\\_MAR2024.pdf](https://cdn.pfizer.com/pfizercom/Waste_and_Water_Methodology_MAR2024.pdf)

#### (9.2.4) Please explain

*Water discharge volumes are monitored by all locations where we maintain operational control and are reported centrally by discharge destination via our global environmental reporting system. Locations report monthly discharge volumes. Total water discharge is reported annually in our Impact report.*

### Water discharges – volumes by destination

#### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

#### (9.2.2) Frequency of measurement

Select from:

☒ At least once a month

#### (9.2.3) Method of measurement

*Volume data for water discharged to municipal treatment plants is obtained through utility invoices and/or internal flow meters. Discharges to fresh and salt water are monitored through internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed periodically. See Pfizer's website for our calculation methodology.*  
[https://cdn.pfizer.com/pfizercom/Waste\\_and\\_Water\\_Methodology\\_MAR2024.pdf](https://cdn.pfizer.com/pfizercom/Waste_and_Water_Methodology_MAR2024.pdf)

#### (9.2.4) Please explain

*Water discharge volumes are monitored by all sites under Pfizer's operational control and are reported centrally by discharge destination via our global environmental reporting system. Locations report monthly discharge volumes.*

### Water discharges – volumes by treatment method

#### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ At least once a month

### (9.2.3) Method of measurement

*All sites where we maintain operational control monitor their treatment processes and track discharge volumes through invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed periodically. Discharges are managed in accordance with the jurisdictional requirements applicable to the location. Pfizer's calculation methodology is available on our website.*

### (9.2.4) Please explain

*Pfizer collects information on wastewater treatment technologies and quantities of wastewater discharged at our sites within operational control via our global environmental reporting system.*

## Water discharge quality – by standard effluent parameters

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ At least once a month

### (9.2.3) Method of measurement

*Water is monitored through sampling and is tested onsite and by external labs as required by site permits and applicable regulations. Monitoring data is maintained by the site and is not collected at the corporate level, but conformance with applicable requirements is reviewed periodically through our EHS audit program.*

#### (9.2.4) Please explain

*Pfizer requires all sites where we maintain operational control to monitor wastewater discharge quality and meet all applicable permit and regulatory requirements. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits. Water discharge quality is monitored as frequently as required by local regulations.*

### Water discharge quality – emissions to water (nitrates, phosphates, pesticides, and/or other priority substances)

#### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

#### (9.2.2) Frequency of measurement

Select from:

☒ Other, please specify :As required by local regulations

#### (9.2.3) Method of measurement

*Water discharge quality is monitored through sampling and is tested onsite and by external certified labs as required by site permits and applicable regulations. Monitoring data is maintained by the site and is not collected at the corporate level, but conformance with applicable requirements is reviewed periodically through Pfizer's EHS audit program.*

#### (9.2.4) Please explain

*Pfizer requires all sites where we maintain operational control to monitor wastewater discharge quality and meet all applicable permit and regulatory requirements. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits.*

### Water discharge quality – temperature

#### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Other, please specify :As required by local regulations

### (9.2.3) Method of measurement

*Water discharge quality, including temperature, is monitored through sampling as required by site permits and applicable regulations. This data is maintained by the site and is not collected at the corporate level, but conformance with applicable requirements is reviewed periodically through Pfizer's EHS audit program.*

### (9.2.4) Please explain

*Pfizer requires all sites where we maintain operational control to monitor wastewater discharge quality, including temperature, and meet all applicable permit and regulatory requirements. Sites are required to notify corporate as well as the relevant regulatory authority (as appropriate) of any monitoring results that exceed applicable permit and/or regulatory limits. Water temperature is monitored as frequently as required by local regulations.*

## Water consumption – total volume

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ At least once a year

### (9.2.3) Method of measurement

*Aggregated monthly or quarterly data is used to calculate water consumption annually.*

### (9.2.4) Please explain

*Water withdrawal and discharge volumes are monitored by all sites under Pfizer's operational control and are reported monthly.*

## Water recycled/reused

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ At least once a month

### (9.2.3) Method of measurement

*Volume data is obtained through flowmeters and/or estimated based on operations and engineering knowledge and data. Sites within operational control report monthly recycled water volumes via our global environmental reporting system.*

### (9.2.4) Please explain

*All sites under Pfizer's operational control where recycled water is used monitor volumes and report centrally.*

## The provision of fully-functioning, safely managed WASH services to all workers

### (9.2.1) % of sites/facilities/operations

Select from:

☒ 100%

### (9.2.2) Frequency of measurement

Select from:

☒ Continuously

### (9.2.3) Method of measurement

*Pfizer's Global Environment, Health and Safety (EHS) Standards require all facilities to provide safe, fully functioning WASH services for all employees. Compliance with our standard is monitored through our internal audit program. In addition, compliance with WASH standards is also reviewed through the sites' periodic EHS self-assessment program. Finally, colleagues can report any issues through the Compliance Helpline.*

#### **(9.2.4) Please explain**

*Pfizer's Global Environment, Health and Safety Standards require all facilities to provide safe, fully functioning WASH services for all employees.*  
*[Fixed row]*

**(9.2.2) What are the total volumes of water withdrawn, discharged, and consumed across all your operations, how do they compare to the previous reporting year, and how are they forecasted to change?**

#### **Total withdrawals**

##### **(9.2.2.1) Volume (megaliters)**

26625

##### **(9.2.2.2) Comparison with previous reporting year**

*Select from:*

☒ Much lower

##### **(9.2.2.3) Primary reason for comparison with previous reporting year**

*Select from:*

☒ Increase/decrease in business activity

##### **(9.2.2.4) Five-year forecast**

*Select from:*

☒ Lower

##### **(9.2.2.5) Primary reason for forecast**

Select from:

☒ Increase/decrease in business activity

#### (9.2.2.6) Please explain

*Water withdrawals decreased by 14% compared to 2024. The decrease was primarily due to production and operational efficiency changes that occurred in 2025. Pfizer collects and reports water withdrawal for locations where we maintain operational control. Water withdrawal volumes are measured and monitored at the site level through a combination of municipal and internal flow meters and are reported centrally via our global environmental reporting system. Total annual water withdrawal is calculated by summing monthly/quarterly data for the year for all sites within Pfizer's operational control. Water withdrawal is expected to reduce over the next 5 years based on decrease in business activity & reductions in production volume. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year.*

### Total discharges

#### (9.2.2.1) Volume (megaliters)

23858

#### (9.2.2.2) Comparison with previous reporting year

Select from:

☒ Much lower

#### (9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.2.4) Five-year forecast

Select from:

☒ Lower

#### (9.2.2.5) Primary reason for forecast

Select from:

☒ Increase/decrease in business activity

#### (9.2.2.6) Please explain

*Pfizer's wastewater discharge decreased by 14% compared to 2024 primarily due to production and operational efficiency changes that occurred in the 2025 calendar year. Water discharge volumes are monitored by all locations where we maintain operational control and are reported centrally by discharge destination via our global environmental reporting system. Total volume data is obtained through utility invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed on an ongoing basis. Total annual water discharge is calculated by summing monthly/quarterly data for the year for all sites within Pfizer's operational control. Water discharge is expected to reduce over the next 5 years based on decrease in business activity & reductions in production volume. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year.*

### Total consumption

#### (9.2.2.1) Volume (megaliters)

2767

#### (9.2.2.2) Comparison with previous reporting year

Select from:

☒ Much lower

#### (9.2.2.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.2.4) Five-year forecast

Select from:

☒ Lower

#### (9.2.2.5) Primary reason for forecast

Select from:

☒ Increase/decrease in business activity

#### (9.2.2.6) Please explain

*Pfizer's total water consumption decreased by 14% compared to 2024 primarily due to production and operational efficiency changes that occurred in the 2025 calendar year. Water consumption is calculated at the corporate level by subtracting total water discharged from total water withdrawn. The consumption corresponds to water incorporated in products, as well as water lost through evaporation in cooling towers. Total consumption is expected to reduce over the next 5 years based on decrease in business activity & reductions in production volume. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year.*

[Fixed row]

**(9.2.4) Indicate whether water is withdrawn from areas with water stress, provide the volume, how it compares with the previous reporting year, and how it is forecasted to change.**

#### (9.2.4.1) Withdrawals are from areas with water stress

Select from:

☒ Yes

#### (9.2.4.2) Volume withdrawn from areas with water stress (megaliters)

1384

#### (9.2.4.3) Comparison with previous reporting year

Select from:

☒ Lower

#### (9.2.4.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in efficiency

#### (9.2.4.5) Five-year forecast

Select from:

☒ Lower

#### (9.2.4.6) Primary reason for forecast

Select from:

☒ Increase/decrease in business activity

#### (9.2.4.7) % of total withdrawals that are withdrawn from areas with water stress

5.20

#### (9.2.4.8) Identification tool

Identification tool used

☒ WRI Aqueduct

#### (9.2.4.9) Please explain

*Pfizer's methodology used to identify sites located in water-stressed areas is described in the Pfizer Water Stewardship position statement published in Jan 2022 and is based on the UN CEO Water Mandate definition of water stress which considers other physical aspects related to water resources in addition to water scarcity, including water quality, environmental flows, and the accessibility of water. Our methodology uses the WRI Aqueduct tool, considering all indicators outlined in the tool in our assessment, including those related to water quality, environmental flows, and water accessibility. Based on Pfizer's assessment methodology, the use of water from facilities operating in water-stressed areas decreased by 5% due to changes in business activity. Based on Pfizer's assessment methodology, 10% of our sites within operational control are located in "High" or "Extremely High" water-stressed areas. We require these sites to develop water stewardship plans. The percentage of water withdrawn from water-stressed areas in 2025 was 5.20%. Water withdrawal from areas with water stress is expected to decrease in the next five years due to increases in efficiency and implementation of water stewardship projects. Water stress assessments are required to be carried out every three years. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year.*

[Fixed row]

#### (9.2.7) Provide total water withdrawal data by source.

## Fresh surface water, including rainwater, water from wetlands, rivers, and lakes

### (9.2.7.1) Relevance

Select from:

☒ Relevant

### (9.2.7.2) Volume (megaliters)

652

### (9.2.7.3) Comparison with previous reporting year

Select from:

☒ Lower

### (9.2.7.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

### (9.2.7.5) Please explain

*Pfizer's use of fresh surface water is primarily for non-contact cooling water and includes water sources from lakes and a small amount of rain. Pfizer's use of fresh surface water decreased by 10% compared to 2024 due to production changes at our Strangnas, Sweden site (our primary user of surface water) in 2025. Going forward, we anticipate fresh surface water withdrawal to continue to decrease due to changes in business activity. Water withdrawal volumes are measured and monitored at the site level through a combination of municipal and internal flow meters and are reported centrally via our global environmental reporting system. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

## Brackish surface water/Seawater

### (9.2.7.1) Relevance

Select from:

☒ Not relevant

#### (9.2.7.5) Please explain

*Pfizer does not currently use brackish surface water in our operations, and we do not anticipate using brackish surface water or seawater in our operations in the coming years.*

### Groundwater – renewable

#### (9.2.7.1) Relevance

Select from:

☒ Relevant

#### (9.2.7.2) Volume (megaliters)

18775

#### (9.2.7.3) Comparison with previous reporting year

Select from:

☒ Much lower

#### (9.2.7.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.7.5) Please explain

*Pfizer uses ground water for manufacturing operations, non-contact cooling, and potable and sanitary purposes. Pfizer's groundwater withdrawal decreased by 17% compared to 2024, primarily driven by reduced production at the Kalamazoo, Michigan site and the elimination of non-contact cooling water use across 10 chillers at the site. Groundwater withdrawal is forecast to reduce over 5 years based on decrease in business activity & reductions in production volume. Water withdrawal volumes are measured and monitored at the site level through a combination of municipal and internal flow meters and are reported centrally via our global environmental reporting system. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year.*

### Groundwater – non-renewable

### (9.2.7.1) Relevance

Select from:

☒ Not relevant

### (9.2.7.5) Please explain

*Pfizer's groundwater use is limited to renewable water from shallow wells. Pfizer's operating sites do not withdraw water from non-renewable groundwater sources, and we do not anticipate doing so in the future.*

## Produced/Entrained water

### (9.2.7.1) Relevance

Select from:

☒ Not relevant

### (9.2.7.5) Please explain

*Pfizer does not use produced water in operations. Given our need for high quality and very pure water, it is expensive and energy intensive to source produced water. Going forward, we do not anticipate using produced water in our operations.*

## Third party sources

### (9.2.7.1) Relevance

Select from:

☒ Relevant

### (9.2.7.2) Volume (megaliters)

7198

### (9.2.7.3) Comparison with previous reporting year

Select from:

☒ Lower

#### (9.2.7.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.7.5) Please explain

*Pfizer's use of municipal water decreased by 5% compared to 2024, primarily due to changes in business activity. Water withdrawal is forecast to reduce over 5 years based on decrease in business activity & reductions in production volume. Water withdrawal volumes are measured and monitored at the site level through a combination of municipal and internal flow meters and are reported centrally via our global environmental reporting system. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

*[Fixed row]*

#### (9.2.8) Provide total water discharge data by destination.

##### Fresh surface water

#### (9.2.8.1) Relevance

Select from:

☒ Relevant

#### (9.2.8.2) Volume (megaliters)

15696

#### (9.2.8.3) Comparison with previous reporting year

Select from:

☒ Much lower

#### (9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.8.5) Please explain

*Pfizer's discharge to surface water decreased by 20% vs. 2024, primarily driven by lower production at the Kalamazoo, Michigan, site and elimination of non-contact cooling water use across 10 chillers at the site. Wastewater discharge is forecast to reduce over 5 years based on decrease in business activity & reductions in production volume. Water discharge volumes are monitored by all locations under our operational control and are reported centrally by discharge destination via our global environmental reporting system. Total volume data is obtained through utility invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed on an ongoing basis. Total annual water discharge is calculated by summing monthly/quarterly data for the year for all sites within Pfizer's operational control. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year.*

### Brackish surface water/seawater

#### (9.2.8.1) Relevance

Select from:

☒ Relevant

#### (9.2.8.2) Volume (megaliters)

903

#### (9.2.8.3) Comparison with previous reporting year

Select from:

☒ Lower

#### (9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.8.5) Please explain

*Pfizer's discharges to brackish surface water/sea water bodies decreased by 6% compared to 2024 due to production changes. Discharge to brackish surface water/sea water is forecast to reduce over 5 years based on decrease in business activity & reductions in production volume. Water discharge volumes are monitored by all locations where we maintain operational control and are reported centrally by discharge destination via our global environmental reporting system. Total volume data is obtained through utility invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed on an ongoing basis. Total annual water discharge is calculated by summing monthly/quarterly data for the year for all sites within Pfizer's operational control. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

### Groundwater

#### (9.2.8.1) Relevance

Select from:

☒ Not relevant

#### (9.2.8.5) Please explain

*Pfizer does not discharge to groundwater.*

### Third-party destinations

#### (9.2.8.1) Relevance

Select from:

☒ Relevant

#### (9.2.8.2) Volume (megaliters)

7258

#### (9.2.8.3) Comparison with previous reporting year

Select from:

☒ About the same

#### (9.2.8.4) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.8.5) Please explain

*Pfizer's discharge to third party (municipal) wastewater treatment facilities increased by 1% compared to 2024, due to production changes. We do not discharge any wastewater to other organizations for further use. Wastewater discharge is forecast to reduce over 5 years based on decrease in business activity & reductions in production volume. Water discharge volumes are monitored by all locations where we maintain operational control and are reported centrally by discharge destination via our global environmental reporting system. Total volume data is obtained through utility invoices and/or internal flow meters. In some cases, discharges may be estimated using operations and engineering data. Estimation methodologies are documented and reviewed on an ongoing basis. Total annual water discharge is calculated by summing monthly/quarterly data for the year for all sites within Pfizer's operational control. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to*  
[Fixed row]

**(9.2.9) Indicate the highest level to which your wastewater is treated (either by your organization or a third party) before being discharged to the environment.**

**Quaternary treatment**

#### (9.2.9.1) Volume (megaliters)

566

#### (9.2.9.2) Comparison of treated volume with previous reporting year

Select from:

☒ Lower

#### (9.2.9.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.9.4) % of discharge volume treated in compliance with local regulatory standards

Select from:

☒ 100

#### (9.2.9.5) Factors considered in determining appropriate treatment level beyond local regulatory standards

Select all that apply

☒ Internally developed water quality standards or guidelines

☒ Sector-specific standards

☒ Profile of the receiving waterbody

#### (9.2.9.6) Please explain

*Six Pfizer sites provide onsite quaternary treatment of wastewater prior to further treatment off-site or discharge to surface water, in accordance with applicable laws and permit requirements. The volume of wastewater to which quaternary treatment was applied in 2025 was 7% lower than in 2024 mainly due to implementation of water conservation initiatives at our McPherson, Kansas site. This volume represents approximately 6% of our total wastewater discharge. Beyond regulatory compliance, treatment levels are informed by internal water quality standards, relevant sector guidance, and the sensitivity and characteristics of the receiving waterbody, ensuring a precautionary and environmentally protective approach. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

### Tertiary treatment

#### (9.2.9.1) Volume (megaliters)

872

#### (9.2.9.2) Comparison of treated volume with previous reporting year

Select from:

☒ Lower

#### (9.2.9.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.9.4) % of discharge volume treated in compliance with local regulatory standards

Select from:

☒ 100

#### (9.2.9.5) Factors considered in determining appropriate treatment level beyond local regulatory standards

Select all that apply

☒ Internally developed water quality standards or guidelines

☒ Sector-specific standards

☒ Profile of the receiving waterbody

#### (9.2.9.6) Please explain

*Seven Pfizer sites provide onsite tertiary treatment of wastewater prior to further treatment off-site or discharge to surface water, in accordance with applicable laws and permit requirements. The volume of wastewater to which tertiary treatment was applied in 2025 was 3% lower than in 2024 mainly due to production mix at our Puurs, Belgium and Nagoya, Japan sites as well as downsizing at our Sandwich, UK site. This volume represents approximately 10% of our total wastewater discharge. Beyond regulatory compliance, treatment levels are informed by internal water quality standards, relevant sector guidance, and the sensitivity and characteristics of the receiving waterbody, ensuring a precautionary and environmentally protective approach. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

### Secondary treatment

#### (9.2.9.1) Volume (megaliters)

751

#### (9.2.9.2) Comparison of treated volume with previous reporting year

Select from:

☒ Lower

#### (9.2.9.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.9.4) % of discharge volume treated in compliance with local regulatory standards

Select from:

☒ 100

#### (9.2.9.5) Factors considered in determining appropriate treatment level beyond local regulatory standards

Select all that apply

☒ Internally developed water quality standards or guidelines

☒ Sector-specific standards

☒ Profile of the receiving waterbody

#### (9.2.9.6) Please explain

*Five Pfizer sites provide onsite secondary treatment of wastewater prior to further treatment off-site or discharge to surface water, in accordance with applicable laws and permit requirements. The volume of wastewater processed through secondary treatment at Pfizer facilities in 2025 decreased by 8% compared to 2024 mainly due to production mix at our Sanford, North Carolina site. This volume represents 8% of our total wastewater discharge. Beyond regulatory compliance, treatment levels are informed by internal water quality standards, relevant sector guidance, and the sensitivity and characteristics of the receiving waterbody, ensuring a precautionary and environmentally protective approach. Pfizer defines "lower" as a decrease between 2-10% when compared to the previous year.*

### Primary treatment only

#### (9.2.9.1) Volume (megaliters)

39

#### (9.2.9.2) Comparison of treated volume with previous reporting year

Select from:

☒ Much lower

#### (9.2.9.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

#### (9.2.9.4) % of discharge volume treated in compliance with local regulatory standards

Select from:

☒ 100

#### (9.2.9.5) Factors considered in determining appropriate treatment level beyond local regulatory standards

Select all that apply

☒ Internally developed water quality standards or guidelines

☒ Sector-specific standards

☒ Profile of the receiving waterbody

#### (9.2.9.6) Please explain

*Three Pfizer sites provide onsite primary treatment of wastewater prior to discharge for offsite wastewater treatment. The volume of wastewater processed through primary treatment at Pfizer facilities in 2025 decreased by 15% compared to 2024 due to implementation of water conservation initiatives at our Melbourne, Australia facility. This volume represents less than 1% of our total wastewater discharge. Beyond regulatory compliance, treatment levels are informed by internal water quality standards, relevant sector guidance, and the sensitivity and characteristics of the receiving waterbody, ensuring a precautionary and environmentally protective approach. Pfizer defines "much lower" as a decrease over 10% when compared to the previous year.*

#### No treatment

#### (9.2.9.1) Volume (megaliters)

21629

#### (9.2.9.2) Comparison of treated volume with previous reporting year

Select from:

☒ Much lower

#### (9.2.9.3) Primary reason for comparison with previous reporting year

Select from:

☒ Increase/decrease in business activity

(9.2.9.4) % of discharge volume treated in compliance with local regulatory standards

Select from:

☒ 100

(9.2.9.6) Please explain

*Pfizer's discharge to the natural environment without treatment includes non-contact cooling water and utility wastewater (e.g., cooling tower blowdown and boiler blowdown). This water is monitored to help ensure compliance with the site's discharge permits (e.g., temperature, turbidity, etc.). Pfizer also discharges to third party wastewater treatment facilities, such as municipal wastewater treatment plants, without pre-treatment where permitted by local regulatory requirements and site discharge permits or agreements. The volume of water discharged from Pfizer sites without treatment decreased by 15% compared to 2024 primarily driven by reduced production at the Kalamazoo, Michigan site and the elimination of non-contact cooling water use across 10 chillers at the site. Pfizer does not discharge any wastewater to other organizations for further use. Beyond regulatory compliance, treatment levels are informed by internal water quality standards, relevant sector guidance, and the sensitivity and characteristics of the receiving waterbody, ensuring a precautionary and environmentally protective approach. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year.*

Unknown

(9.2.9.1) Volume (megaliters)

0

(9.2.9.6) Please explain

Not relevant  
[Fixed row]

**(9.2.10) Provide details of your organization's emissions of nitrates, phosphates, pesticides, and other priority substances to water in the reporting year.**

### (9.2.10.2) Categories of substances included

Select all that apply

- ☒ Nitrates
- ☒ Phosphates
- ☒ Priority substances listed under the EU Water Framework Directive

### (9.2.10.3) List the specific substances included

*Nitrates, phosphates and other priority substances are monitored across our network of sites where required by local regulatory requirements and site discharge permits. This data is not aggregated at the corporate level.*

### (9.2.10.4) Please explain

*Nitrates, phosphates and other priority substances are monitored across our network of sites where required by local regulatory requirements and site discharge permits. This data is not aggregated at the corporate level.*

*[Fixed row]*

**(9.3) In your direct operations and upstream value chain, what is the number of facilities where you have identified substantive water-related dependencies, impacts, risks, and opportunities?**

### Direct operations

#### (9.3.1) Identification of facilities in the value chain stage

Select from:

- ☒ Yes, we have assessed this value chain stage and identified facilities with substantive water-related dependencies, impacts, risks, and opportunities

#### (9.3.2) Total number of facilities identified

8

#### (9.3.3) % of facilities in direct operations that this represents

Select from:

☒ 1-25

**(9.3.4) Please explain**

*For 2025, we identified our facilities in La Jolla, California, US; Andover, Massachusetts, US; Toluca, Mexico; Ascoli, Italy; Vizag, India; Chennai, India; King Abdullah Economic City (KAEC), Saudi Arabia, and Sanford, North Carolina, US, as facilities exposed to water risks. Although these sites do not present a substantive risk to Pfizer's overall operation, they are important priorities from a water risk perspective and illustrative of the work we are doing to advance water stewardship across our operations.*

**Upstream value chain**

**(9.3.1) Identification of facilities in the value chain stage**

Select from:

☒ No, we have assessed this value chain stage but did not identify any facilities with substantive water-related dependencies, impacts, risks, and opportunities

**(9.3.4) Please explain**

*Pfizer uses natural hazard analysis and mapping tools to monitor short-, medium- and long-term physical threats for more than 5,000 contract manufacturers and material suppliers. We did not identify any contract manufacturers or material suppliers with substantive water-related dependencies, impacts, risks, and opportunities.*  
*[Fixed row]*

**(9.3.1) For each facility referenced in 9.3, provide coordinates, water accounting data, and a comparison with the previous reporting year.**

**Row 1**

**(9.3.1.1) Facility reference number**

Select from:

☒ Facility 1

#### (9.3.1.2) Facility name (optional)

KAEC, Saudi Arabia

#### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

#### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

#### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

Saudi Arabia

☒ Other, please specify :Saudi Arabia; Red Sea, East Coast

#### (9.3.1.8) Latitude

22.5102

#### (9.3.1.9) Longitude

39.1004

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

**(9.3.1.13) Total water withdrawals at this facility (megaliters)**

12.1

**(9.3.1.14) Comparison of total withdrawals with previous reporting year**

Select from:

☒ Much higher

**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

0

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

12.1

**(9.3.1.21) Total water discharges at this facility (megaliters)**

3.6

**(9.3.1.22) Comparison of total discharges with previous reporting year**

*Select from:*

☒ Much higher

**(9.3.1.23) Discharges to fresh surface water**

0

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

**(9.3.1.26) Discharges to third party destinations**

3.6

**(9.3.1.27) Total water consumption at this facility (megaliters)**

8.4

**(9.3.1.28) Comparison of total consumption with previous reporting year**

*Select from:*

☒ Much higher

**(9.3.1.29) Please explain**

*The total water withdrawal, water discharges and consumption at the KAEC, Saudi Arabia facility increased by 16%. The increase was due to the site running an additional shift for 6 months, which was not the case during 2024. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year.*

## Row 2

### (9.3.1.1) Facility reference number

Select from:

☒ Facility 3

### (9.3.1.2) Facility name (optional)

La Jolla, California, US

### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

### (9.3.1.7) Country/Area & River basin

United States of America

☒ Other, please specify :San Diego, California

#### (9.3.1.8) Latitude

32.898

#### (9.3.1.9) Longitude

-117.2287

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

#### (9.3.1.13) Total water withdrawals at this facility (megaliters)

46.7

#### (9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Much lower

#### (9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

#### (9.3.1.16) Withdrawals from brackish surface water/seawater

0

#### (9.3.1.17) Withdrawals from groundwater - renewable

0

#### (9.3.1.18) Withdrawals from groundwater - non-renewable

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

46.7

**(9.3.1.21) Total water discharges at this facility (megaliters)**

37.4

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Much lower

**(9.3.1.23) Discharges to fresh surface water**

0

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

**(9.3.1.26) Discharges to third party destinations**

37.4

**(9.3.1.27) Total water consumption at this facility (megaliters)**

**(9.3.1.28) Comparison of total consumption with previous reporting year***Select from:*☒ Much lower**(9.3.1.29) Please explain**

*The total water withdrawal, discharge and consumption at the La Jolla, California facility decreased by 53%. This was due to exit of one building during 2025. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year.*

**Row 3****(9.3.1.1) Facility reference number***Select from:*☒ Facility 4**(9.3.1.2) Facility name (optional)***Chennai, India***(9.3.1.3) Value chain stage***Select from:*☒ Direct operations**(9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility***Select all that apply*☒ Risks**(9.3.1.5) Withdrawals or discharges in the reporting year**

Select from:

☒ Yes, withdrawals only

#### (9.3.1.6) Reason for no withdrawals and/or discharges

Wastewater used for irrigation

#### (9.3.1.7) Country/Area & River basin

India

☒ Other, please specify :India East Coast

#### (9.3.1.8) Latitude

12.9922

#### (9.3.1.9) Longitude

80.2437

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

#### (9.3.1.13) Total water withdrawals at this facility (megaliters)

1.3

#### (9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Much lower

#### (9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

0

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

1.3

**(9.3.1.27) Total water consumption at this facility (megaliters)**

1.3

**(9.3.1.28) Comparison of total consumption with previous reporting year**

Select from:

☒ Much lower

**(9.3.1.29) Please explain**

*Water withdrawal was 11% lower while discharge was 0% different at the Chennai, India site. Consumption decreased by 11%. The decrease in water withdrawal and consumption was due to a reuse initiative at the site. Discharge remained the same as it is used onsite for irrigation purposes. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to the previous year. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year.*

## Row 4

### (9.3.1.1) Facility reference number

Select from:

☒ Facility 5

### (9.3.1.2) Facility name (optional)

Vizag, India

### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

### (9.3.1.7) Country/Area & River basin

India

☒ Other, please specify :India East Coast

### (9.3.1.8) Latitude

13.0494

#### (9.3.1.9) Longitude

80.239

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

#### (9.3.1.13) Total water withdrawals at this facility (megaliters)

288.5

#### (9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Lower

#### (9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

#### (9.3.1.16) Withdrawals from brackish surface water/seawater

0

#### (9.3.1.17) Withdrawals from groundwater - renewable

0

#### (9.3.1.18) Withdrawals from groundwater - non-renewable

0

#### (9.3.1.19) Withdrawals from produced/entrained water

0

**(9.3.1.20) Withdrawals from third party sources**

288.5

**(9.3.1.21) Total water discharges at this facility (megaliters)**

143.2

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ About the same

**(9.3.1.23) Discharges to fresh surface water**

0

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

**(9.3.1.26) Discharges to third party destinations**

143.2

**(9.3.1.27) Total water consumption at this facility (megaliters)**

145.3

**(9.3.1.28) Comparison of total consumption with previous reporting year**

Select from:

☒ Lower

### (9.3.1.29) Please explain

*Water withdrawal at the Vizag, India site decreased by 4% and water discharge increased by 1%. The site water consumption decreased by 9%. These differences are due to changes in the production schedule. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to the previous year.*

## Row 5

### (9.3.1.1) Facility reference number

Select from:

☒ Facility 6

### (9.3.1.2) Facility name (optional)

*Ascoli, Italy*

### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

Italy

☒ Other, please specify :Italy East Coast

#### (9.3.1.8) Latitude

42.8446

#### (9.3.1.9) Longitude

13.6541

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

#### (9.3.1.13) Total water withdrawals at this facility (megaliters)

131.8

#### (9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Higher

#### (9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes

0

#### (9.3.1.16) Withdrawals from brackish surface water/seawater

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

90.6

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

41.2

**(9.3.1.21) Total water discharges at this facility (megaliters)**

131.8

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Higher

**(9.3.1.23) Discharges to fresh surface water**

79.1

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

#### (9.3.1.26) Discharges to third party destinations

52.7

#### (9.3.1.27) Total water consumption at this facility (megaliters)

0

#### (9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ About the same

#### (9.3.1.29) Please explain

*Water withdrawal and discharges at the Ascoli, Italy plant were 7% higher due to changes in the production schedule. Water consumption in 2025 remained approximately the same compared to the previous reporting period. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to the previous year. Pfizer defines "higher" as an increase of 2% to 10% when compared to the previous year.*

### Row 6

#### (9.3.1.1) Facility reference number

Select from:

☒ Facility 7

#### (9.3.1.2) Facility name (optional)

*Toluca, Mexico*

#### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

#### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

#### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

Mexico

☒ Other, please specify :Río Lerma

#### (9.3.1.8) Latitude

19.2897

#### (9.3.1.9) Longitude

-99.6251

#### (9.3.1.10) Located in area with water stress

Select from:

☒ Yes

#### (9.3.1.13) Total water withdrawals at this facility (megaliters)

33.6

#### (9.3.1.14) Comparison of total withdrawals with previous reporting year

Select from:

☒ Higher

**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

33.6

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

0

**(9.3.1.21) Total water discharges at this facility (megaliters)**

32.7

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Much higher

#### (9.3.1.23) Discharges to fresh surface water

0

#### (9.3.1.24) Discharges to brackish surface water/seawater

0

#### (9.3.1.25) Discharges to groundwater

0

#### (9.3.1.26) Discharges to third party destinations

32.7

#### (9.3.1.27) Total water consumption at this facility (megaliters)

0.9

#### (9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Much lower

#### (9.3.1.29) Please explain

*In 2025, water withdrawal at the Toluca, Mexico site increased by 3% and wastewater discharge increased by 25%, contributing to an 86% decrease in water consumption, driven mainly by changes in production mix and reduced site headcount. Pfizer defines "higher" as an increase of 2% to 10% when compared to the previous year. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year. Pfizer defines "much lower" as a decrease of more than 10% compared to the previous year.*

#### Row 7

#### (9.3.1.1) Facility reference number

Select from:

☒ Facility 8

#### (9.3.1.2) Facility name (optional)

Andover, Massachusetts, US

#### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

#### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

#### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

United States of America

☒ Other, please specify :Atlantic Ocean Seaboard

#### (9.3.1.8) Latitude

42.6135

#### (9.3.1.9) Longitude

-71.1716

**(9.3.1.10) Located in area with water stress**

Select from:

☒ Yes

**(9.3.1.13) Total water withdrawals at this facility (megaliters)**

512.8

**(9.3.1.14) Comparison of total withdrawals with previous reporting year**

Select from:

☒ About the same

**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

0

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

512.8

**(9.3.1.21) Total water discharges at this facility (megaliters)**

406.4

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ About the same

**(9.3.1.23) Discharges to fresh surface water**

0

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

**(9.3.1.26) Discharges to third party destinations**

406.4

**(9.3.1.27) Total water consumption at this facility (megaliters)**

106.5

**(9.3.1.28) Comparison of total consumption with previous reporting year**

Select from:

☒ About the same

### (9.3.1.29) Please explain

*Water withdrawal and discharge at the Andover, Massachusetts plant did not change while consumption was 1% higher due to site production changes. Pfizer defines "about the same" as an increase or decrease of 0% to 2% compared to the previous year.*

### Row 8

#### (9.3.1.1) Facility reference number

Select from:

☒ Facility 9

#### (9.3.1.2) Facility name (optional)

Sanford, North Carolina, US

#### (9.3.1.3) Value chain stage

Select from:

☒ Direct operations

#### (9.3.1.4) Dependencies, impacts, risks, and/or opportunities identified at this facility

Select all that apply

☒ Risks

#### (9.3.1.5) Withdrawals or discharges in the reporting year

Select from:

☒ Yes, withdrawals and discharges

#### (9.3.1.7) Country/Area & River basin

United States of America

☒ Cape Fear River

**(9.3.1.8) Latitude**

35.5428

**(9.3.1.9) Longitude**

-79.1758

**(9.3.1.10) Located in area with water stress**

Select from:

☒ Yes

**(9.3.1.13) Total water withdrawals at this facility (megaliters)**

356.8

**(9.3.1.14) Comparison of total withdrawals with previous reporting year**

Select from:

☒ Lower

**(9.3.1.15) Withdrawals from fresh surface water, including rainwater, water from wetlands, rivers and lakes**

0

**(9.3.1.16) Withdrawals from brackish surface water/seawater**

0

**(9.3.1.17) Withdrawals from groundwater - renewable**

0

**(9.3.1.18) Withdrawals from groundwater - non-renewable**

0

**(9.3.1.19) Withdrawals from produced/entrained water**

0

**(9.3.1.20) Withdrawals from third party sources**

356.8

**(9.3.1.21) Total water discharges at this facility (megaliters)**

308.1

**(9.3.1.22) Comparison of total discharges with previous reporting year**

Select from:

☒ Lower

**(9.3.1.23) Discharges to fresh surface water**

0

**(9.3.1.24) Discharges to brackish surface water/seawater**

0

**(9.3.1.25) Discharges to groundwater**

0

**(9.3.1.26) Discharges to third party destinations**

308.1

### (9.3.1.27) Total water consumption at this facility (megaliters)

48.6

### (9.3.1.28) Comparison of total consumption with previous reporting year

Select from:

☒ Much higher

### (9.3.1.29) Please explain

Water withdrawal at the Sanford, North Carolina site decreased by 6% and wastewater discharge decreased by 10% compared with the previous year. Water consumption increased by 35%, primarily due to higher cooling tower evaporation losses in 2025. Pfizer defines "lower" as a decrease of 2% to 10% compared to the previous year. Pfizer defines "much higher" as an increase of more than 10% when compared to the previous year.

[Add row]

## (9.3.2) For the facilities in your direct operations referenced in 9.3.1, what proportion of water accounting data has been third party verified?

### Water withdrawals – total volumes

#### (9.3.2.1) % verified

Select from:

☒ 76-100

#### (9.3.2.2) Verification standard used

Select all that apply

☒ ISAE 3000

### Water withdrawals – volume by source

#### (9.3.2.1) % verified

Select from:

☒ Not verified

### (9.3.2.3) Please explain

*Assurance of 2025 water data was limited to water withdrawal, water discharges and water consumption totals.*

## Water withdrawals – quality by standard water quality parameters

### (9.3.2.1) % verified

Select from:

☒ Not verified

### (9.3.2.3) Please explain

*Assurance of 2025 water data was limited to water withdrawal, water discharges and water consumption totals.*

## Water discharges – total volumes

### (9.3.2.1) % verified

Select from:

☒ 76-100

### (9.3.2.2) Verification standard used

Select all that apply

☒ ISAE 3000

## Water discharges – volume by destination

### (9.3.2.1) % verified

Select from:

☒ Not verified

### (9.3.2.3) Please explain

*Assurance of 2025 water data was limited to water withdrawal, water discharges and water consumption totals.*

## Water discharges – volume by final treatment level

### (9.3.2.1) % verified

Select from:

☒ Not verified

### (9.3.2.3) Please explain

*Assurance of 2025 water data was limited to water withdrawal, water discharges and water consumption totals.*

## Water discharges – quality by standard water quality parameters

### (9.3.2.1) % verified

Select from:

☒ Not verified

### (9.3.2.3) Please explain

*Assurance of 2025 water data was limited to water withdrawal, water discharges and water consumption totals.*

## Water consumption – total volume

### (9.3.2.1) % verified

Select from:

☒ 76-100

### (9.3.2.2) Verification standard used

Select all that apply

☒ ISAE 3000

[Fixed row]

### (9.4) Could any of your facilities reported in 9.3.1 have an impact on a requesting CDP supply chain member?

Select from:

☒ No, CDP supply chain members do not buy goods or services from facilities listed in 9.3.1

### (9.5) Provide a figure for your organization's total water withdrawal efficiency.

|  | Revenue (currency) | Total water withdrawal efficiency | Anticipated forward trend                                                                                      |
|--|--------------------|-----------------------------------|----------------------------------------------------------------------------------------------------------------|
|  | 62579000000        | 2350384.98                        | We expect water withdrawal to reduce based on decrease in business activity & reductions in production volume. |

[Fixed row]

### (9.13) Do any of your products contain substances classified as hazardous by a regulatory authority?

#### (9.13.1) Products contain hazardous substances

Select from:

☒ Unknown

#### (9.13.2) Comment

*At Pfizer we produce medicines and vaccines regulated by health authorities around the world for quality, safety, and efficacy. Additional guidance is needed to understand how this question applies to the bio-pharma sector.*  
[Fixed row]

## **(9.14) Do you classify any of your current products and/or services as low water impact?**

### **(9.14.1) Products and/or services classified as low water impact**

Select from:

☒ Yes

### **(9.14.2) Value chain stage where low water impact is assessed**

Select all that apply

☒ Direct operations

☒ Upstream value chain

### **(9.14.3) Indicator used to assess water impact**

Water quality

☒ Lower water pollution than conventional processes

### **(9.14.4) Have you used a certification standard to classify your products/services as low water impact?**

Select from:

☒ Yes, please specify standard :Alignment with AMRIA Responsible Manufacturing Standard

### **(9.14.5) Definition used to classify low water impact**

*Pfizer considers antibiotic active pharmaceutical ingredient (API) and drug product (DP) manufactured at sites or by our suppliers that have received the BSI Kitemark™ for Minimized Risk of AMR Certification, based on the AMRIA Antibiotic Manufacturing Standard, as lower water impact. This is because the AMRIA Antibiotic Manufacturing Standard aims to improve water quality through a risk-based framework designed to limit discharge of antibiotic API to wastewater. While we*

have not yet pursued Certification of all our antibiotic API and DP, our antibiotic manufacturing sites and suppliers are all required to adhere to the AMRIA Antibiotic Manufacturing Standard. With respect to water consumption/withdrawal, we do not classify specific products as “low water impact” externally; however, our manufacturing sites are required to adhere to our internal Water Stewardship Standard which requires a comprehensive water stewardship program including minimization of water withdrawal and consumption. We maintain similar expectations for our manufacturing suppliers.

#### (9.14.7) Please explain

BSI Kitemark™ for Minimized Risk of AMR Certification API and DP include Emblaveo (Melbourne), Tygacil (Catania) and Azithromycin (Ringaskiddy). Our commitment to responsible manufacturing also extends to our external partners; for example, we helped support the Kitemark BSI certification at ACS Donbas in Zitromax production, Shandong Anxin Pharmaceutical Co., Ltd for Piperacilin, Qilu Antibiotics Pharmaceutical Co., Ltd. for Cefoperazone Sodium API and Chongqing Carelife Pharmaceutical Co., Ltd for Clindamycin. The decision regarding whether to seek certification is driven in part by requests from markets.  
[Fixed row]

### (9.15) Indicate whether you have targets relating to water pollution, water withdrawals, WASH, or other water-related categories.

#### Water pollution

##### (9.15.1) Target set in this category

Select from:

☒ No, and we do not plan to within the next two years

##### (9.15.3) Primary reason for not setting a target in this category

Select from:

☒ No standardized procedure

##### (9.15.4) Explain why you do not have a target set in this category

Pfizer is committed to limiting discharges of active pharmaceutical ingredient (API) to wastewater from our manufacturing processes, following the responsible manufacturing practices set out in the AMR Industry Alliance (AMRIA) Antibiotic Manufacturing Standard. This framework provides science-based thresholds, including Predicted No Effect Concentrations (PNECs), which inform our environmental risk assessments. Current Science Based Targets Network (SBTN) freshwater methodologies focus on nutrient pollution and do not address pharmaceutical pollutants; therefore, the AMRIA framework provides a more relevant and scientifically robust basis for managing and reducing our water pollution impacts.

## Water withdrawals

### (9.15.1) Target set in this category

Select from:

☒ Yes

### (9.15.2) Science-based target set in this target category according to SBTN guidance

Select from:

☒ No, but we plan to within the next two years

## Water, Sanitation, and Hygiene (WASH) services

### (9.15.1) Target set in this category

Select from:

☒ No, and we do not plan to within the next two years

### (9.15.3) Primary reason for not setting a target in this category

Select from:

☒ Other, please specify :Pfizer's Global Environment, Health and Safety Standards require all facilities to provide safe, fully functioning WASH services for all employees and therefore a WASH target is not relevant for our organization.

### (9.15.4) Explain why you do not have a target set in this category

*Pfizer's Global Environment, Health and Safety Standards require all facilities to provide safe, fully functioning WASH services for all employees and therefore a WASH target is not relevant for our organization.*

## Other

### (9.15.1) Target set in this category

Select from:

☒ No, and we do not plan to within the next two years

[Fixed row]

### (9.15.1) Provide details of your water-related targets and the progress made.

#### Row 1

##### (9.15.1.1) Target reference number

Select from:

☒ Water target 1

##### (9.15.1.2) Target coverage

Select from:

☒ Business division

##### (9.15.1.3) Category of target & Quantitative metric

Water withdrawals

☒ Reduction in total water withdrawals

##### (9.15.1.4) Date target was set

01/01/2020

##### (9.15.1.5) End date of base year

12/31/2019

##### (9.15.1.6) Base year figure

11637356.1

#### (9.15.1.7) End date of target year

12/31/2030

#### (9.15.1.8) Target year figure

11055488

#### (9.15.1.9) Reporting year figure

10488395.2

#### (9.15.1.10) Target status in reporting year

Select from:

☒ Underway

#### (9.15.1.11) % of target achieved relative to base year

197

#### (9.15.1.12) Global environmental treaties/initiatives/frameworks aligned with or supported by this target

Global environmental treaties/initiatives/frameworks aligned with or supported by this target

☒ Sustainable Development Goal 6

#### (9.15.1.13) Explain target coverage and identify any exclusions

*Pfizer has established an internal target to reduce water withdrawal, excluding non-contact cooling water, 5% by 2030 compared to a 2019 baseline. This target covers Pfizer's manufacturing sites, which account for approximately 95% of Pfizer's water withdrawal. Water withdrawal data for this target is presented in cubic meters.*

#### (9.15.1.14) Plan for achieving target, and progress made to the end of the reporting year

Manufacturing sites are required to set annual water withdrawal targets and to maintain site masterplans which include water conservation projects. Pfizer's water withdrawal excluding non-contact cooling water decreased by 4% in 2025 compared to 2024 and remained 13% lower than the 2019 baseline.

**(9.15.1.16) Is this a science-based target according to SBTN?**

Select from:

☒ No

**(9.15.1.18) Further details of target**

Water withdrawal is expected to reduce over the next 5 years based on decrease in business activity & reductions in production volume.  
[Add row]

C13. Further information & sign off

(13.1) Indicate if any environmental information included in your CDP response (not already reported in 7.9.1/2/3, 8.9.1/2/3/4, and 9.3.2) is verified and/or assured by a third party?

|  |                                                                                                           |
|--|-----------------------------------------------------------------------------------------------------------|
|  | Other environmental information included in your CDP response is verified and/or assured by a third party |
|  | Select from:<br><input checked="" type="checkbox"/> Yes                                                   |

[Fixed row]

(13.1.1) Which data points within your CDP response are verified and/or assured by a third party, and which standards were used?

Row 1

(13.1.1.1) Environmental issue for which data has been verified and/or assured

Select all that apply

☒ Climate change

(13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change  
☒ Renewable Electricity/Steam/Heat/Cooling consumption

(13.1.1.3) Verification/assurance standard

General standards

☒ ASAE 3000

#### (13.1.1.4) Further details of the third-party verification/assurance process

*Renewable electricity consumption was verified to the limited assurance level. Verification is performed annually. Renewable electricity consumption is relevant to target Row 1 in module 7.*

#### (13.1.1.5) Attach verification/assurance evidence/report (optional)

*ERM CVS - Limited and Reasonable Assurance Report for Pfizer 2025 CDP [FINAL].pdf*

### Row 2

#### (13.1.1.1) Environmental issue for which data has been verified and/or assured

*Select all that apply*

☒ Climate change

#### (13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change

☒ Other data point in module 7, please specify :Emissions Intensity

#### (13.1.1.3) Verification/assurance standard

General standards

☒ ASAE 3000

#### (13.1.1.4) Further details of the third-party verification/assurance process

*Emissions intensity data for facilities within Pfizer's operational control were verified to the limited assurance level. Verification is performed annually.*

#### (13.1.1.5) Attach verification/assurance evidence/report (optional)

*ERM CVS - Limited and Reasonable Assurance Report for Pfizer 2025 CDP [FINAL].pdf*

#### Row 3

##### (13.1.1.1) Environmental issue for which data has been verified and/or assured

*Select all that apply*

☒ Climate change

##### (13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change

☒ Other data point in module 7, please specify :Total Scope 3 GHG emissions from categories 1, 2, 3, 4, 5, 6, 7, 8, 9 and 15.

##### (13.1.1.3) Verification/assurance standard

General standards

☒ ASAE 3000

##### (13.1.1.4) Further details of the third-party verification/assurance process

*In addition to obtaining assurance for individual Scope 3 categories as reported in module 7, Pfizer obtains limited assurance of total Scope 3 emissions from categories 1, 2, 3, 4, 5, 6, 7, 8, 9 and 15 annually.*

#### (13.1.1.5) Attach verification/assurance evidence/report (optional)

*ERM CVS - Limited and Reasonable Assurance Report for Pfizer 2025 CDP [FINAL].pdf*

#### Row 4

##### (13.1.1.1) Environmental issue for which data has been verified and/or assured

Select all that apply

☒ Climate change

(13.1.1.2) Disclosure module and data verified and/or assured

Environmental performance – Climate change

☒ Waste data

(13.1.1.3) Verification/assurance standard

General standards

☒ ASAE 3000

(13.1.1.4) Further details of the third-party verification/assurance process

*Hazardous waste for facilities within Pfizer's operational control were verified to the limited assurance level. Verification is performed annually.*

(13.1.1.5) Attach verification/assurance evidence/report (optional)

*ERM CVS - Assurance Report for Pfizer 2025 Impact Report [FINAL].pdf*

*[Add row]*

**(13.2) Use this field to provide any additional information or context that you feel is relevant to your organization's response. Please note that this field is optional and is not scored.**

|  |                        |
|--|------------------------|
|  | Additional information |
|  | NA                     |

[Fixed row]

**(13.3) Provide the following information for the person that has signed off (approved) your CDP response.**

#### **(13.3.1) Job title**

*Executive Vice President, Chief Global Supply and Quality Officer*

#### **(13.3.2) Corresponding job category**

*Select from:*

☒ President

[Fixed row]

**(13.4) Please indicate your consent for CDP to share contact details with the Pacific Institute to support content for its Water Action Hub to facilitate collective action in priority basins.**

*Select from:*

☒ Yes, CDP may share our Disclosure Submission Lead contact details with the Pacific Institute

